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Preface	  
Cryptococcosis	   remains	   the	   leading	   cause	   of	   fungal	   meningitis	   worldwide,	  caused	  by	  the	  intracellular	  pathogens	  Cryptococcus	  neoformans	  and	  Cryptococcus	  
gattii.	  Although	  the	  majority	  of	  cryptococcosis	  cases	  occur	  in	  HIV	  patients,	  there	  is	   growing	   incidence	   of	   this	   disease	   in	   otherwise	   healthy	   individuals.	   To	   date,	  however,	   few	   studies	   address	   how	   this	   fungal	   pathogen	   is	   able	   to	   evade	   host	  innate	   immune	   responses	   in	   individuals	   with	   intact	   antifungal	   defenses.	  Interestingly,	   most	   healthy	   individuals	   are	   thought	   to	   harbor	   infections	   from	  early	  childhood	  onwards	  that	  are	  either	  resolved	  or	  become	  latent.	  Macrophages	  are	  a	  key	  host	  cell	  for	  cryptococcal	  infection;	  however,	  C.	  neoformans	  has	  evolved	  mechanisms	   to	  evade	  killing	  by	  macrophages,	   including	  vomocytosis	   (non-­‐lytic	  expulsion	   from	   phagosomes).	   We	   sought	   to	   quantify	   the	   extent	   of	   individual	  variation	   in	   this	   early	   phagocyte	   response	   within	   a	   small	   cohort	   of	   healthy	  volunteers.	  Here	  we	  discuss	  how	  underlying	  host	  innate	  immune	  responses	  vary	  between	   human	   hosts	   in	   response	   to	   cryptococcal	   disease	   caused	   by	   C.	  
neoformans.	  We	  also	  assess	  current	  understanding	  of	  how	  immune	  responses	  in	  different	   hosts	   may	   be	   predictive	   of	   protection	   from,	   or	   susceptibility	   to	  cryptococcal	   meningitis	   (CM).	   We	   find	   that	   rates	   of	   both	   intracellular	   fungal	  proliferation	   and	   non-­‐lytic	   expulsion	   (vomocytosis)	   are	   remarkably	   variable	  between	  individuals,	   irrespective	  of	  gender,	  and	  that	   in	  vitro	  host	  inflammatory	  cytokine	   profiles	   are	   not	   determinants	   of	   this	   variation.	  We	   also	   provide	   data	  associating	   TLR4	   with	   the	   vomocytosis	   of	   C.	   neoformans	   from	   mouse	   bone	  marrow	   derived	   macrophages	   (bMDMs).	   We	   thereafter	   questioned	   whether	  genetic	   variation	   in	   known	   innate	   immune	   genes	   (Toll-­‐like	   receptor	   2	   (TLR2);	  
	   5	  
TLR4;	   the	  C-­‐type	  Lectin,	  Dectin-­‐1;	   the	  mitogen-­‐activated	  protein	   (MAP)	  kinase,	  ERK5;	  and	   the	  autophagy	  protein,	  Galectin-­‐8	   (GAL8)	  may	  underlie	   some	  of	   the	  person-­‐to-­‐person	   variation	   we	   had	   observed.	   Our	   analysis	   detected	   a	   TLR4	  polymorphism	  (rs4986791)	  in	  one	  individual	  among	  9	  healthy	  adults	  that	  was	  of	  no	  observed	  immune	  consequence	  during	  in	  vitro	  challenge	  of	  host	  macrophages	  with	  C.	  neoformans;	  suggesting	  that	  larger	  GWAS	  studies	  be	  carried	  out	  to	  verify	  the	  association	  of	   these	  polymorphisms	  with	  susceptibility	   to	  cryptococcosis	   in	  immunocompetent	  hosts.	  Lastly,	  given	  the	  ability	  of	  C.	  neoformans	  to	  manipulate	  phagosome	   maturation,	   we	   screened	   13	   off-­‐patent	   drugs	   from	   the	   Prestwick	  Chemical	   Library®,	   for	   activity	   against	   intracellular	  C.	  neoformans.	  We	  present	  data	  that	  proposes	  Fendiline	  Hydrochloride	  as	  a	  potential	  anticryptococcal	  drug	  capable	  of	  eliminating	   intracellular	   fungi,	  but	  not	  extracellular	  cryptococci,	  and	  recommend	   calcium	   channel	   blockers	   as	   potential	   targets	   for	   future	  anticryptococcal	  treatments.	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  Cryptococcal	  Meningitis	  CMV	  ............................................................................................................................	  cytomegalovirus	  CNS	  .............................................................................................................	  Central	  Nervous	  System	  CrAg	  .......................................................................................................	  Cryptococcal	  Antigen	  Test	  CSF	  .....................................................................................................................	  Cerebral	  Spinal	  fluid	  DMEM	  .............................................................................	  Dulbecco's	  modified	  Eagle's	  medium	  DMSO	  ................................................................................................................	  dimethyl	  sulphoxide	  DRF	  ................................................................................................	  Damage-­‐response	  framework	  ELISA	  .............................................................................	  Enzyme-­‐linked	  immunosorbent	  assay	  ERK5	  ............................................................................	  Extracellular-­‐signal-­‐regulated	  kinase	  5	  FBS	  .......................................................................................................................	  Fetal	  Bovine	  Serum	  FCGR	  ....................................................................................................................	  Fc	  gamma	  receptor	  FCGR3A	  ......................................................................................................	  Fc	  Gamma	  Receptor	  3A	  FcγR	  .....................................................................................................................	  Fc	  gamma	  receptor	  FDA	  ........................................................................................	  US	  Food	  and	  Drug	  Administration	  GAL8	  .......................................................................................................................................	  Galectin-­‐8	  GXMGal	  ..............................................................................................................	  Galactoxylomannan	  GFP	  .......................................................................................................	  Green	  fluorescence	  protein	  GlcCer	  ...................................................................................................................	  Glucosylceramides	  GM-­‐CSF	  .............................................	  granulocyte-­‐macrophage	  colony-­‐stimulating	  factor	  GWAS	  .........................................................................................	  genome-­‐wide	  association	  study	  GXM	  ...............................................................................................................	  Glucuronoxylomannan	  H99	  .....................................................................	  C.	  neoformans	  var.	  grubii	  serotype	  A	  strain	  HIV	  ...........................................................................................	  Human	  Immunodefeciency	  Virus	  HMDMs	  ....................................................................	  Human	  Monocyte	  derived	  macrophages	  IFN-­‐γ	  ......................................................................................................................	  Interferon	  Gamma	  IL-­‐12RB1	  ..................................................................	  Interleukin	  12	  Receptor	  Subunit	  Beta	  1	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IL-­‐1α	  ...................................................................................................................	  Interleukin-­‐	  1	  alpha	  IL-­‐1β	  ....................................................................................................................	  Interleukin	  -­‐	  1	  beta	  IL-­‐6	  .................................................................................................................................	  Interleukin	  -­‐	  6	  iNOS	  ................................................................................................................	  Inducible	  Nitric	  Oxide	  IPR	  .................................................................................................	  Intracellular	  proliferation	  rate	  IRIS	  ..........................................................	  Immune	  Reconstitution	  Inflammatory	  Syndrome	  LDH	  ..............................................................................................................	  Lactate	  dehydrogenase	  L-­‐DOPA	  ..............................................................	  levodopa	  or	  L-­‐3,4-­‐dihydroxyphenylalanine	  LFA	  ........................................................................................................................	  Lateral	  Flow	  Assay	  LOAD	  ............................................................................................	  late-­‐onset	  Alzheimer’s	  Disease	  LP	  ..............................................................................................................................	  Lumbar	  Puncture	  LPS	  .........................................................................................................................	  Lipopolysaccaride	  M1	  ..........................................................................................	  Classically	  Activated	  macrophages	  M2	  ....................................................................................	  Alternatively	  Activated	  macrophages	  MAb	  ..................................................................................................................	  Monoclonal	  antibody	  MALDI-­‐TOF……………..…….……….………………………matrix-­‐assisted	   laser	   desorption	  	  ionization	  time-­‐of-­‐flight	  mass	  spectrometry	  MAP	  .......................................................................................................	  mitogen-­‐activated	  protein	  MAPKs	  .................................................................................	  mitogen-­‐activated	  protein	  kinases	  MBL	  .............................................................................................................	  Mannose-­‐binding	  lectin	  MDMs	  .......................................................................................	  Monocyte-­‐derived	  macrophages	  miRNAs	  ...............................................................................................................................	  MicroRNAs	  MLST	  .................................................................................................	  Multilocus	  Sequence	  Typing	  MOI...............................................................................................................	  multiplicity	  of	  infection	  MyD88	  ............................................................	  Myeloid	  differentiation	  primary	  response	  88	  NF-­‐κB	  .........................................................................................................	  Nuclear	  Factor-­‐Kappa	  B	  NO	  ........................................................................................................................................	  Nitric	  Oxide	  PAMPs	  ......................................................................	  pathogen-­‐associated	  molecular	  patterns	  PBMCs	  ............................................................................	  Primary	  peripheral	  blood	  monocytes	  PCR	  ........................................................................................................	  Polymerase	  chain	  reaction	  PHS	  ...................................................................................................................	  Pooled	  human	  Serum	  PLB	  .............................................................................................................................	  Phospholipase	  B	  PMA	  .......................................................................................................	  phorbol	  myristate	  acetate	  PRRs	  .............................................................................................	  Pattern	  Recognition	  Receptors	  RBC	  ................................................................................................................................	  Red	  Blood	  Cell	  RNS	  ........................................................................................................	  Reactive	  Nitrogen	  Species	  ROS	  ............................................................................................................	  Reactive	  Oxygen	  Species	  SCID	  .................................................................................	  Severe	  Combined	  Immunodeficiency	  SNPs	  .........................................................................................	  small	  nucleotide	  polymorphisms	  SOT	  ...............................................................................................................	  Solid	  Organ	  Transplant	  STAT1	  ...................................................	  Signal	  transducer	  and	  activator	  of	  transcription	  1	  TB	  ........................................................................................................................................	  Trypan	  blue	  Th1	  ...........................................................................................................	  Type	  1	  immune	  response	  Th17	  .....................................................................................................	  Type	  17	  immune	  reactions	  Th2	  ...........................................................................................................	  Type	  2	  immune	  response	  THP-­‐1	  ......................................................................................	  Human	  macrophage-­‐like	  cell	  line	  TLR2	  ....................................................................................................................	  Toll-­‐like	  receptor	  2	  TLR4	  ....................................................................................................................	  Toll-­‐like	  receptor	  4	  TLRs	  ......................................................................................................................	  Toll-­‐like	  Receptors	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TNFα	  ................................................................................................	  Tumor	  Necrosis	  Factor	  alpha	  TRAF	  ...............................................................	  TNF	  receptor	  associated	  factorprotein	  family	  UPEC	  ............................................................................................	  UroPathogenic	  Escherichia	  coli	  YPD	  ..........................................................................................	  Yeast	  Extract–Peptone–Dextrose	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Chapter	  1	  –	  Introduction	  
	  Parts	  of	  this	  chapter	  have	  been	  adapted	  from	  the	  review	  below:	  GARELNABI,	   M.	   and	   MAY,	   R.C.	   2018.	   Variability	   In	   Innate	   Host	   Immune	  Responses	   To	   Cryptococcosis.	   Manuscript	   in	   press,	   Memórias	   do	   Instituto	  Oswaldo	  Cruz.	  
Abstract	  
Cryptococcosis	  is	  a	  fungal	  disease	  caused	  by	  members	  of	  the	  genus	  Cryptococcus,	  with	   a	   high	   frequency	   of	   cases	   being	   due	   to	   the	   opportunistic	   pathogens	  
Cryptococcus	   neoformans	   and	   Cryptococcus	   gattii.	   Although	   the	   majority	   of	  cryptococcosis	  cases	  occur	  in	  HIV	  patients,	  there	  is	  growing	  evidence	  to	  support	  the	   pathogenicity	   of	   Cryptococcus	   spp.	   towards	   otherwise	   healthy	   individuals.	  To	  date,	  however,	  few	  studies	  address	  how	  this	  fungal	  pathogen	  is	  able	  to	  evade	  host	   innate	   immune	   responses	   in	   individuals	   with	   more	   robust	   antifungal	  defenses.	  Here	  we	  discuss	  how	  underlying	  host	   innate	   immune	  responses	  vary	  between	   human	   hosts	   in	   response	   to	   cryptococcal	   disease	   caused	   by	   C.	  
neoformans.	  We	  also	  assess	  current	  understanding	  of	  how	  immune	  responses	  in	  different	   hosts	   may	   be	   predictive	   of	   protection	   from,	   or	   susceptibility	   to	  cryptococcal	  meningitis	  (CM).	  
	   15	  
Literature	  Review	  
THE	  IMMUNE	  SYSTEM	  The	  immune	  system	  is	  a	  combination	  of	  immune	  cells	  and	  molecules	  that	  defend	  the	  body	   from	  physical,	   chemical	   and	  biological	   invasion	  by	  pathogens	   such	  as	  viruses,	   bacteria	   and	   fungi.	   It	   spans	   a	   number	   of	   tissue	   groups	   and	   organ	  systems,	  and	  consists	  of	  highly	  orchestrated	  cells	  and	  substances	  that	  are	  able	  to	  detect	   differences	   between	   invasive	   pathogens	   and	   the	   body’s	   own	   cells	   and	  microbiome	  (self)	  [1].	  Immune	  cells	  are	  generated	  in	  organs	  such	  as	  the	  spleen,	  bone	   marrow	   and	   lymph	   nodes,	   and	   monitor	   how	   the	   body	   responds	   to	   an	  invasive	  pathogen	  in	  order	  to	  mount	  the	  most	  effective	  defense	  against	  it.	  This	  is	  known	   as	   the	   immune	   response.	   Immune	   responses	   are	   classified	   as	   either	  innate	   or	   adaptive	   (explained	   below);	   the	   two	   arms	   of	   immunity	   that	   interact	  with	  each	  other	  to	  effectively	  bring	  about	  pathogen	  clearance.	  However,	  in	  some	  cases,	  the	  immune	  system	  may	  fail	  to	  self-­‐recognize	  and	  mount	  an	  attack	  against	  the	  body’s	  own	  cells,	  leading	  to	  the	  development	  of	  autoimmune	  diseases.	  	  
The	  innate	  immune	  system	  	  Upon	   infection,	   the	   first	   line	  of	  defense	   is	   the	   innate	   immunity.	  This	  arm	  of	   the	  immune	   system	   is	   inherited,	   rapid,	   and	   considered	   to	   be	   ‘non-­‐specific’;	   it	  includes	  anatomical	  and	  chemical	  deterrents	  such	  as	  the	  epithelial	  and	  mucous	  membranes,	  and	  internal	  defenses	  such	  as	  myeloid	  cells	  (macrophages,	  dendritic	  cells,	  masT-­‐cells	  and	  natural	  killer	  (NK)	  cells).	   Innate	   immunity	  also	  consists	  of	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molecular	   components	   such	   as	   the	   complement	   system,	   cytokines	   and	   acute-­‐phase	  proteins	  which	  may	  act	  as	  inflammatory	  mediators	  [1].	  Pertaining	  to	  this	  thesis,	  the	  characteristics	  of	  macrophages,	  the	  complement	  system	  and	  cytokines	  will	  be	  described	  below.	  	  
Macrophages	  A	   major	   component	   of	   innate	   immune	   cells	   are	   macrophages.	   These	   are	  phagocytic	  cells	  which	  develop	  from	  blood-­‐borne	  monocytes	  with	  the	  ability	  to	  distinguish	   between	  host	   and	  pathogen	   cells	   via	   highly	   specialized	   cell	   surface	  receptors	   [1].	   They	   are	   able	   to	   engulf	   pathogens	   within	   an	   intracellular	  compartment	   known	   as	   a	   phagosome,	   that	   matures	   into	   a	   phagolysozome	  capable	   of	   destroying	   a	   phagocytosed	   pathogen	   following	   acidification	   of	   the	  phagolysosomal	  lumen	  [2,	  3].	  	  	  	  Aside	   from	   their	   phagocytic	   abilities,	   macrophages	   comprise	   a	   dynamic	  population	   of	   cells	   capable	   of	   other	   functions	   such	   as	   tissue	   repair	   and	  remodeling,	   that	   are	   determined	   by	   signals	   in	   the	   macrophage’s	   local	  microenvironment	  [4].	  These	  stimuli	  influence	  macrophages	  to	  differentiate	  and	  express	  cell	  surface	  receptors	  that	  enable	  them	  to	  respond	  to	  cytokines	  released	  by	  other	  macrophages	  and	  surrounding	  cells,	  and	  pattern	  recognition	  receptors	  (PRRs)	   to	   detect	   pathogen-­‐associated	  molecular	   patterns	   (PAMPs)	   and	   trigger	  phagocytosis.	  Macrophages	  derived	  from	  tissue-­‐surrounding	  monocytes	  are	  able	  to	  differentiate	  into	  multiple	  phenotypes	  to	  fulfill	  different	  roles	  in	  host	  defense,	  tissue	   repair	   and	   immune	   modulation	   [5].	   In	   general,	   macrophages	   are	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considered	   as	   being	   either	   classically	   (M1)	   or	   alternatively	   activated	   (M2),	  although	  other	  macrophage	  activation	  states	  have	  been	  suggested	  [6,	  7].	  The	  M1	  macrophage	   activation	   state	   is	   considered	   microbicidal	   and	   arises	   following	  exposure	   to	   GM-­‐CSF	   and	   inflammatory	   stimuli	   such	   as	   IFN-­‐γ	   and	   LPS	   in	   vitro;	  whereas	  M2	  macrophages	  are	  activated	   in	   the	  presence	  of	  M-­‐CSF	  and	   IL-­‐4	  and	  demonstrate	  functions	  in	  tissue	  restoration.	  	  	  The	  macrophage	  arsenal	   to	  destroy	  engulfed	  pathogens	   includes	   the	   release	  of	  proinflammatory	  cytokines	  and	  chemokines	  that	  extend	  cell	  mediated	  immunity	  by	  increasing	  monocyte	  and	  neutrophil	  recruitment	  to	  the	  site	  of	   infection,	  and	  antigen	   presentation	   to	   T-­‐cells	   (described	   below).	   Response	   to	   cytokine	  signaling	   results	   in	   the	   production	   of	   reactive	   nitrogen	   species	   such	   as	   nitric	  oxide	   (NO)	   [8],	   reactive	   oxygen	   species	   (ROS)	   and	   hydrogen	   peroxide	   into	   the	  phagolysozome,	   along	  with	   other	   enzymes	   to	   eliminate	   the	   pathogen	   from	   the	  host.	   In	   macrophages,	   NO	   is	   made	   by	   inducible	   nitric	   oxide	   synthase	   (iNOS)	  enzyme.	  NO	  plays	  a	  role	   in	   intracellular	  and	  extracellular	  signaling,	   free	  radical	  damage,	  and	  is	  crucial	  in	  the	  destruction	  of	  intracellular	  pathogens	  [8,	  9].	  	  
The	  complement	  system	  	  The	  complement	  system	  is	  a	  soluble	  component	  of	  the	  innate	  immune	  system.	  It	  consists	   of	   a	  number	  of	   plasma	  proteins	   that	   interact	  with	   each	  other	   to	  mark	  pathogens	   for	   destruction	   by	   innate	   immune	   cells	   in	   a	   process	   known	   as	  opsonization.	  Macrophages	  have	  receptors	  for	  both	  antibodies	  and	  complement,	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and	  are	  able	  to	  use	  either	  or	  both	  methods	  of	  activation	  to	  enhance	  phagocytosis	  [10].	   Complement	   activation	  occurs	   via	   one	  of	   three	  pathways:	   1)	   the	   classical	  pathway	   following	   the	   formation	   of	   antibody-­‐antigen	   complexes;	   2)	   the	  alternative	  pathway	  upon	  sensing	  pathogen	  cell	  wall	  components;	  and	  3)	  via	  the	  lectin	   pathway	   following	   binding	   of	   the	   mannose	   protein	   to	   microbial	  carbohydrates	   [11].	   This	   culminates	   in	   the	   deposition	   of	   the	   complement	  component	  C3b	  on	  the	  surface	  of	  pathogens	  to	  initiate	  phagocytosis	  and	  trigger	  a	  series	   of	   inflammatory	   responses	   and	   the	   enhancement	   of	   the	   antimicrobial	  capabilities	  of	  innate	  immune	  cells	  [1].	  	  	  
Cytokines	  	  Another	  soluble	  component	  of	  the	  innate	  immune	  system	  is	  cytokines.	  They	  act	  as	  chemical	  messengers	  that	  are	  released	  by	  cells	  to	  relay	  signals	  both	  internally	  and	  externally.	  There	  are	  more	  the	  60	  cytokines	  on	  record,	  released	  by	  a	  variety	  of	   cells	   [12].	   A	   cytokine	   released	   by	   a	   particular	   cell	   type	   will	   initiate	  inflammatory	   responses	   in	   a	   cell	   expressing	   a	   receptor	   for	   that	   particular	  cytokine	   in	   order	   to	   bring	   about	   pathogen	   elimination	   [13].	   The	   specificity	   of	  cytokine-­‐releasing	   and	   cytokine	   receptor-­‐expressing	   cells	   describes	   the	  complexity	   of	   immune	   responses	   to	   a	   variety	   of	   pathogens	   [12].	   For	   example,	  certain	   classes	   of	   cytokines	   –	   the	   interferons-­‐	   are	   released	   predominantly	   by	  virally	  infected	  cells,	  and	  have	  been	  shown	  to	  confer	  antimicrobial	  properties	  to	  surrounding	   cells.	   Cytokines	   are	   classified	   as	  being	   either	  pro-­‐inflammatory	  or	  anti-­‐inflammatory	   [12].	  Well	   characterized	  pro-­‐inflammatory	   cytokines	   include	  tumor	   necrosis	   factor-­‐alpha	   (TNF-­‐α),	   interferon-­‐gamma	   (IFN-­‐γ),	   interleukin-­‐1	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(IL-­‐1),	  IL-­‐12,	  IL-­‐18	  and	  granulocyte-­‐macrophage	  colony	  stimulating	  factor	  (GM-­‐CSF);	   while	   anti-­‐inflammatory	   cytokines	   include	   IL4,	   IL-­‐10,	   IL-­‐13,	   interferon-­‐alpha	   (IFN-­‐α)	   and	   transforming	   growth	   factor-­‐beta	   (TGF-­‐β)	   [14].	   However,	  depending	  on	   the	  circumstances,	  a	  cytokine	  may	  behave	  as	  either	  pro-­‐	  or	  anti-­‐	  inflammatory	  [12,	  14].	  	  	  
The	  adaptive	  immune	  system	  	  The	   more	   specialized	   part	   of	   the	   immune	   system	   is	   known	   as	   the	   acquired	  (adaptive)	   immune	  system.	  This	   is	  a	  delayed	  response	  to	  pathogens	  represents	  the	  second	  line	  of	  defense.	  Adaptive	  immune	  responses	  are	  generated	  primarily	  in	  the	  secondary	  lymphoid	  tissues	  (spleen,	  lymph	  nodes	  and	  mucosa-­‐associated	  lymph	  tissue),	  and	  involve	  the	  proliferation	  of	  lymphoid	  cells	  (T	  and	  B	  cells)	  that	  interact	  with	  components	  of	  the	  innate	  immune	  system	  to	  eliminate	  pathogens.	  This	   branch	   of	   immunity	   can	   further	   be	   divided	   into	   two	   types:	   humoral	  immunity	   (involves	   B	   cells),	   and	   cell-­‐mediated	   immunity	   (driven	   by	   T-­‐cells).	  Both	  B	  cells	  and	  T-­‐cells	  develop	  from	  pluripotent	  stem	  cells	   in	  fetal	   liver	  tissue	  and	   in	   the	   bone	   marrow.	   Whilst	   B	   cells	   mature	   in	   the	   bone	   marrow,	   T-­‐cells	  migrate	  towards	  the	  thymus	  where	  they	  mature	  and	  differentiate	  into	  effector	  T-­‐cells	  (including	  T	  killer	  cells,	  regulatory	  T-­‐cells	  and	  T	  helper	  cells)	  [12].	  	  The	   adaptive	   immune	   system	   is	   also	   capable	   of	   developing	   an	   immunological	  memory	   to	   previous	   infections.	   During	   a	   primary	   infection,	   a	   subset	   of	  proliferating	   lymphoid	   cells	   differentiate	   into	   memory	   cells	   that	   lay	   dormant	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until	  activated	  upon	  secondary	  infection.	  This	  allows	  a	  more	  rapid	  and	  stronger	  adaptive	  immune	  response	  to	  be	  mounted	  when	  circulating	  memory	  cells	  detect	  a	   pathogen	   during	   a	   subsequent	   exposure	   and	   differentiate	   into	   effector	   cells	  [12].	  
	  
Interactions	  between	  innate	  and	  adaptive	  immunity	  	  A	   typical	   immune	   response	   involves	   complex	   interactions	   between	   both	   the	  innate	   and	   adaptive	   immune	   responses.	  Whilst	   the	   innate	   immune	   response	   is	  mounted	  immediately,	  the	  adaptive	  response	  may	  take	  several	  days	  to	  come	  into	  effect.	  Therefore,	  innate	  immunity	  acts	  as	  a	  primary	  global	  response	  to	  infection,	  which	   is	   followed	   by	   an	   adaptive,	   more	   specialized	   immune	   response	   to	   an	  invading	  pathogen.	  	  Upon	   infection,	   specialized	   cells	   known	   as	   antigen-­‐presenting	   cells	   (which	  include	  dendritic	  cells,	  B	  cells,	  and	  activated	  macrophages)	  activate	  myeloid	  cells	  by	   presenting	   degraded	   antigens	   to	   T-­‐cells	   via	   MHC	   molecules	   on	   the	   cell’s	  surface,	  in	  order	  to	  initiate	  clearance	  of	  the	  pathogen	  (Fig.	  1)	  [1].	  MHC	  molecules	  are	  cell-­‐surface	  glycoproteins	  encoded	  by	  a	  cluster	  of	  genes	  known	  as	  the	  major	  histocompatibility	   complex	   (MHC);	   they	   bind	   specific	   epitopes	   following	  degradation	   of	   an	   antigen	   by	   an	   antigen-­‐presenting	   cell	   [12].	   There	   are	   two	  predominant	  types	  of	  MHC	  molecules:	  Type	  1	  (MHC	  I)	  and	  Type	  2	  (MHC	  II).	  T-­‐helper	  cell	   lineages	  are	  characterized	  by	   the	  set	  of	  markers	  and	  receptors	   they	  express;	   the	   two	   main	   classes	   of	   T-­‐cells	   express	   either	   of	   two	   cell-­‐surface	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proteins	  known	  as	  CD8	  and	  CD4,	  which	  act	  as	  co-­‐receptors	  that	  confer	  functional	  diversity	   in	   T-­‐cells,	   and	   determine	   the	   interactions	   between	   T-­‐cells	   and	   other	  cells	   [12].	   	  CD8	  expressing	  T-­‐cells	  (CD8+)	  bind	  MHC	  I,	  while	  CD4-­‐expressing	  T-­‐cells	  bind	  MHC	  II.	  In	  addition	  to	  T-­‐cells’	  ability	  to	  clear	  pathogens,	  they	  are	  also	  involved	   in	   activating	   macrophages	   for	   the	   purpose	   of	   clearing	   intracellular	  pathogens	   and	   assisting	   B-­‐cells	   to	   produce	   antigen-­‐specific	   antibodies	   (Fig.	   1)	  [1].	  	  	  
	  
Figure	  1.	  Illustration	  of	  the	  interaction	  between	  the	  innate	  and	  adaptive	  immune	  system.	  Upon	  entry	  
into	   the	  body,	   a	   pathogen	   is	   first	   encountered	  by	  macrophages	   that	  phagocytose	   and	  degrade	   the	  
pathogen.	  This	  is	  followed	  by	  antigen	  presentation	  to	  T-­‐cells,	  which	  differentiate	  into	  T	  killer-­‐cells	  
that	  directly	  kill	  the	  pathogen,	  or	  into	  T	  helper-­‐cells	  that	  initiate	  the	  production	  of	  antigen-­‐specific	  
antibodies	  by	  B-­‐cells,	  also	  resulting	  in	  pathogen	  destruction.	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T	  helper-­‐cells	  also	  have	  diverse	  specificities:	  Type	  1	  (Th1)	  T	  helper	  cells	  secrete	  the	   cytokines	   interleukin-­‐2	   (IL-­‐2)	   and	   interferon-­‐γ	   and	   activate	   macrophages;	  while	   Type	   2	   (Th2)	   T	   helper	   cells	   secrete	   the	   IL-­‐4,	   IL-­‐5,	   IL-­‐6,	   and	   IL-­‐10	   and	  inhibit	  Th1	  responses	  [1].	  Another	  T-­‐cell	  lineage	  is	  the	  Type	  17	  (Th17)	  T	  helper-­‐cells	   that	   are	   memory	   effector	   cells	   and	   have	   been	   associated	   with	   mounting	  inflammatory	   responses	   to	   pathogens	   by	   releasing	   the	   proinflammatory	  cytokines	  IL-­‐17,	  IL-­‐21,	  IL-­‐22	  and	  IL-­‐26	  [12].	  	  Overall,	  depending	  on	  the	  nature	  of	  the	  pathogen,	  components	  in	  the	  innate	  and	  adaptive	  immune	  system	  will	  undergo	  complex	  interactions	  to	  a	  degree	  of	  high	  specificity	  towards	  a	  particular	  antigen,	  in	  able	  to	  orchestrate	  effective	  immune	  clearance	  of	  the	  pathogen.	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CRYPTOCOCCOSIS	  	  Cryptococcosis	  is	  a	  potentially	  fatal	  fungal	  disease	  caused	  by	  infectious	  members	  of	  the	  genus	  Cryptococcus,	  of	  which	  the	  two	  species	  Cryptococcus	  neoformans	  and	  
Cryptococcus	  gattii	   are	  highly	  pathogenic	   towards	  humans	   [15,	  16].	  The	  severe	  form	  of	  the	  disease	  -­‐	  Cryptococcal	  Meningitis	  (CM)-­‐	  remains	  the	  leading	  cause	  of	  fungal	  meningitis	  worldwide,	  and	  the	  cause	  for	  15%	  of	  AIDs-­‐related	  deaths	  [17].	  In	  2014,	  up	  to	  223,100	  cases	  of	  CM	  were	  reported	  globally,	  with	  approximately	  181,100	   deaths	   resulting	   from	   severe	   disease	   [17,	   18].	   While	   clinical	  manifestations	   of	   the	   disease	   vary	   between	   species,	   the	   majority	   (80%)	   of	  cryptococcosis	  cases	  are	  HIV-­‐associated,	  and	  are	  caused	  by	  C.	  neoformans.	  Over	  the	   last	   century,	   cryptococcosis	   has	   emerged	   as	   a	   fungal	   disease	   of	   significant	  clinical	  importance,	  placing	  it	  as	  the	  second	  most	  common	  cause	  of	  AIDs-­‐related	  deaths	  after	  tuberculosis	  [17-­‐19].	  	  	  Prior	   to	   the	   1950s,	   less	   than	   300	   clinical	   cases	   of	   cryptococcosis	   had	   been	  reported;	   the	   subsequent	   drastic	   rise	   in	   incidence	   was	   attributed	   to	   the	  emergence	  of	  the	  HIV/AIDS	  pandemic	  in	  the	  1960s,	  and	  increased	  frequency	  of	  immunosuppressed	   patients	   [20].	   	   However,	   C.	   neoformans	   also	   causes	   CM	   in	  non-­‐HIV,	   immunocompromised	  patients	  and	  at	  a	  rising	  frequency	  in	   ‘otherwise	  healthy’	  individuals	  [15,	  21-­‐23].	  	  Previous	  assumptions	  that	  C.	  gattii	  was	  geographically	  restricted	  to	  tropical	  and	  subtropical	   regions	   were	   dismissed	   following	   a	   C.	   gattii	   outbreak	   that	   struck	  Vancouver	  Island,	  Canada	  in	  1999	  [24-­‐26],	  followed	  by	  the	  subsequent	  spread	  of	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the	  disease	  across	  North	  Western	  America	  in	  immunocompetent	  individuals	  [27,	  28].	   Clinical	   presentation,	   risk	   factors	   to	   the	   infection	   and	   response	   to	  treatments	   of	   cryptococcosis	   caused	   by	   either	   species	   vary	   between	  HIV/AIDs	  patients	   and	   non-­‐HIV	   patients	   [29].	   Because	   otherwise	   healthy	   cryptococcosis	  patients	   have	   been	   shown	   to	   present	  with	   less	   definitive	   symptoms	   than	   their	  immunocompromised	   counterparts,	   the	   disease	   is	   often	  misdiagnosed	   and	   can	  lead	   to	   fatalities,	   necessitating	   a	   deeper	   understanding	   of	   the	   etiology	   of	   the	  infection	  in	  both	  patient	  groups	  [22,	  29].	  	  	  Prior	   to	   the	   US	   Northwest	   Pacific/Canada	   British	   Columbia	   outbreak,	  
Cryptococcus	  gattii	   had	   been	   localized	   to	   tropical	   and	   sub-­‐tropical	   regions	   [30,	  31].	  This	  brought	  to	  light	  the	  expanding	  geographical	  limitations	  of	  the	  pathogen,	  suggesting	  a	  role	  for	  climate	  change	  in	  elevating	  the	  potential	  threat	  of	  disease	  to	  public	  health	  [32,	  33].	  	  	  
HISTORY,	  NOMENCLATURE	  AND	  TAXONOMY	  	  	  The	  fungus	  was	  first	  described	  in	  1894	  by	  Otto	  Busse	  and	  Francesco	  Sanfelice	  in	  isolates	  from	  a	  bone	  infection	  in	  a	  female	  patient,	  and	  in	  fermenting	  peach	  juice,	  respectively	   [34,	   35].	   Sanfelice	   chose	   to	   name	   the	   yeast	   Saccharomyces	  
neoformans,	   based	   on	   the	   form	   colonies	   took;	   however,	   the	   yeast	   was	   later	  renamed	  Cryptococcus	  neoformans	  in	  1901	  by	  Jean-­‐Paul	  Vuillemin	  because	  it	  did	  not	   produce	   ascospores,	   a	   distinctive	   feature	   of	   members	   of	   the	   genus	  
Saccharomyces	   [36].	   	   In	   1896,	   Ferdinand	   Curtis	   reported	   a	   ‘yeast-­‐like’	   fungus	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from	   a	   patient’s	   hip	   tumor,	   which	   he	   termed	   Saccharomyces	   subcutaneous	  
tumefaciens	   due	   to	   variation	   in	   its	   culture	   compared	   to	   yeasts	   previously	  described	  by	  Busse	  and	  Sanfelice	  [37].	  	  	  Both	  C.	  neoformans	  and	  C.	  gattii	  are	  basidiomycetes	  that	  are	  distinguishable	  from	  other	  yeasts	  such	  as	  Candida	  and	  Saccharomyces	  by	  the	  presence	  of	  an	  extensive	  polysaccharide	   capsule,	  melanin	   formation,	   and	  urease	  activity	   (Fig.	  1a).	  These	  characteristics	  also	  function	  as	  virulence	  factors	  that	  enable	  the	  yeasts	  to	  invade	  and	  thrive	  within	  host	  systems.	  




b)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  c)	  
	  
Figure	  2-­‐	  a)	  the	  structure	  of	  Cryptococcus;	  b)	  The	  Cryptococcus	  capsule	  when	  stained	  with	  India	  ink;	  
c)	  Cryptococcal	  production	  of	  melanin	  in	  response	  to	  diphenols.	  b)	  and	  c)	  were	  adapted	  from	  [38].	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Confusion	   surrounding	   the	   nomenclature	   of	   the	   etiological	   agents	   of	  cryptococcosis	   arose	   in	   the	   early	   twentieth	   century	   with	   subsequent	   isolation	  and	   identification	   of	   the	   yeast	   by	   other	   names	   such	   as	   Cryptococcus	   hominis,	  
Blastomyces	   neoformans	   and	   Torula	   histolytica.	   This	   dispute	   was	   resolved	   by	  concluding	   that	   cryptococcosis	   was	   cased	   by	   the	   species	   Cryptococcus	  
neoformans	  that	  consisted	  of	  two	  varieties	  based	  on	  their	  serological	  differences:	  
Cryptococcus	   neoformans	   and	   Cryptococcus	   gattii	   [39-­‐42].	   The	   species	   was	  further	   characterized	   based	   on	   its	   capsular	   interactions	  with	   rabbit	   polyclonal	  sera,	  and	  divided	  into	  four	  serotypes:	  C.	  neoformans	  var.	  grubii	  (serotype	  A),	  C.	  neoformans	  var.	  gattii	   (serotypes	  B	  and	  C)	  and	  C.	  neoformans	  var.	  neoformans	  (serotype	  D)	  [43,	  44].	  	  	  The	   rising	   popularity	   of	  molecular	   approaches	   in	   the	   late	   twentieth	   and	   early	  twenty-­‐first	  centuries	  allowed	  for	  further,	  more	  detailed	  taxonomic	  classification	  of	   Cryptococcus	   neoformans	   and	   Cryptococcus	   gattii.	   Molecular	   clock	   analysis,	  genotyping,	  and	  multilocus	  sequence	  typing	  (MLST)	  were	  used	  to	  categorize	  the	  two	   species	   into	   eight	  molecular	   subtypes:	  VNI,	  VNII,	   and	  VNB	   (C.	   neoformans	  var.	  grubbi);	  VNIII	  (serotype	  AD	  hybrid);	  VNIV	  (C.	  neoformans	  var.	  neoformans);	  and	  VGI-­‐VGIV	  (C.	  gattii)	  [37,	  45].	  These	  studies	  revealed	  that	  the	  strain	  isolated	  by	   Curtis	   was	   the	   first	   clinical	   isolate	   of	   Cryptococcus	   gattii	   [46,	   47],	   and	  disproved	  early	  taxonomic	  grouping	  of	  C.	  neoformans	  	  and	  C.	  gattii	  under	  a	  single	  species.	   It	   was	   also	   estimated	   that	   the	   different	   serotypes	   diverged	   from	   each	  other	  approximately	  forty	  million	  years	  ago	  [48].	  Due	  to	  significant	  genetic	  and	  biological	   differences	   between	   serotypes	   A	   and	   D,	   and	   serotypes	   B	   and	   C,	   C.	  neoformans	  var.	  gattii	  was	  elevated	  to	  species	  level	  [47,	  49].	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  Further	   taxonomic	   revisions	   followed,	   as	   further	   molecular	   and	   genetic	  characterization	   studies	   revealed	   more	   extensive	   differences	   within	   the	   two	  species	  complexes.	  In	  2015,	  following	  phylogenetic	  analysis	  of	  115	  Cryptococcus	  spp.	  isolates,	  it	  was	  proposed	  that	  C.	  neoformans	  be	  divided	  into	  two	  species,	  and	  
C.	  gattii	  into	  five	  species	  [50].	  Hagen	  et	  al.	  described	  seven	  species	  within	  the	  C.	  
neoformans	  and	  C.	  gattii	  complexes	  that	  were	  distinguishable	  from	  each	  other	  by	  MALDI-­‐TOF,	   based	   on	   differences	   in	   their	   pathogenicity,	   biochemical	   and	  physiological	   features,	  and	  susceptibility	   to	  antifungals	   [50].	  However,	   in	  2017,	  Kwon-­‐Chung	   et	   al.	   presented	   an	   argument	   for	   the	   adoption	   of	   a	   “species	  complex”	   system	   of	   nomenclature,	   in	   order	   to	   avoid	   further	   confusion	   around	  the	   taxonomy	  of	   clades	  within	   the	  C.	  neoformans	   and	  C.	  gattii	   groups	   [51].	  The	  group	   believed	   that	   the	   proposal	   made	   in	   2015	   was	   premature	   due	   to	  predictions	  that	  the	  designation	  of	  species	  based	  on	  phylogenetics	  would	  change.	  They	   also	   discussed	   the	   current	   controversy	   surrounding	   species	  characterization	  based	  on	   lineage	   rather	   than	  phenotypic	   traits;	   and	  described	  the	  ensuing	  confusion	  that	  would	  arise	  in	  the	  published	  literature	  and	  in	  clinical	  practise	   [51].	   In	  response,	  Hagen	  et	  al.	   expressed	  contrasting	  views	  to	   those	  of	  Kwon-­‐Chung	   et	   al.,	   arguing	   that	   the	   “species	   complex”	   system	   would	   not	  eliminate	   the	   feared	   confusion,	   but	   rather	   delay	   the	   identification	   of	   clinically	  relevant	   differences	   between	   clades	   and	   ultimately	   cripple	   clinical	   approaches	  [52].	  To-­‐date,	  a	  consensus	  within	  the	  scientific	  community	  is	  yet	  to	  be	  reached.	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ECOLOGY	  AND	  EPIDEMIOLOGY	  
	  Cryptococcus	  spp.	  are	  both	  pathogens	  and	  environmental	  yeasts	  that	  are	  able	  to	  adapt	   to	   changes	   in	   their	   internal	   and	   external	   environments	   through	   various	  survival	   mechanisms	   such	   as	   the	   control	   of	   signal	   transduction	   pathways	   and	  making	  changes	  to	  their	  physiology	  and	  morphology.	  Found	  in	  the	  soil,	  tree	  bark	  and	   in	   pigeon	   droppings	   (Fig.	   2);	   C.	   neoformans	   is	   isolated	   mainly	   from	   bird	  guano	   [53],	   while	   the	   environmental	   habitat	   of	   C.	   gattii	   is	   tree	   bark	   [54].	   The	  yeast	   interacts	   with	   organisms	   within	   the	   soil	   such	   as	   other	   fungi,	   bacteria,	  amoebae,	   insects	   and	   nematodes	   [2];	   and	   one	   important	   ecological	   factor	   of	  clinical	  relevance	  is	  its	  interactions	  in	  the	  soil	  with	  phagocytic	  amoebae	  [55-­‐57].	  This	   predator-­‐prey	   relationship	   is	   thought	   to	   have	   played	   a	  major	   role	   in	   the	  evolution	  of	  Cryptococcus	  as	  a	  human	  pathogen	  with	  the	  ability	  to	  survive	  within	  macrophages	  [37,	  55-­‐58].	  In	  2018,	  Watkins	  et	  al.	  showed	  that	  the	  social	  amoeba,	  
Dictyostelium	  discoideum,	   interacted	  with	  C.	  neoformans	   in	   a	  manner	   similar	   to	  mammalian	  macrophages;	  in	  this	  report,	  the	  group	  described	  the	  phagocytosis	  of	  
C.	  neoformans	  by	  the	  amoeba	  as	  “an	  apparently	  normal	  phagocytic	  transit”	  [57].	  	  	  
C.	  gattii	   is	  mainly	  prevalent	   in	   tropical	   to	  sub-­‐tropical	   climates	   including	  South	  East	  Asia,	   Sub-­‐Saharan	  Africa	   and	  Brazil	   [31];	  whereas	  C.	  neoformans	   	   is	   up	   to	  eightfold	  more	   frequently	   isolated	   across	   the	   globe	   [59].	  Analysis	   of	   the	   global	  geographical	   distribution	   of	   cryptococcosis	   revealed	   that	   C.	   neoformans	   var.	  grubii	   caused	   82%	   of	   infections	   worldwide;	   while	   C.	   neoformans	   var.	  neoformans	  was	  attributed	  to	  20%-­‐30%	  of	  CM	  cases	  in	  HIV	  patients	  in	  northern	  Europe	  [60].	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EPIDEMIOLOGY	  	  Infection	  begins	  upon	   inhalation	  of	  basidiospores	  and	  encapsulated	  yeasT-­‐cells	  from	   the	   environment	   (Fig.	   2)	   [61],	   triggering	   the	   innate	   immune	   system.	  Macrophages	   play	   an	   integral	   role	   in	   anti-­‐cryptococcal	   defense,	   with	   alveolar	  macrophages	  acting	  as	  first	  responders	  in	  the	  lungs	  where	  they	  detect	  and	  engulf	  cryptococcal	  spores	  [62,	  63].	  As	  intracellular	  pathogens,	  cryptococci	  are	  capable	  of	   survival	   and	   replication	   within	   host	   macrophages	   [64,	   65];	   the	   spores	  germinate	  and	  lead	  to	  a	  localized	  lung	  infection,	  which	  later	  disseminates	  to	  the	  Central	  Nervous	  System	  (CNS)	  [66],	  leading	  to	  the	  development	  of	  Cryptococcal	  Meningoencephalitis	   [67,	  68].	   It	  has	  been	  shown	   that	  non-­‐engulfed	  cryptococci	  gain	  entry	   into	   the	  CNS	  by	  utilizing	   the	  virulence	   factor	  urease,	   and	  a	   secreted	  metalloprotease	  to	  transmigrate	  into	  the	  CNS	  [69,	  70];	  whereas	  the	  mechanism	  of	   transport	   of	   phagocytosed	   yeasts	   across	   the	   blood-­‐brain	   barrier	   (BBB),	   is	  thought	   to	   occur	   via	   the	   “Trojan	   Horse	   Model”	   [66,	   71].	   Recent	   evidence	   in	  support	  of	  the	  latter	  route	  of	  transmigration	  has	  also	  revealed	  a	  higher	  expulsion	  rate	  of	  C.	  neoformans	  than	  C.	  gattii	  from	  human	  macrophage-­‐like	  cell	  line	  (THP-­‐1)	  across	  an	  In	  vitro	  model	  of	  the	  BBB	  [66].	  This	  finding	  potentially	  describes	  the	  higher	  risk	  of	  developing	  CM	  due	  to	  C.	  neoformans	  infections	  rather	  than	  C.	  gattii.	  Thus,	   timing	   of	   recruitment	   and	   activation	   of	   inflammatory	   cells	   in	   the	   brain	  following	  Cryptococcus	  neoformans	  migration,	  plays	  a	  crucial	  role	  in	  determining	  the	   outcome	   of	   disease	   [72].	   Hosts	   with	   intact	   immune	   systems	   mount	   an	  immune	  response	  that	  leads	  to	  clearance	  of	  the	  infection,	  or	  the	  establishment	  of	  a	   latent,	   asymptomatic	   infection	   accompanied	   by	   the	   formation	   of	  cryptococcomas.	   Patients	  with	   impaired	   cell-­‐mediated	   immunity	   are	   unable	   to	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effectively	  clear	  C.	  neoformans.	  Therefore,	  effective	  innate	  immune	  activation	  and	  a	  sufficient	  inflammatory	  response	  is	  key	  to	  the	  control	  of	  cryptococcosis.	  	  	  	  
	  
Figure	  3-­‐	  The	  epidemiology	  of	  cryptococcosis.	  Cryptococcal	  spores	  are	  inhaled	  from	  environmental	  
sources	  such	  as	  tree	  bark	  and	  bird	  guano,	  causing	  a	  pulmonary	  infection.	  Disseminated	  infections	  in	  
the	  central	  nervous	  system	  lead	  to	  Cryptococcal	  meningitis.	  
	  It	   is	  currently	  assumed	  that	  a	  primary	  cryptococcal	   infection	  may	  occur	  during	  childhood,	   followed	  by	   a	   period	  of	   dormancy;	   reactivation	   then	  occurs	   later	   in	  life	   during	   immunosuppression	   [73].	   However,	   there	   is	   much	   debate	  surrounding	  latency	  and	  reactivation	  of	  cryptococcal	  infections.	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LIFE	  CYCLE	  AND	  MATING	  TYPES	  	  
Cryptococcus	  is	  a	  bipolar	  heterothallic	   fungus	  that	  exists	  as	   two	  haploid	  mating	  types,	   MATa	   and	   MATα	   (Fig.	   4)	   [37,	   74].	   The	   yeast	   is	   able	   to	   undergo	   sexual	  reproduction	  as	  well	  as	  haploid	  fruiting	  in	  order	  to	  produce	  basidiospores.	  	  	  Both	   mating	   types	   undergo	   budding	   and	   propagate	   asexually.	   When	   they	   are	  within	  proximity	  of	   each	  other,	  MATα	  and	  MATa	   cells	   release	   the	  pheromones	  MFα	   and	   MFa	   respectively	   [37].	   This	   exchange	   of	   pheromones	   induces	   the	  development	  of	  conjugation	  tubes	  in	  MATα	  cells,	  and	  isotropic	  growth	  in	  MATa	  cells.	   When	   the	   conjugation	   tubes	   fuse	   with	   the	   swollen	   MATa	   cells,	  heterokaryotic	  hyphae	  develop,	  followed	  by	  the	  formation	  of	  basidia	  at	  their	  tips.	  Meiotic	   division	   takes	   place	   after	   the	   fusion	   of	   the	  MATa	   and	  MATα	   nuclei	   to	  produce	  haploid	  spores	  [45].	  	  	  
	  
Figure	  4-­‐	  adapted	  from	  [38]	  The	  heterothallic	  life	  cycle	  of	  Cryptococcus.	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  The	   MATα	   mating	   type	   is	   more	   common	   in	   nature,	   and	   constitutes	  approximately	   99.9%	   of	   all	   Cryptococcus	   clinical	   isolates;	   However,	   MATa	   has	  been	   found	   to	  occur	  at	   a	  higher	   frequency	   (up	   to	  10%	  of	   isolates)	   in	  Southern	  Africa	   [75],	   which	   is	   currently	   considered	   the	   evolutionary	   home	   of	   C.	  
neoformans	   [76].	   Litvintseva	   et	  al.,	   first	   suggested	   an	   “out	   of	   Africa”	  model	   via	  which	   the	  global	  VNI	  population	  arose	   from	  an	  African	  VNI	  ancestor	  dispersed	  through	  pigeon	  migration	  [76].	  This	  model	  was	  later	  supported	  by	  findings	  from	  [77]	   and	   [78]	   that	   showed	   lower	   genetic	   diversity	   of	   VNI	   populations	   in	  Southeast	  Asia	  and	  South	  America,	  respectively.	  	  	  	  	  
VIRULENCE	  FACTORS	  
THE	  CRYPTOCOCCUS	  CAPSULE	  The	  C.	  neoformans	   capsule	   is	   the	  most	   extensively	   studied	   in	   comparison	  with	  other	   fungal	   capsules.	   Observable	   either	   by	   staining	   with	   India	   ink	   (Fig.	   1b),	  scanning	   electron	   microscopy,	   or	   fluorescence;	   the	   capsule	   was	   the	   first	  distinguishable	  feature	  in	  identifying	  Cryptococcus	  neoformans	  isolates.	  	  This	   structure	   plays	   a	   critical	   role	   in	   the	   establishment	   and	   progression	   of	  cryptococcosis	  [79],	  mediating	  host	  responses	  to	  infection	  and	  immune	  evasion	  and	  modulation	   through	   interactions	  with	   various	   components	   of	   the	   immune	  system	  [80,	  81].	  Capsule	  growth	   is	  coordinated	  with	  cell	  cycle	  progression	   [82,	  83],	   and	   distal	   growth	   has	   been	   shown	   to	   occur	   in	   response	   to	   mammalian	  serum	   [84],	   triggering	   the	   formation	   of	   gianT-­‐cells,	   large	   enough	   to	   escape	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uptake	  by	  phagocytes	  [85].	  The	  capsule	  also	  facilitates	  intracellular	  survival	  of	  C.	  
neoformans	  by	  enabling	  it	  to	  evade	  killing	  by	  reactive	  oxygen	  species	  released	  by	  host	  immune	  cells	  [86].	  	  	  The	  C.	  neoformans	  capsule	  is	  composed	  of	  polysaccharides,	  which	  make	  it	  highly	  hydrophilic	  [87].	  These	  can	  be	  found	  mainly	  attached	  to	  the	  yeast’s	  cell	  wall,	  or	  within	  the	  extracellular	  matrix,	  where	  they	  are	  actively	  being	  transported	  from	  the	   inside	   of	   the	   cells	   in	   vesicles	   (Fig.1a)	   [88].	   The	   polysaccharides	   associated	  with	   capsular	   formation	   include	   glucuronoxylomannan	   (GXM),	   which	  comprises	   90-­‐95%	   of	   the	   entire	   capsule	   (Fig.	   1a),	   and	   galactoxylomannan	  (GXMGal),	   in	   lower	   proportions	   of	   5-­‐8%	   [89,	   90].	   Recent	   evidence	   has	  shown	  that	  GXM	  in	  particular,	  plays	  a	  crucial	  role	  early	  on	  in	  the	  infection	  by	  acting	  as	  an	  anti-­‐phagocytic	  cloak	  for	  C.	  neoformans	  [91];	  and	  allows	  cryptococci	  to	  modulate	  host	  immune	  responses	  at	  different	  stages	  of	  infection,	  which	  will	  be	  discussed	  below.	  The	  capsule	  may	  also	  contain	  mannan,	  xylose,	  hyaluronic	  acid,	  sialic	   acid	   and	   glucoronic	   acid	   residues	   at	   varying	   ratios	   [37,	   92,	   93].	   The	  glucoronic	  acid	  residues	  confer	  a	  strong	  negative	  charge	  on	  the	  capsule	  structure	  [94],	   while	   Glucosylceramides	   (GlcCer)	   are	   involved	   in	   the	   regulation	   of	  virulence	  in	  C.	  neoformans	  [95].	  	  	  Capsule	   structure	   varies	   depending	   on	   strain,	   stage	   of	   disease,	   and	   molecular	  subtype.	   The	   existence	   of	   these	   polysaccharide	   components	   in	   different	   ratios	  within	   the	   cryptococcal	   capsule	   confers	   chemotype	   variability,	   a	   defining	  characteristic	   of	   each	   Cryptococcus	   serotype	   [96-­‐98].	   Acapsular	   C.	   neoformans	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mutants	   have	   been	   shown	   to	   be	   less	   virulent	   than	   wild-­‐type	   and	   capsule-­‐reconstituted	  strains	  [99],	  however,	  non-­‐encapsulated	  yeast	  cells	  have	  also	  been	  shown	   to	   successfully	   infiltrate	   immunocompromised	   individuals	   and	   bring	  about	   disease,	   suggesting	   the	   involvement	   of	   additional	   virulence	   factors	   in	  maintaining	  proliferation	  and	  dissemination	  within	  the	  host	  [2].	  	  
	  
MELANIN	  FORMATION	  AND	  LACCASE	  PRODUCTION	  	  A	   number	   of	   fungal	   species	   produce	   and	   deposit	   the	   pigment	   melanin	   within	  their	  cell	  walls	  as	  a	  form	  of	  protection	  from	  environmental	  stress.	  C.	  neoformans	  produces	  a	  particular	  type	  of	  melanin	  –	  eumelanin-­‐	  	  in	  the	  presence	  of	  diphenolic	  and	   polyphenolic	   molecules	   such	   as	   L-­‐DOPA	   [100];	   and	   in	   response	   to	   host	  defenses	  during	  infection	  [101].	  This	  phenotypic	  characteristic	  was	  also	  used	  as	  a	   diagnostic	   tool	   for	   identification	   of	   Cryptococcus	   species	   [102].	   Melanin	   was	  identified	   as	   a	   virulence	   factor	   when	   melanin-­‐lacking	   C.	   neoformans	   mutants	  were	  shown	  to	  be	  less	  virulent	  than	  their	  melanin	  producing	  counterparts	  [103].	  This	   feature	  has	  since	  been	  reported	  to	  provide	  the	  yeast	  with	  protection	  from	  antifungal	  drugs	  [37].	  	  Pigment	  production	   is	   reliant	  on	   the	  presence	  of	   the	   cell	  wall	   enzyme,	   laccase,	  which	  is	  responsible	  for	  oxidizing	  phenolic	  compounds	  and	  iron	  [104].	  A	  number	  of	   additional	   genes,	   transcription	   factors,	   pathways	   and	   enzymes	   involved	   in	  copper	   transport,	   chitin	   synthesis	   and	   chromatin	   remodeling	   contribute	   to	  melanin	  formation	  [37,	  105].	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  Aside	   from	   its	   role	   in	   melanin	   formation,	   laccase	   acts	   as	   an	   independent	  virulence	   factor	   [106],	   providing	   C.	   neoformans	   protection	   from	   killing	   by	  alveolar	  macrophages	  via	  its	  iron	  oxidase	  activity	  [107].	  C.	  neoformans	  	  produces	  two	  copies	  of	  the	  laccase	  enzyme:	  CNLAC1	  and	  CNLAC2;	  expressed	  by	  the	  LAC1	  and	   LAC	   2	   genes,	   respectively.	   Of	   the	   two,	   CNLAC1	   is	   the	   most	   abundantly	  expressed	  form	  of	  the	  enzyme	  and	  is	  solely	  involved	  in	  virulence	  and	  protection	  of	   Cryptococcus	   neoformans	   [104].	   Laccase	   also	   plays	   a	   role	   in	   signaling	   [64].	  Sabiiti	  et	  al.	  analyzed	  sixty-­‐five	  C.	  neoformans	  isolates	  from	  clinical	  trial	  patients	  with	  matched	   clinical	   data	  were	   assayed	   in	   vitro,	   and	   found	   that	   isolates	  with	  greater	   laccase	   activity	   were	   more	   resistant	   to	   clearance	   following	   antifungal	  treatment,	  and	  more	  likely	  to	  survive	  ex	  vivo	  in	  purified	  CSF,	  highlighting	  a	  role	  for	   laccase-­‐dependent	   melanin	   pathways	   in	   determining	   patient	   clinical	  outcomes	  [64].	  	  	  
OTHER	  VIRULENCE	  FACTORS	  	  A	   number	   of	   other	   features	   allow	   Cryptococcus	   neoformans	   and	   Cryptococcus	  
gattii	   to	   thrive	   as	   human	   pathogens,	   in	   additional	   to	   the	   virulence	   factors	  mentioned	  above.	  Unlike	  other	  cryptococcal	  species,	  C.	  neoformans	  and	  C.	  gattii	  are	  able	  to	  grow	  at	  37	  °C,	  rendering	  the	  mammalian	  host	  an	  ideal	  physiological	  environment	  for	  the	  yeasts	  [105].	  C.	  neoformans	  produces	  degradation	  enzymes	  that	  support	  its	  pathogenicity.	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The	   two	   best-­‐established	   cryptococcal	   hydrolytic	   enzymes	   are	   urease	   and	  phospholipase	   B	   (PLB).	   Phospholipase	   B	   has	   been	   shown	   to	   enhance	   yeast	  adherence	   to	   lung	   epithelial	   cells	   during	   the	   early	   stages	   of	   infection	   [108];	  increase	   uptake	   by	   phagocytes	   and	   survival	   within	   macrophages	   through	   the	  production	   of	   eicosanoids	   from	   macrophage-­‐secreted	   arachidonic	   acid	   [109];	  improves	   dissemination	   across	   the	   BBB[37,	   71];	   and	   improves	   intracellular	  proliferation	  and	   control	   titan	   cell	  morphology	   [110].	  Cryptococcal	  urease	  also	  plays	   a	   role	   in	   virulence	  by	  promoting	  Type	  2	   (Th2)	   immune	   responses	   in	   the	  host,	   rather	   than	   Th1	   fungicidal	   responses	   [111,	   112]	   and	   facilitating	   fungal	  invasion	  of	  the	  CNS	  by	  increasing	  transmigration	  sites	  at	  the	  BBB	  [113,	  114].	  	  More	   recent	   molecular	   genetic	   studies	   have	   recognized	   genes	   that	   mediate	  mammalian	   infection	   [115];	  Confer	  hypersensitive	   to	   fluconazole	  and	  oxidative	  stress	   [116];	   express	   proteins	   essential	   for	   growth	   at	   high	   temperature	   [117];	  and	   code	   for	   transcription	   factors	   that	   control	   complex	   developmental	   events,	  linking	   fungal	   development	   and	   virulence	   [118].	   A	   unique	   group	   of	   proteins	  involved	   in	   Cryptococcus	   virulence	   have	   also	   been	   identified	   in	   a	   study	  comparing	  the	  protein	  secretomes	  of	  virulent	  and	  non-­‐virulent	  strains	  [119].	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MACROPHAGE	  INTERACTIONS	  WITH	  CRYPTOCOCCUS	  SPP.	  	  	  A	   number	   of	   human	   fungal	   pathogens	   such	   as	   Candida	   albicans,	   Aspergillus	  
fumigatus	   and	   Cryptococcus	   neoformans	   have	   evolved	   various	   strategies	   of	  avoiding	  death	  including	  evasion	  of	  engulfment	  by	  phagocytes	  and	  intracellular	  parasitism	   [120].	   Pathogenicity	   of	   C.	   neoformans	   toward	   the	   human	   host	   is	  thought	  to	  have	  evolved	  from	  the	  yeast’s	  ability	  to	  protect	   itself	   from	  killing	  by	  its’	   ancestral	   predators	   and	   environmental	   phagocytes	   –	   amoebae	   such	   as	   D.	  
discoideum	   [57,	   58].	   Recent	   findings	   by	   Watkin’s	   et	   al.	   show	   that	   like	  macrophages,	   the	   amoeba	   was	   unable	   to	   kill	   C.	   neoformans;	   and	   that	   other	  processes	   such	   as	   vomocytosis	   (described	  below)	  of	   the	   yeast	  were	   conserved	  between	  hosts	  and	  amoebae	  [57].	  This	  emphasizes	  the	  role	  of	  macrophages	  as	  a	  crucial	   factor	   in	   understanding	   the	   facultative	   intracellular	   abilities	   of	  
Cryptococcus	  neoformans	  [121-­‐124].	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Figure	   5.	   Immune	   responses	   leading	   to	   either	   fungal	   clearance,	   of	   disseminated	   cryptococcal	  
disease.	   	  Macrophages	  recognize	  and	  engulf	  Cryptococcus	  spp.	  and	  present	  cryptococcal	  antigen	  to	  
T-­‐cells.	  This	  leads	  to	  the	  activation	  of	  naïve	  T-­‐cells	  that	  develop	  into	  Th1,	  Th17	  or	  Th2	  CD4+	  T-­‐cells.	  
Th1	  and	  Th17	  T-­‐cells	  release	   IFN-­‐γ 	  and	   IL-­‐17,	  respectively,	   to	  generate	  classically	  activated	  (M1)	  
macrophages	   that	   aid	   in	   fungal	   clearance.	   Th2	   T-­‐cells	   release	   IL-­‐4	   and	   IL-­‐13	   to	   generate	  
alternatively	  activated	  macrophages	  (M2)	  that	  enable	  cryptococcal	  dissemination.	  
	  	  Macrophage	   activation	   states	   directly	   influence	   the	   control	   of	   cryptococcosis.	  Classically	  activated	  macrophages	  are	  triggered	  by	  Th1-­‐type	  CD4+	  T-­‐cells	   [125-­‐127]	   that	   produce	   interferon-­‐γ	   (IFN-­‐γ),	   and	   direct	   macrophages	   to	   release	  proinflammatory	   cytokines	   and	   chemokines	   when	   activated	   by	  lipopolysaccharide	   (LPS)	  and	   IFN-­‐γ	   [127-­‐129];	   concluding	   in	   the	  production	  of	  nitric	   oxide	   (NO),	   a	   crucial	   factor	   in	   macrophage	   elimination	   of	   intracellular	  pathogens	   [9].	   M1	   responses	   have	   been	   associated	   with	   increased	   fungal	  clearance	   (Fig.	   5)	   and	   with	   enhanced	   signaling	   of	   the	   activation	   of	   signal	  transducer	  and	  activators	  of	   transcription1	  (STAT1)	  of	   the	   Janus	  kinase	   (JAK)/	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(STAT)	   pathway	   [130,	   131],	   that	   mediates	   the	   release	   of	   pro-­‐inflammatory	  cytokines,	   reactive	   oxygen	   (ROS)	   and	   nitrogen	   species	   such	   as	   NO	   [132].	  Cytokines	  released	  by	  M1	  macrophages	   include	  (TNF-­‐α,	   IL-­‐1α,	   IL-­‐1β,	  and	  IL-­‐6);	  Th1	  cytokines	  (IFN-­‐γ	  and	  IL-­‐12);	  and	  Th17	  cytokines	  (IL-­‐17A	  and	  IL-­‐22)	  [133].	  	  	  Conversely,	   M2	   macrophages	   are	   triggered	   by	   Th2-­‐type	   CD4+	   T-­‐cells	   [7,	   12].	  They	   produce	   anti-­‐inflammatory,	   Th2	   cytokines	   (IL-­‐4	   and	   IL-­‐13)	   and	   have	  widely	   been	   associated	   with	   mediating	   immune	   responses	   to	   helminth	  infections,	  as	  well	  as	  tissue	  repair	  [12].	  Alternatively	  activated	  macrophages	  are	  characterized	   by	   expressing	   cell	   surface	   markers	   like	   Fizz1	   (Found	   in	  Inflammatory	   Zone	   1),	   chitinase-­‐like	   protein	   (Ym1),	   CD36	   (fatty	   acid	  translocase),	  and	  CD206	  [7].	  In	  contrast	  to	  classically	  activated	  macrophages,	  M2	  cells	  produce	  of	  low	  levels	  of	  IL-­‐12	  and	  iNOS,	  and	  culminate	  in	  the	  induction	  of	  arginase	  1	  (Arg1)	  [7,	  12].	  	  M2	   macrophage	   responses	   have	   been	   associated	   with	   reduced	   cryptococcal	  clearance	   and	   increased	   intracellular	   yeast	   proliferation	   (Figure	   4)	   [132,	   134,	  135].	  There	  is	  evidence	  that	  suggests	  C.	  neoformans	  prompts	  the	  release	  of	  anti-­‐inflammatory	  cytokines	   that	  aid	  survival	  within	   the	  host	  cell	   [134].	   In	  a	  mouse	  model,	   pulmonary	   infection	   revealed	   that	   higher	   fungal	   burden	   and	  dissemination	   was	   associated	   with	   Th2	   type	   responses	   and	   an	   M2	   cytokine	  profile	  (including	  IL-­‐4,	  IL-­‐5,	  IL-­‐10,	  and	  IL-­‐13)	  that	  rendered	  hosts	  vulnerable	  to	  severe	  disease	  and	  mortality	  [134].	  It	  has	  also	  been	  suggested	  that	  defects	  in	  the	  STAT1	  signal	  transduction	  pathway	  may	  promote	  M2	  macrophage	  activation	  and	  decreased	   killing	   of	   cryptococci.	   Infection	   of	   STAT1-­‐/-­‐	   mice	   with	   an	   IFN-­‐γ	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producing	  strain	  of	  C.	  neoformans	  showed	  decreased	  expression	  of	  M1	  activation	  markers,	  along	  with	  an	  enlarged	  M2	  macrophage	  population	  that	  correlated	  with	  decreased	  nitric	  oxide	  (NO)	  production	  and	  high	  mortality	  rates	  [131].	  	  	  However,	   the	  broad	   categorization	  of	  macrophages	   into	   two	  distinct	   activation	  states	   is	   not	   representative	   of	   the	   plasticity	   in	   gene	   expression	   that	   regulates	  macrophage	  activation	  markers	   in	  vivo	   [9].	  A	  number	  of	  studies	  have	   identified	  macrophage	  subpopulations	  that	  express	  both	  M1	  and	  M2	  markers	  of	  activation	  in	   different	   proportions;	   which	   influenced	   macrophage	   elimination	   of	  intracellular	   pathogens.	   Arora	   et	   al.	   analyzed	   cytokine	   profiles	   and	   compared	  macrophage	  activation	  status	  in	  C.	  neoformans-­‐infected	  wild-­‐type,	  IL-­‐4	  knockout	  (IL-­‐4	   -­‐/-­‐),	   and	   IFN-­‐γ	   knockout	   C57BL/6	   mice	   [135].	   The	   group	   showed	   that	  cytokine	  expression	   in	   infected	  WT	  mice	   interchanged	  between	  a	  Th1	  and	  Th2	  bias	  based	  on	  the	  IFN-­‐γ:IL-­‐4	  ratio	  that	  mediates	  macrophage	  polarization	  states.	  The	  group	  also	  identified	  macrophages	  that	  displayed	  both	  M1	  and	  M2	  markers	  of	  activation,	  as	  well	  as	  expressing	  iNOS	  and	  Arg-­‐1.	  In	  addition,	  they	  showed	  that	  concurrent	  stimulation	  with	  both	  IL-­‐4	  and	  IFN-­‐γ	  lead	  to	  the	  upregulation	  of	  both	  M1	   and	   M2	   cytokines	   in	   the	   same	   cells	   [135].	   These	   results	   highlight	   the	  interplay	   between	   macrophage	   activation	   states,	   and	   how	   this	   plasticity	   may	  impact	  the	  progression	  and	  outcome	  of	  C.	  neoformans	  infections.	  	  	  Among	   the	  PRRs,	  Toll-­‐like	   receptors	   (TLRs)	  are	   the	  best	   characterized	  and	  are	  responsible	  for	  the	  regulation	  of	  signaling	  pathways	  including	  nuclear	  factor-­‐κB	  (NF-­‐κB)	   and	  mitogen-­‐activated	   protein	   kinases	   (MAPKs)[136,	   137].	   The	   CD14	  receptor	  in	  association	  with	  TLR4,	  and	  TLR2	  [138]	  recognize	  cryptococcal	  GXM,	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driving	  localized	  immune	  recognition	  and	  enhanced	  phagocytosis	  [62,	  139-­‐141].	  Yauch	   et	   al.	   showed	   that	   MyD88-­‐deficient	   mice	   showed	   significantly	   reduced	  survival	  rates	  in	  comparison	  to	  wild-­‐type	  C57BL/6	  mice	  following	  intranasal	  and	  intravenous	   infection	   with	   C.	   neoformans;	   while	   CD14-­‐deficient	   mice	   only	  showed	   reduced	   survival	   following	   intravenous	   infection;	   and	   TLR2-­‐deficient	  mice	   were	   susceptible	   to	   intranasal	   infection	   [141].	   However,	   they	   observed	  similar	  mortality	  in	  TLR4-­‐deficient	  C3H/HeJ	  mice	  and	  control	  C3H/HeOuJ	  mice;	  excluding	  the	  involvement	  of	  TLR4	  in	  cryptococcal	  clearance.	  Further	  analysis	  of	  CD14−/−,	   TLR2−/−,	   and	  MyD88−/−	  mice	   showed	   no	  major	   differences	   in	   Th2	  cytokine	   production	   in	   comparison	   to	   wild	   type	   mice.	   They	   also	   showed	   that	  MyD88-­‐deficient	  mice	  exhibited	  increased	  numbers	  of	   lung	  CFU	  and	  serum	  and	  lung	  GXM	  levels	  in	  comparison	  with	  other	  knock	  out	  mice;	  which	  correlated	  with	  decreased	   survival	   of	   these	   mice	   [141].	   Shoham	   et	   al.	   transfected	   Chinese	  hamster	   ovary	   fibroblasts	  with	   human	   TLR2,	   TLR4,	   and/or	   CD14	   and	   showed	  that	   TLR4	   and	   CD14	   interacted	   with	   fluorescently	   labeled	   cryptococcal	   GXM	  [138].	   They	   also	   constructed	   an	   NFκB-­‐dependent	   reporter	   to	   evaluate	   nuclear	  translocation	  of	  NFκB	  via	  this	  interaction.	  The	  group	  showed	  that	  GXM	  activated	  Chinese	   hamster	   ovary	   fibroblasT-­‐cells,	   PBMC	   and	   RAW	   264.7	   cells	   that	   had	  been	   transfected	   with	   TLR4	   and	   CD14,	   and	   induced	   nuclear	   translocation	   of	  NFκB.	   However,	   this	   interaction	   was	   unable	   to	   activate	   MAPK	   pathways,	   nor	  induce	  TNF-­‐α	  production	  [138].	  	  The	   nuclear	   factor-­‐κB	   (NFκB)	   is	   a	   family	   of	   transcription	   factors,	   capable	   of	  modulating	   the	   expression	   of	   cytokines.	   Members	   of	   this	   family	   include	   RelA	  (p65),	  NFκB	  1	  (p50),	  NFκB2	  (p52),	  c-­‐Rel	  and	  RelB	  [142].	  The	  nuclear	  factor-­‐κB	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(NFκB)-­‐dependent	  pathway	  is	  activated	  following	  triggering	  of	  TLRs,	  and	  results	  in	  the	  expression	  of	  inflammatory	  Th1	  cytokines	  (such	  as	  TNF-­‐α,	  IL-­‐1β,	  and	  IFN-­‐γ;	  Fig.	  6)	  and	  the	   induction	  of	   iNOS	  expression	   in	  attempts	  to	  kill	   the	  pathogen	  [143,	  144]	  [145,	  146]	  .	  Upon	  activation	  of	  TLR4,	  the	  cytoplasmic	  adapter	  protein	  (MyD88)	  recruits	  the	  serine–threonine	  kinases	  IRAK1	  and	  IRAK4,	  in	  association	  with	   tumor	   necrosis	   factor	   receptor-­‐associated	   factor	   (TRAF6).	   Activation	   and	  phosphorylation	  of	  TRAF6	  results	  in	  the	  activation	  of	  NFκB-­‐inducing	  kinase	  and	  the	   subsequent	   activation	   of	   inhibitory	   protein	   kappa	   B	   (IκB)	   kinase.	   IκB	   is	   a	  cytoplasmic	  protein	  that	  constitutively	  binds	  to	  the	  NFκB,	  which	  is	  composed	  of	  two	   subunits,	   p50	   and	   p65	   [12].	   Activation	   of	   IκB	   dissociates	   it	   from	   NFκB,	  allowing	   for	   the	  nuclear	   translocation	  of	  NFκB	  and	   initiating	   the	   expression	  of	  proinflammatory	   cytokines	   [147].	   	   The	  p50	   and	  p65	  NFκB	   subunits	   have	  been	  shown	   to	   play	   different	   roles	   in	   the	   induction	   of	   anti-­‐inflammatory	   and	   pro-­‐inflammatory	  cytokines,	  respectively	  [142].	  The	  p50	  subunit	  has	  been	  shown	  to	  induce	   the	   expression	   of	   IL-­‐10;	   mice	   lacking	   the	   p50	   subunit	   were	   more	  susceptible	   to	   lethal	   endotoxemia,	   and	   macrophages	   derived	   from	   these	   mice	  produced	  reduced	  levels	  of	  IL-­‐10,	  and	  increased	  production	  of	  TNF-­‐α	  and	  IL-­‐12	  following	  exposure	  to	  LPS	  [142].	  Conversely,	  the	  p65	  subunit	  of	  NFκB	  has	  been	  associated	  with	   the	  expression	  of	  pro-­‐inflammatory	   cytokines	   like	  TNF-­‐α	   [148,	  149];	  and	  iNOS	  [150].	  However,	  optimal	  production	  of	  TNF-­‐α	  requires	  a	  cohort	  of	   pathways	   including	   mitogen-­‐activated	   protein	   kinase	   (MAPK)	   cascades,	   the	  extracellular	   signal-­‐regulated	   kinase	   (ERK),	   p38	   MAPK,	   and	   stress-­‐activated	  protein	  kinase	  (SAPK)/c-­‐JUN	  N-­‐terminal	  kinase	  (JNK)[151]	  [138].	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Additionally,	   the	  NFκB	   pathway	   can	   be	  modulated	   by	   both	   shed	  GXM	   and	   live	  cryptococci	  via	  different	  mechanisms	  depending	  on	  the	  stage	  of	  infection	  [152].	  Early	   on	   in	   pulmonary	   infection,	   GXM	   acts	   as	   an	   anti-­‐phagocytic	   cloak	   for	   C.	  
neoformans	   [91].	   Following	   ingestion	   by	  macrophages,	   cryptococci	   continue	   to	  produce	  and	  shed	  the	  polysaccharide	  [91],	  which	  has	  been	  shown	  to	  reduce	  LPS-­‐associated	   proinflammatory	   cytokine	   responses	   both	   in	   vitro	   [153]	   and	   in	   a	  murine	  infection	  model	  by	  inhibiting	  MyD88	  activation	  following	  its	  interaction	  with	  the	  FcγRIIB	  receptor	  (Fig.	  6)	  [153,	  154].	  Furthermore,	  Hayes	  et	  al.	  recently	  showed	   in	   RAW	   264.7	   murine	   macrophages	   that	   extracellular	   GXM	   inhibited	  LPS-­‐induced	   nuclear	   translocation	   of	   the	   p65	   protein,	   while	   intraphagosomal	  GXM	   increased	   the	   duration	   of	   nuclear	   translocation	   of	   the	   p65	   and	   IκBα	  proteins,	  consequentially	  eliminating	  the	  expression	  of	  TNFα	  or	  inducible	  nitric	  oxide	  synthase	  (iNOS)	  [152].	  	  	  Thus,	   the	   interplay	   between	   Th1	   and	   Th2	   host	   responses	   during	   cryptococcal	  infection	   is	   a	   major	   determinant	   of	   disease	   outcome	   [135,	   155].	   Host	  susceptibility	   studies	   in	   mice	   have	   shown	   that	   production	   of	   the	   Th1-­‐type	  cytokines	   IFN-­‐γ	   and	   IL-­‐12,	   as	   well	   as	   the	   pro-­‐inflammatory	   cytokine	   TNF-­‐α	  confers	  protection	  against	  cryptococcosis	  [156-­‐160].	  GXM	  has	  also	  been	  shown	  to	   directly	   inhibit	   T-­‐cell	   proliferation	   in	   mice,	   leading	   to	   dampened	   Th1	  responses	  and	  diminished	  resolution	  of	  the	  infection	  [161].	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  Fig.	  6	  (above)	  shows	  the	  classical	  and	  alternative	  activation	  pathways	  that	   lead	  to	   M1	   and	   M2	   macrophages,	   respectively,	   during	   pulmonary	   cryptococcal	  infection.	   Based	   on	   early	   interaction	   of	   the	   fungus	  with	   alveolar	  macrophages,	  cryptococci	  will	   also	   encounter	   antigen-­‐specific	   antibodies,	   and	   T-­‐cells	   in	   lung	  tissue;	   additionally,	   complement-­‐	   and	   antibody-­‐mediated	   phagocytosis	   will	  occur	  primarily	  in	  the	  blood.	  	  However,	   it	   is	   important	   to	   note	   the	   difference	   in	   iNOS	   expression	   between	  human	  and	  mouse-­‐derived	  macrophages	  both	  in	  vivo	  and	  in	  vitro	  [162-­‐164],	  and	  
Figure	  6.	  illustration	  of	  pathways	  leading	  to	  either	  M1	  activated	  macrophages	  (left-­‐	  lighly	  shaded),	  or	  M2	  
activated	   macrophages	   (right-­‐	   dark	   shade)	   during	   pulmonary	   cryptococcal	   infection.	   M1	   activated	  
macrophages	  are	  marked	  by	  the	  production	  of	  pro-­‐inflammatory	  cytokines	  and	  nitric	  oxide	  (NO)	   leading	  
to	  pathogen	  destruction;	  while	  M2	  activated	  macrophages	  are	  marked	  by	  the	  release	  of	  anti-­‐inflammatory	  
pathogens	  and	  Arginase	  1,	  allowing	  cryptococcal	  cells	  to	  thrive	  and	  disseminate.	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controversy	  has	  emerged	  following	  disparities	  in	  data	  disproving	  or	  supporting	  the	   ability	   of	   human	   macrophages	   to	   express	   iNOS.	   Murray	   and	   Teitelbaum	  showed	  that	  L-­‐arginine-­‐dependent	  generation	  of	  reactive	  nitrogen	  intermediates	  (RNI)	  was	   species-­‐restricted	   to	  mice,	   and	   absent	   in	   human	  macrophages[164].	  Schneemann	  et	  al.	   also	   showed	   that	  human	  macrophages	   failed	   to	  produce	  NO	  despite	   activation	   with	   endotoxin,	   IFN-­‐γ,	   TNFα,	   G-­‐CSF,	   bacteria	   nor	   with	  proliferating	   lymphocytes	   [165],	   suggesting	   a	   lack	   of	   NO	   activity	   in	   human	  macrophages.	   Furthermore,	   a	   review	   by	   Murray	   discussed	   species-­‐specificity	  issues	  with	  iNOS,	  arginases,	  and	  NO	  production	  [9].	  Mycobacterium	  tuberculosis,	  an	   intracellular	   pathogen	   of	  macrophages,	   has	   also	   been	   shown	   to	   induce	   the	  expression	   of	   iNOS	   in	   human	   macrophages	   [166].	   Disparities	   arise	   between	  mouse	   and	   human	   macrophages	   in	   response	   to	   particular	   intracellular	  pathogens	   such	  as	  M.	  tuberculosis.	  Despite	   the	  establishment	  of	   iNOS	   induction	  and	  NO	  production	  in	  murine	  models	  of	  disease,	  M.	  tuberculosis	  is	  not	  pathogenic	  towards	  mice,	   suggesting	   that	  humans	  evolved	  pathways	  distinct	   from	  rodents	  as	   a	   selective	   pressure.	   This	   review	   emphasized	   the	   importance	   of	  understanding	   the	   differences	   and	   similarities	   in	   inflammatory	   responses	  between	  species,	  as	  this	  would	  affect	  the	  development	  of	  therapeutic	  compounds	  based	  on	  mouse	  models	  [9].	  In	  support	  of	  the	  author’s	  recommendations	  and	  in	  the	  context	  of	  cryptococcal	  disease;	  it	  would	  be	  paramount	  to	  establish	  variation	  in	   gene	   expression	   profiles	   between	   mouse	   and	   human	   macrophages	   both	   in	  
vitro	  and	  in	  vivo	  in	  order	  to	  draw	  accurate	  and	  reliable	  conclusions.	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VOMOCYTOSIS	  	  Aside	  from	  its	  ability	  to	  escape	  killing	  by	  host	  macrophages	  [167],	  Cryptococcus	  
neoformans	   is	   able	   to	  undergo	   ‘lateral	   transfer’	  between	  phagocytes	   [168],	   and	  non-­‐lytic	  escape	  (vomocytosis)	  [121],	  whilst	  maintaining	  its	  ability	  to	  propagate	  and	  disseminate	   further	  within	   the	  macrophages	   [169,	   170].	   	   This	  process	  has	  also	  been	  observed	  in	  other	  pathogenic	  fungi	  such	  as	  Candida	  albicans	  [171]	  and	  
Candida	   kruzei	   [172],	   and	   from	   mammalian	   phagocytes	   [173],	   avian	  macrophages	  [174],	  	  fish	  [175]	  and	  amoebae	  [57],	  suggesting	  that	  this	  extrusion	  phenomenon	  is	  evolutionarily	  conserved.	  	  	  Vomocytosis	  of	  C.	  neoformans	  has	  been	  confirmed	   in	  vivo	  within	  mice,	  and	  may	  possibly	   occur	   more	   frequently	   in	   vivo	   than	   in	   vitro	   [173].	   Furthermore,	  comparison	  of	  vomocytosis	  in	  a	  variety	  of	  cell	  lines	  has	  shown	  that	  vomocytosis	  of	   cryptococci	   from	  primary	  human	  macrophages	  occurs	  more	   frequently	   than	  from	  phagocytic	   cell	   lines	  [170].	  The	  current	  model	   for	   this	  non-­‐lytic	  extrusion	  event	  involves	  the	  fusion	  of	  the	  phagosome	  and	  plasma	  membranes,	  sometimes	  associated	   with	   an	   actin	   flash	   that	   has	   been	   shown	   to	   prevent	   cryptococcal	  expulsion	   within	   an	   ‘actin	   cage’	   that	   surrounds	   the	   phagolysosome	   [170,	  176].	   	  Host	   cell	   requires	   microtubule	   activity	   and	   the	   WASP	   (Wiskott–Aldrich	  syndrome	  protein)–Arp2/3	  (actin-­‐related	  protein	  2/3)	  pathway	  are	  involved	  in	  the	  formation	  of	  actin	  flashes,	  a	  process	  which	  can	  last	  anywhere	  from	  seconds	  to	  hours	  in	  efforts	  by	  the	  host	  cell	  to	  prevent	  cryptococcal	  expulsion	  [176].	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Interestingly,	   a	   number	   of	   studies	   have	   provided	   evidence	   that	   despite	   the	  formation	   of	   actin	   cages,	   host	   actin	   cytoskeleton	   is	   not	   required	   for	  vomocytosis	  [169,	  170,	  176].	  For	  example,	  Watkins	  et	  al.,	   recently	   showed	   that	  vomocytosis	   of	  C.	  neoformans	   from	   the	   phagocytic	   amoeba	  D.	  discoideum	   is	   an	  actin-­‐independent	  process	  [57].	  	  Whilst	  comprehension	  of	  the	  molecular	  mechanisms	  that	  govern	  the	  extrusion	  of	  
C.	  neoformans	  from	  macrophages	  remains	  to	  be	  gained,	  a	  number	  of	  studies	  have	  made	  considerable	  progress	  in	  resolving	  this	  process.	  	  	  The	   complement	   pathway	   plays	   a	   major	   role	   in	   initiating	   chemotaxis	   in	  phagocytic	   cells	   and	   boosting	   the	   engulfing	   abilities	   of	   macrophages	   [177];	  however,	   monoclonal	   antibodies	   can	   affect	   complement	   deposition	   on	   the	  cryptococcal	   capsule	  by	  both	   classical	   pathway	  activation	   and	   steric	  hindrance	  [178].	  Furthermore,	  complement-­‐opsonized	  cryptococci	  have	  been	  shown	  to	  exit	  the	  macrophage	  individually,	  while	  antibody-­‐opsonized	  yeasT-­‐cells	  are	  expelled	  as	   a	   cluster	   [167,	   179].	   The	   mode	   of	   opsonization	   (either	   via	   complement	   or	  antibody)	  has	  been	  shown	  to	  affect	  the	  rate	  of	  vomocytosis	  [180].	  Alvarez	  et	  al.	  showed	  that	  whilst	  phagocytosis	  of	  both	  complement-­‐	  and	  antibody-­‐opsonized	  C.	  
neoformans	   and	   C.	   gattii	   was	   followed	   by	   intracellular	   replication;	   antibody-­‐opsonised	  yeasT-­‐cells	  were	  vomocytosed	  in	  ‘biofilm-­‐like	  microcolonies’,	  whereas	  complement-­‐opsonised	   C.	   neoformans	   dispersed	   as	   individual	   cells	   following	  vomocytosis	   [180].	   The	   group	   found	   that	   antibody-­‐mediated	   phagocytosis	  resulted	  in	  reduced	  dispersal	  of	  C.	  neoformans	  cells,	  suggesting	  a	  more	  complex	  role	  for	  antibodies	  in	  anticryptococcal	  defence.	  In	  addition,	  vomocytosed	  yeasT-­‐
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cells	   contained	   the	   capsule-­‐bound	   antibody	   that	  was	   initially	   used	   to	   opsonize	  cryptococci,	   which	   showed	   that	   the	   mAb	   can	   remain	   bound	   following	  phagocytosis	   and	   phagosome	  maturation,	   and	   cause	   intracellular	   clustering	   of	  cryptococci.	   The	   authors	   speculated	   that	   antibody-­‐mediated	   vomocytosis	   may	  also	  occur	  in	  vivo	  [180].	  In	  cases	  of	  pulmonary	  infection,	  this	  event	  could	  reduce	  local	  dissemination	  and	  promote	  inflammatory	  responses	  against	  C.	  neoformans	  clusters.	  It	  is	  also	  likely	  that	  extracellular	  aggregated	  antibody-­‐bound	  yeasT-­‐cells	  may	   be	   phagocytosed	   by	   other	   cells	   following	   extrusion,	   or	   more	   readily	  accessible	  to	  antifungal	  drugs,	  enabling	  more	  effective	  clearance.	  	  In	   addition,	   treating	   J774	   and	   human	   primary	  monocyte-­‐derived	  macrophages	  with	   either	   Th1	   or	   Th2	   cytokines	   has	   been	   shown	   to	   alter	   the	   rate	   of	  vomocytosis	  [132].	  Voelz	  et	  al.,	  showed	  that	  treatment	  of	  macrophages	  with	  Th1	  cytokines	   IFN-­‐γ	   and	   TNFα,	   and	   the	   Th17	   cytokine	   IL-­‐17,	   did	   not	   significantly	  affect	  the	  vomocytosis	  of	  C.	  neoformans	  in	  comparison	  to	  untreated	  cell	  [132].	  In	  contrast	  treatment	  with	  Th2	  cytokines	  (IL-­‐4	  and	  IL-­‐13)	  considerably	  reduced	  the	  expulsion	  of	  the	  yeast	  from	  macrophages	  [132].	  	  Investigations	  by	  Chayakulkeeree	  et	  al.	  provided	  evidence	  that	  the	  cryptococcal	  virulence	   factor	   phospholipase	   B1	   (Plb1),	   and	   the	   protein	   required	   for	   Plb1	  secretion,	  Sec14-­‐1p,	  played	  an	  essential	  role	  in	  cryptococcal	  dissemination	  to	  the	  CNS	   and	   vomocytosis	   from	  murine	  macrophages	   [181].	  C.	  neoformans	  mutants	  lacking	  either	  Plb1	  or	  Sec14	  showed	  reduced	  virulence,	  dissemination	  to	  the	  CNS	  and	  vomocytosis	   in	  mouse	  models	   	   [181].	   In	  2016,	  Stukes	  et	  al.	   suggested	   that	  the	  membrane	  phospholipid	  binding	  protein,	  annexin	  A2	  (ANXA2)	  played	  a	  role	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in	   the	   phagocytosis	   and	   vomocytosis	   of	   C.	   neoformans;	   where	   macrophages	  derived	  from	  ANXA2-­‐deficient	  mice	  exhibited	  lower	  engulfment	  and	  expulsion	  of	  the	  yeast	  than	  wild	  type	  macrophages	  [182].	  	  More	   recently,	   the	   vomocytosis	   of	   C.	   neoformans	   was	   shown	   be	   under	   the	  inhibition	  of	  a	  MAP	  kinase,	  extracellular	  receptor	  kinase	  5	  (ERK5)	   [120].	  ERK5	  belongs	   to	   the	   group	   of	   extracellular	   signal-­‐regulated	   kinases	   (ERKs),	   also	  known	   as	  mitogen-­‐activated	   protein	   kinases	   (MAPKs),	   are	   involved	   in	   cellular	  proliferation,	  differentiation,	  migration,	  and	  gene	  expression.	  ERK5	   is	  activated	  through	   MEKK2/3	   and	   MEK5	   along	   the	   MAPK	   cascade.	   In	   macrophages,	  activation	  of	  the	  MAPK	  cascade	  occurs	  following	  induction	  with	  either	  bacterial	  LPS,	  or	  the	  proinflammatory	  cytokine	  TNFα	  [183].	  Gilbert	  et	  al.	  exposed	  primary	  human	  macrophages	  and	  J774	  cells	  to	  the	  ERK5	  inhibitor	  XMD17-­‐109,	  and	  noted	  significantly	   increased	   vomocytosis	   in	   both	   cell	   lines.	   They	   also	   showed	   that	  pharmacological	   inhibition	   or	   genetic	   manipulation	  significantly	   increased	  vomocytosis	   in	   primary	   human	   macrophages;	   and	   activation	   of	   the	   ERK5	  signalling	  pathway	  resulted	  in	  significant	  reductions	  in	  vomocytosis	  [184].	  These	  findings	  were	  also	  confirmed	  in	  vivo,	  were	  reducing	  ERK5	  activity	  in	  a	  zebrafish	  model	   encouraged	   vomocytosis,	   and	   reduced	   dissemination	   of	   infection	   was	  observed	  [184].	  	  Whilst	  the	  relevance	  of	  vomocytosis	  in	  disease	  progression	  is	  remains	  unclear;	  it	  is	   likely	   that	   vomocytosis	   of	   cryptococci	   from	   circulating	  monocytes	  would	   be	  left	   vulnerable	   to	   immune	   attack	   from	   other	   components	   of	   both	   innate	   and	  adaptive	   immunity.	   In	   cases	   of	   CNS	   involvement,	   reduced	   vomocytosis	   may	  
	   51	  
hinder	   cryptococcal	   dissemination	   into	   the	   brain	   via	   the	   Trojan	   Horse	   model.	  Hence,	   it	   is	   imperative	   that	   the	   molecular	   mechanisms	   that	   orchestrate	   the	  expulsion	  of	  this	  yeast	  from	  macrophages	  are	  characterized	  both	  in	  vitro	  and	  in	  
vivo.	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VARIATION	  IN	  HOST	  RESPONSES	  TO	  CRYPTOCOCCOSIS	  
EXPERIMENTAL	  MODELS	  OF	  CRYPTOCOCCOSIS	  	  A	  number	  of	  in	  vitro	  and	  in	  vivo	  experimental	  models	  have	  been	  designed	  to	  aid	  the	   study	   of	   cryptococcosis.	   These	   models	   take	   into	   account	   the	   cutaneous,	  pulmonary,	  and	  meningococcal	  forms	  of	  disease	  presentation.	  [185]	  
	  
In	  vitro	  cellular	  models	  for	  macrophages	  include	  the	  J774	  and	  RAW	  cell	  lines	  and	  primary	   cells	   (including	   bone-­‐marrow-­‐derived	   murine	   cells	   and	   peripheral	  blood	  monocyte-­‐derived	  human	  cells)	   [185].	  However,	   interactions	  of	  cell	   lines	  with	   Cryptococcus	   spp.	   have	   been	   shown	   to	   differ	   from	   each	   other.	   Primary	  human	  macrophages	  show	  significantly	  increased	  vomocytosis	  in	  comparison	  to	  J774	  cells	  [170].	  	  	  Several	  In	  vivo	  models	  are	  also	  employed	  in	  cryptococcal	  research.	  Invertebrate	  models	   include	   Caenorhabditis	   elegans,	   amoeboid	   models,	   and	   insect	   models	  such	   as	   Galleria	   mellonella	   and	   Drosophila	   melanogaster;	   while	   vertebrate	  models	   include	   mice	   (Mus	   musculus),	   rats	   (Rattus	   rattus),	   guinea	   pigs	   (Cavia	  
porcellus),	  rabbits	  (Oryctolagus	  cuniculus)	  and	  zebrafish	  (Danio	  rerio)	  [185].	  The	  majority	   of	   investigations	   are	   carried	   out	   in	  mice,	   due	   to	   the	   establishment	   of	  this	   model	   in	   medical	   research	   and	   the	   availability	   of	   a	   variety	   of	   genetic	  backgrounds.	  Interestingly,	  different	  mouse	  strains	  show	  varying	  susceptibilities	  to	   cryptococcal	   disease.	   For	   example	   CBA/J	   mice	   were	   shown	   to	   be	   more	  susceptible	  to	  C.	  neoformans	  infections	  than	  BALB/c	  mice	  [186].	  In	  contrast,	  rats	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represent	  ideal	  candidates	  for	  the	  study	  of	  C.	  gattii	  infections	  due	  to	  their	  natural	  susceptibility	   to	   pulmonary	   cryptococcosis	   [187].	  However,	   they	   are	   unable	   to	  clear	   C.	   neoformans,	   which	   causes	   more	   progressive	   and	   fatal	   disease	   in	   this	  model	   [188].	  More	   recently,	   zebrafish	   have	   gained	   traction	   as	   a	  model	   system	  due	  to	  parallels	  with	  mammalian	  pathogenesis	  of	  cryptococcosis	  [175,	  189],	  with	  the	   particular	   advantage	   of	   studying	   the	   establishment	   and	   maintenance	   of	  fungemia	  at	  a	  low	  cost,	  and	  large	  scale	  using	  mutagenesis,	  screening	  and	  live	  cell	  imaging	  methods	  [185,	  190].	  	  As	  discussed	  previously,	  species-­‐specific	  attributes	  of	  macrophages	  would	  need	  to	   be	   taken	   into	   consideration	   when	   describing	   responses	   to	   C.	   neoformans	  infections	   in	   vitro,	   in	   addition	   to	   the	   variation	   in	   responses	   by	   different	  macrophage	   lineages	   and	   tissue-­‐specificities.	   Additionaly,	   variation	   in	   the	  pathogenesis	   of	   cryptococcal	   disease	   in	   mice	   has	   been	   associated	   with	  differences	   in	   their	   innate	   and	   adaptive	   immune	   responses;	   hence,	   further	  characterization	  of	  intra-­‐species	  differences	  of	  in	  vivo	  models	  of	  cryptococcosis	  is	  also	  warranted.	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VARIATION	  IN	  HUMAN	  HOST	  RESPONSES	  TO	  CRYPTOCOCCOSIS	  	  Whilst	  early	  studies	  of	  the	  manifestations	  of	  cryptococcosis	  have	  shown	  clinical	  and	   prognostic	   differences	   between	   the	   infecting	   species	   [191],	   more	   recent	  investigations	  into	  the	  pathogenesis	  of	  C.	  neoformans	  in	  particular	  have	  revealed	  a	   critical	   role	   for	   host	   immune	   status	   in	   conferring	   protection	   from,	   or	  controlling	  disease	  progression	   towards,	  meningitis	   [192].	  This	  has	   lead	   to	   the	  division	   of	   C.	   neoformans	   patients	   into	   three	   groups:	   HIV-­‐associated;	   Non-­‐HIV	  immunocompromised	   patients;	   and	   ‘otherwise	   healthy’	   immunocompetent	  individuals.	  	  
	  
Immune	  responses	  in	  non-­‐immunocompromised	  individuals	  	  During	   the	   cryptococcosis	   outbreak	   in	   Vancouver	   2003	   that	   affected	   primarily	  non-­‐immunocompromised	   individuals,	   C.	   gattii	   was	   identified	   as	   a	   primary	  pathogen	  of	  the	  healthy.	  However,	  increased	  recognition	  of	  cryptococcosis	  cases	  due	   to	   C.	   neoformans	   in	   other	   immunocompetent	   patients	   provided	   strong	  evidence	   that	   this	   species	   also	   harbors	   capabilities	   as	   a	   primary	   pathogen,	  despite	   early	   classification	   as	   a	   strictly	   opportunistic	   infection	   [193-­‐195].	  Despite	   the	   global	   distribution	   of	   this	   species,	   the	   highest	   frequency	   of	   CM	   in	  immunocompetent	   individuals	   appears	   to	   come	   from	   South	   East	   Asia,	   with	  mortality	   rates	   in	   China,	   Taiwan	   and	   Japan	   estimated	   to	   be	   at	   17%,	   70%	   and	  35%,	  respectively	  [196-­‐199].	  Liu	  et	  al.	  conducted	  a	  retrospective	  analysis	  of	  46	  cases	  of	  cryptococcosis	   in	  adults,	  reported	   in	  Hong	  Kong	  over	  a	  10-­‐year	  period	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from	  1995–2005	  [200].	  The	  group	  identified	  that	  43.5%	  of	  these	  patients	  were	  apparently	   immunocompetent,	   whilst	   37.0%	   had	   non-­‐HIV	   associated	  susceptibilities	   to	   cryptococcosis,	   and	   only	   19.6%	   had	   HIV-­‐associated	  cryptococcosis.	   Interestingly	   they	   found	   that	   62.5%	   of	   cryptococcosis	   cases	   in	  immunocompetent	   patients	   were	   due	   to	   Cryptococcus	   neoformans	   var.	   grubii	  [200].	  	  In	  ‘otherwise	  healthy’	  individuals,	  pulmonary	  cryptococcal	  infection	  is	  generally	  asymptomatic.	   A	   retrospective	   study	   by	  Nadrous	   et	  al.	   of	   cryptococcosis	   in	   42	  immunocompetent	  hosts	   showed	   that	  86%	  of	  patients	  had	   isolated	  pulmonary	  cryptococcosis	   with	   no	   evidence	   of	   fungal	   dissemination	   to	   the	   CNS,	   of	   which	  33%	  were	  asymptomatic,	  and	  92%	  were	  able	  to	  resolve	  the	  infection	  either	  with	  or	   without	   antifungal	   treatment	   or	   surgical	   abscission	   [201].	   Whilst	   no	  quantitation	  of	  innate	  immune	  responses	  to	  infection	  at	  the	  individual	  level	  were	  performed,	  these	  findings	  show	  that	  the	  majority	  of	  cryptococcosis	  patients	  with	  previously	  intact	  immune	  systems	  and	  no	  evidence	  of	  disseminated	  disease	  are	  able	   to	   effectively	   eliminate	   cryptococcal	   infection.	   However,	   impaired	  macrophage	   differentiation	   was	   suggested	   to	   affect	   disease	   outcome	   in	   this	  patient	   group	   [202].	   Macrophage	   differentiation	   is	   regulated	   by	   granulocyte-­‐macrophage	  colony-­‐stimulating	  factor	  (GM-­‐CSF).	  Rosen	  et	  al.	  noted	  the	  presence	  of	   anti–GM-­‐CSF	   autoantibodies	   in	   the	   spinal	   cerebral	   spinal	   fluid	   (CSF)	   of	  patients	  with	  no	  known	  immume	  defects	  prior	  to	  cryptococcosis,	  and	  associated	  the	   inhibition	  of	   the	  activity	  of	  GM-­‐CSF	  with	  poor	  disease	  prognosis	   in	  cases	  of	  CM	  due	  to	  C.	  neoformans	  in	  otherwise	  healthy	  hosts	  [202].	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Further	   attempts	   to	   characterize	   predispositions	   to	   CM	   in	   immunocompetent	  individuals	   have	   identified	   genetic	   background	   as	   a	   risk	   factor	   for	   developing	  severe	   cryptococcosis.	   Polymorphisms	   in	   the	   Fc	   gamma	   receptor	   (FcγR)	   [203,	  204]	   and	   mannose-­‐binding	   lectin	   (MBL)	   [205]	   have	   been	   shown	   to	   increase	  susceptibility	  to	  cryptococcal	  infections.	  
	  
Immune	  responses	  in	  HIV	  patients	  	  Cryptococcal	   meningitis	   is	   the	   second	   largest	   cause	   of	   mortality	   among	   HIV	  patients	   worldwide.	   Disease	   prevalence	   became	   more	   apparent	   among	  immunocompromised	   patients	   particularly	   during	   the	   HIV	   pandemic	   in	   the	  1970s;	  where	  80%	  of	  CM	  sufferers	  were	  HIV-­‐seropositive.	  However,	  as	  of	  2014,	  the	   frequency	  of	  cryptococcal	  disease	  among	  this	  group	  has	  dropped	  to	  a	   third	  [206,	  207];	  it	  was	  estimated	  that	  223,100	  cases	  of	  CM	  in	  HIV	  patients	  occur	  each	  year	  worldwide,	  causing	  181,100	  deaths	  annually	  [17].	  This	  is	  considered	  to	  be	  due	   to	   widespread	   availability	   of	   antiretroviral	   (ART)	   drugs;	   analysis	   of	  cryptococcosis	  epidemiology	  in	  2	  parts	  of	  the	  United	  States	  showed	  a	  significant	  reduction	  in	  HIV-­‐associated	  cryptococcal	  disease	  between	  1992	  and	  2000	  [207].	  However,	  was	  noted	  that	  HIV	  patients	  in	  the	  USA	  who	  developed	  cryptococcosis	  had	   limited	   access	   to	   ARTs	   [207],	   as	   were	   HIV	   patients	   from	   the	   developing	  world	  where	  HIV	  prevalence	  remains	  high	  [208].	  Even	  despite	   the	  provision	  of	  ARTs	   in	   Sub-­‐Saharan	   Africa,	  mortality	   due	   to	  HIV-­‐associated	   CM	   remains	   high	  [208,	  209].	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  T-­‐cell	   depletion	   in	   HIV	   patients	   is	   a	   determining	   immunological	   feature	   that	  renders	   this	   group	   susceptible	   to	   CM;	   where	   low	   T-­‐cell	   infiltration	   of	   the	   CSF	  rather	   than	   alternative	   macrophage	   activation	   has	   been	   shown	   to	   be	   a	   major	  determinant	  of	  disease	  outcome	  in	  HIV-­‐associated	  cryptococcosis	  [210].	  	  	  However,	   in	   a	   recent	   study,	   Neal	   et	   al.	   demonstrated	   in	   a	   murine	   model	   that	  whilst	   CD4+	   T-­‐cells	   assist	   in	   the	   clearance	   of	   the	   fungal	   disease,	   they	   also	  contribute	   to	   disease	   dissemination	   in	   the	   CNS	   as	   well	   as	   tissue	   damage	   as	   a	  result	   of	   immunotherapy,	   leading	   to	   Immune	   Reconstitution	   Inflammatory	  Syndrome	  (IRIS)	  [211].	  IRIS	  develops	  as	  the	  balance	  between	  pro-­‐inflammatory	  and	   anti-­‐inflammatory	   responses	   is	   altered,	   and	   has	   been	   observed	   in	   HIV-­‐infected	   patients	   following	   the	   initiation	   of	   ART,	   and	   in	   non-­‐HIV,	  immunocompromised	   patients	   following	   the	   secession	   of	   immunosuppressive	  drugs	  [212].	  Based	  on	  the	  model	  by	  Neal	  et	  al.,	  depletion	  of	  CD4+	  T-­‐cell	   in	  mice	  considerably	  impaired	  the	  production	  of	  IFN-­‐γ,	  the	  accumulation	  of	  CD8+	  T-­‐cells	  and	   myeloid	   cells,	   and	   cryptococcal	   clearance	   from	   the	   CNS,	   improved	   the	  clinical	   outcomes	   of	   disease	   and	   survival	   rates	   [211].	   Hence,	   hyperpro-­‐inflammatory	  responses	  in	  this	  patient	  group	  may	  lead	  to	  CM-­‐associated	  fatalies.	  	  Other	  reports	  have	  identified	  a	  number	  of	  protective	  immune	  traits	  and	  markers	  of	   susceptibility	   to	   acquiring	   CM	   in	   HIV-­‐seropositive	   patients.	   Cerebral	   spinal	  fluid	  (CSF)	  cytokine	  profiles	  can	  reliably	  report	  disease	  progression	  and	  predict	  mortality	   in	   HIV	   patients.	   Data	   from	   several	   patient	   cohorts	   agree	   that	  inflammatory	  and	  Th1	  cytokine	   responses	   confer	  protective	  advantages	   in	  HIV	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patients	   [210,	   213,	   214].	   HIV-­‐seropositive	   hosts	   with	   high	   CSF	   levels	   of	  interleukin	   (IL)-­‐6,	   interferon-­‐γ	   (IFN-­‐γ),	   IL-­‐8,	   IL-­‐12,	   TNF-­‐α	   and	   CXCL10	   show	  improved	  fungal	  clearance	  and	  survival	  rates;	  while	  increased	  levels	  of	  IL-­‐4	  and	  IL-­‐10	   have	   been	   associated	   with	   high	   serum	   levels	   of	   cryptococcal	   GXM	   that	  impairs	  monocyte	  activation	  and	  cripples	  cell-­‐mediated	  responses	  to	  infection	  -­‐	  effectively	  predicting	  mortality	  in	  this	  group	  of	  patients	  [214-­‐216].	  	  	  Interestingly,	  not	  all	  HIV	  patients	  develop	  cryptococcosis.	  This	   is	   thought	   to	  be	  largely	   due	   to	   the	   contribution	   of	   genetic	   factors	   to	   disease	   susceptibility.	  Following	   the	   association	   of	   polymorphisms	   in	   the	   FcγR	  with	   susceptibility	   to	  cryptococcosis	   in	   non-­‐HIV	   patients	   [203-­‐205],	   Rohatgi	   et	   al.	   showed	   that	   HIV	  patients	   who	   were	   either	   heterozygous	   or	   homozygous	   for	   the	   Fc	   gamma	  receptor	   3A	   polymorphism	   (FCGR3A)	   158V	   allele,	   were	   2.1-­‐	   and	   21-­‐fold	   at	  higher	   risk	   of	   developing	   cryptococcal	   disease	   than	   individuals	   without	   the	  allele,	  respectively	  [217].	  IgG	  mediates	  phagocytosis	  via	  the	  Fc-­‐gamma	  receptor	  in	   macrophages,	   where	   the	   FCGR	   subunit,	   FCGR3A,	   is	   crucial	   for	   signal	  transduction	   and	   initiation	   of	   macrophage	   effector	   functions	   towards	   a	  pathogen.	   A	   functional	   consequence	   of	   the	   158V	   allele	   to	   the	   FCGR3A	   is	  increased	  affinity	  to	  IgG;	  resulting	  in	  increased	  phagocytosis	  of	  C.	  neoformans	  by	  host	   macrophages.	   However,	   increased	   uptake	   may	   result	   in	   impaired	  destruction	   of	   C.	   neoformans	   by	   macrophages,	   and	   increased	   dissemination	   to	  the	  CNS	  via	  the	  Trojan	  horse	  model	  resulting	  in	  cryptococcal	  disease	  as	  observed	  by	  Rohatgi	  et	  al.	  The	  group	  suggested	  that	  increased	  recognition	  of	  C.	  neoformans	  and	   immune	  activation	   leading	   to	  a	   rise	   in	  phagocytic	  uptake	  as	   the	   functional	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implication	   of	   this	   allele.	   These	   findings	   provide	   an	   alternative	   approach	   for	  identification	  of	  at-­‐risk	  individuals,	  and	  more	  personalized	  treatment	  strategies.	  
	  
Immune	  responses	  in	  non-­‐HIV,	  immunocompromised	  patients	  	  This	  group	  of	  patients	  is	  highly	  heterogenous,	  encompassing	  a	  range	  of	  patients	  from	  solid	  organ	   transplant	   (SOT)	   recipients	   to	   those	  with	  underlying	   immune	  defects	  such	  as	  sarcoidosis,	  diabetes	  mellitus,	  and	  patients	  receiving	  anti-­‐cancer	  treatments	   [218].	   As	   cryptococcal	   infections	   in	   this	   group	   represents	   a	   small	  fraction	  of	   the	  overall	  disease	  burden	  and	  associated	  mortality,	   the	  majority	  of	  epidemiological	   data	   on	   susceptibility	   to	   cryptococcosis	   in	   non-­‐HIV,	  immunocompromised	  patients	  is	  derived	  from	  clinical	  reports	  and	  retrospective	  studies.	  	  Susceptibility	   to	   developing	   CM	   in	   this	   patient	   group	   arises	   due	   to	   weakened	  innate	   and	   adaptive	   immune	   responses.	   Cases	   of	   cryptococcal	   disease	   in	  sarcoidosis	  patients	  are	  rare,	  but	  are	  due	  to	  impaired	  T-­‐cell-­‐mediated	  immunity.	  Delayed	   identification	   of	   cryptococcal	  meningitis	   occurs	   in	   43%	  of	   patients,	   as	  CNS	  involvement	  in	  sarcoidosis	  is	  often	  misdiagnosed	  as	  neurosarcoidosis	  [219].	  A	  meta-­‐analysis	   of	   40	   sarcoidosis	   patients	  with	   cryptococcal	  meningitis	   found	  that	  early	  and	  late	  diagnosis	  of	  CM	  in	  this	  patient	  group	  resulted	  in	  unfavourable	  outcomes	   in	   21%,	   and	   41%	   of	   patients,	   respectively;	   and	   CM-­‐associated	  mortality	  was	  19%	  [219].	  	  
	   60	  
Cryptococcosis	   has	   also	   been	   shown	   to	   present	   as	   a	   lethal	   complication	   in	  patients	   with	   type-­‐2	   diabetes	   mellitus	   (DMII).	   These	   patients	   are	   considered	  susceptible	  to	  cryptococcosis	  as	  a	  result	  of	  persistent	  hyperglycemia	  that	  impairs	  innate	   and	   adaptive	   immune	   responses,	   providing	   a	   suitable	   environment	   for	  infectious	   pathogens	   to	   thrive	   in	   [220].	   A	   retrospective	   study	   of	   30	  cryptococcosis	   cases	   in	   DMII	   Chinese	   patients	   found	   that	   69%	   of	   patients	  received	   delayed	   diagnosis,	   while	   60%	   received	   insufficient	   antifungal	  treatment,	  and	  fatalities	  due	  to	  CM	  in	  DMII	  patients	  were	  33%	  [220].	  	  	  Cryptococcal	   disease	   has	   long	   been	   identified	   in	   cancer	   patients,	  with	   the	   first	  cases	  being	  reported	  early	  in	  the	  20th	  century	  [221].	  Increased	  risk	  of	  developing	  CM	   in	   cancer	   patients	   is	   considered	   to	   arise	   following	   the	   induction	   of	  lymphocyte-­‐depleting	  chemotherapeutic	  regimens	  and	  prolonged	  corticosteroid	  treatments	  that	   impair	  T-­‐cell	  mediated	  immunity	  [221].	  Spec	  et	  al.	  conducted	  a	  retrospective	   study	   to	  address	   the	   impact	  of	   infectious	  disease	  consultation	  on	  non-­‐HIV,	  cryptococcosis	  patients	   [222].	  The	  group	  analysed	  data	   from	  a	  cohort	  of	  147	  patients	  with	  cryptococcosis	  over	  13	  years,	  and	  reported	  that	  induction	  of	  chemotherapy	  in	  cancer	  patients	  was	  associated	  with	  a	  ~2.1	  fold	  increase	  in	  risk	  of	  mortality	  due	  to	  cryptococcal	   infection.	  Furthermore,	   they	  showed	  that	  68%	  of	  patients	  who	  had	   consulted	  with	   an	   infectious	  disease	  physician	  were	  more	  likely	   to	   receive	   early	   diagnosis	   of	   cryptococcal	   disease,	   received	   prolonged	  antifungal	  treatment	  regimens,	  and	  were	  at	  a	  lower	  risk	  of	  mortality	  [222].	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Similar	  to	  HIV-­‐sufferers,	  organ	  transplant	  recipients	  also	  present	  with	  defects	  in	  T-­‐cell-­‐mediated	   immune	   responses	   to	   cryptococcosis	   due	   to	  immunosuppression	   [193].	   Approximately	   2.8%	   of	   organ	   transplant	   recipients	  acquire	  cryptococcal	  infections,	  with	  an	  overall	  death	  rate	  of	  42%	  [223].	  In	  SOT	  patients,	   the	   severity	   of	   infection	   has	   been	   associated	   with	   the	   level	   of	  immunosuppression	  [223].	  	  	  Studies	   have	   shown	   that	   the	   type	   of	   immunosuppressive	   treatment(s)	  administered	   to	   this	   group	   influences	   their	   susceptibility	   to	   CNS-­‐associated	  cryptococcosis,	  responses	  to	  antifungal	  treatments,	  and	  likely	  fatality	  [193,	  223].	  Analysis	   of	   127	   transplant	   recipients	   who	   were	   treated	   with	   tacrolimus,	  cyclosporine,	   or	   a	   combination	   of	   cyclosporine	   and	   azathioprine	   revealed	   that	  SOT	   patients	   who	   were	   treated	   with	   tacrolimus	   as	   a	   primary	  immunosuppressive	  agent	  were	  significantly	  less	  likely	  to	  have	  CNS	  involvement	  than	  those	  who	  received	  non-­‐tacrolimus	  treatments	  (78%	  versus	  11%,	  p	  =0.001)	  [223].	  	  	  Tacrolimus	   and	   cyclosporine	   act	   as	   selective	   inhibitors	   of	   the	   calcineurin	  pathway,	   impairing	   T-­‐cell	   mediated	   immunity	   and	   proinflammatory	   cytokine	  production,	   while	   azathioprine	   inhibits	   purine	   and	   nucleic	   acid	   synthesis	  affecting	   cell	   metabolism.	   Interestingly,	   both	   Tacrolimus	   and	   cyclosporine	   are	  also	  toxic	  to	  C.	  neoformans	  via	  inhibition	  of	  fungal	  homologues	  of	  calcineurin	   in	  
vitro	  may	  invoke	  antifungal	  effects	  in	  vivo	  [223].	  Furthermore,	  administration	  of	  azathioprine	  as	  a	  sole	   immunosuppressant,	  delayed	  the	  onset	  of	  cryptococcosis	  in	  transplant	  recipients,	  and	  was	  associated	  with	  CNS	  involvement	  [223].	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  Another	  study	  by	  Saha	  et	  al.	  provided	  serological	  evidence	   that	   the	  majority	  of	  cryptococcal	   infections	   in	   these	   patients	   were	   due	   to	   reactivation	   of	   pre-­‐transplantation	   infections	   [224].	   Individuals	  with	  circulating	  antibodies	  against	  Cryptococcus	   prior	   to	   organ	   transplantation	   acquired	   cryptococcosis	   sooner	  than	  those	  without	  previous	  exposure	  to	  the	  pathogen,	  and	  were	  more	  likely	  to	  develop	  CM.	  Disease	  progression	  in	  this	  subset	  was	  also	  dependent	  on	  the	  type	  of	   organ	   transplanted,	   although	   transmission	   of	   infection	   from	  organ	   donor	   to	  recipient	  has	  rarely	  been	  observed	  [218].	  
	  
DIAGNOSIS,	  TREATMENT	  AND	  VACCINE	  DEVELOPMENT	  	  
DIAGNOSIS	  	  Cases	  of	  cryptococcosis	  are	  typically	  confirmed	  by	  the	  detection	  of	  cryptococcal	  antigen	  (CrAg)	  by	  either	  lateral	  flow	  immunoassay	  (LFA),	  or	  latex-­‐agglutination	  test.	   A	   positive	   result	   in	   immunocompromised	   patients	   may	   be	   predictive	   of	  disease	  progression	   to	  Cryptococcal	  Meningitis,	  which	   is	   diagnosed	  via	   lumbar	  puncture	  (LP),	  examination	  of	  the	  Cerebral	  Spinal	  Fluid	  (CSF)	  opening	  pressure;	  staining	  with	  India	  ink;	  or	  CrAg	  screening	  [60].	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TREATMENT	  	  Due	   to	   its	   virulence	   mechanisms	   and	   cryptococcal	   resistance	   to	   various	  antifungal	  drugs	  [225],	   there	   is	  a	   limited	  range	  of	  effective	  antifungal	  therapies	  available	  for	  the	  treatment	  of	  Cryptococcus	  neoformans	   infections.	  Furthermore,	  the	   varieties	   of	   antifungal	   therapies	   are	   off-­‐patent	   drugs,	   based	   on	   different	  classes	  of	  molecules	  that	  target	  distinct	  fungal	  attributes.	  	  	  The	   current	   gold-­‐standard	   treatment	   regimen	   for	   cryptococcosis	   patients	  includes	   a	   combination	   of	   Amphotericin	   B	   (AmB)	   and	   5-­‐flucytosine	   (5FC);	  however,	   due	   to	   the	  unavailability	   of	  AmB	   in	   resource-­‐limited	   settings	   such	   as	  Asia	  and	  Africa	  [226],	  fluconazole	  (FLU)	  is	  used	  either	  as	  a	  sole	  treatment,	  or	  in	  combination	  with	  5FU	  [227,	  228].	  Although	  the	  provision	  of	  this	  combination	  of	  treatments	   has	   greatly	   improved	   the	   3-­‐month	   prognosis	   of	   HIV	   patients	   with	  cryptococcal	   meningitis	   in	   developed	   nations	   [229],	   the	   mortality	   rates	   in	  developing	  countries	  remain	  high	  [228,	  230].	  	  	  Each	   drug	   presents	  with	   different	   limitations	   in	   the	   treatment	   of	   cryptococcal	  meningitis.	   Amphotericin	   B	   is	   a	   polyene	   macrolide	   antifungal	   that	   binds	   to	  ergosterol	   in	  the	  fungal	  cell	  membrane,	  resulting	  in	  increased	  permeability	  and	  cell	  death	  [231,	  232].	  Fluconazole	  also	  inhibits	  ergosterol	  synthesis	  and	  acts	  as	  a	  fungistatic	   agent	   against	   C.	   neoformans	  [233].	   However,	   unlike	   AmB	   and	   5FU,	  fluconazole	   is	   a	   cost-­‐effective,	   widely	   available	   antifungal	   drug,	   that	   benefits	  from	   low	   toxicity	   and	   is	   better	   tolerated	   amongst	   HIV-­‐associated	   CM	   patients	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[233-­‐235].	  AmB	  has	  also	  been	  shown	  to	  act	  as	  an	  immunomodulator,	  influencing	  cytokine	   secretion	   [236],	   and	   promoting	   the	   release	   of	   nitric	   oxide	   by	  macrophages	   to	   eliminate	   engulfed	   cryptococci	   [237,	   238].	   Whilst	   AmB	   is	  currently	  regarded	  the	  most	  effective	  anticryptococcal	  drug,	  its	  use	  is	  limited	  by	  it’s	  dose-­‐related	  toxicity,	  as	  it	  is	  also	  able	  to	  bind	  cholesterol	  in	  mammalian	  cell	  membranes,	   leading	   to	   the	   development	   of	   nephrotoxicity	   (kidney	   toxicity),	  electrolyte	  imbalance,	  and	  anemia	  [231,	  232].	  Hence,	  monitoring	  of	  serum	  levels	  of	  potassium	  and	  creatinine,	   and	  electrolyte	   supplementation	   is	  key	   in	   limiting	  the	  effects	  of	  AmB	  toxicity	  in	  cryptococcosis	  patients.	  	  Flucytosine	   acts	   indirectly	   as	   an	   antifungal	   following	   the	   conversion	   of	  flucytosine	  into	  5-­‐fluorouracil	  (5FU)	  within	  the	  cytosol	  of	  vulnerable	  fungal	  cells	  [226].	  Once	  taken	  up	  by	  the	  fungal	  cell	  through	  the	  action	  of	  cytosine	  permease,	  flucytosine	   is	   converted	   into	   5FU	   by	   cytosine	   deaminase	   (not	   present	   in	  humans).	  5FU	  then	  excerts	   it’s	  antifungal	  role	  by	   inhibiting	  DNA	  synthesis,	  and	  disrupting	  RNA	  translation	  [226].	  While	  this	  drug	  has	  shown	  to	  be	  effective	  as	  a	  monotherapy	  against	  cryptococcosis	  with	  limited	  toxicity	  at	   low	  doses,	  cases	  of	  antimicrobial	   resistance	   have	   arisen	   [239].	   Symptoms	   of	   toxicity	   due	   to	   FU	  include	   neutropenia;	   hepatotoxicity,	   diarrhoea	   and	   vomiting	   [226],	   where	  toxicity	  presents	  as	  problematic	  but	  not	  fatal	  in	  patients	  receiving	  high	  doses	  of	  the	   drug.	   At	   peak	   concentration,	   high	   doses	   in	   patient	   serum	   have	   been	  associated	   with	   drug-­‐related	   reactivity.	   Currently,	   FU	   is	   administered	   in	  combination	  with	  AmB	  as	  the	  most	  effective	  treatment	  regimen	  for	  CM	  [240].	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Tenforde	   et	   al.	   recently	   presented	  data	   from	  13	   randomized	   clinical	   trials	   that	  enrolled	  2426	  participants	  and	  compared	  antifungal	  induction	  therapies	  used	  for	  the	   first	   episode	   of	   HIV-­‐associated	   cryptococcal	   meningitis	   was	   compiled	   and	  analysed,	  in	  efforts	  to	  identify	  the	  most	  effective	  therapy	  at	  reducing	  the	  risk	  of	  death	   from	  HIV-­‐associated	   CM	   [241].	   The	   group	   found	   that	   based	   on	   resource	  availability,	   one-­‐week	   AmB-­‐	   and	   5FC-­‐based	   therapy	   was	   the	  most	   superior	   in	  areas	  with	  access	  to	  AmB;	  while	  an	  all-­‐oral	  regimen	  of	  two	  weeks	  5FC	  and	  FLU	  was	  effective	  in	  resource-­‐limited	  environments.	  They	  also	  found	  no	  reduction	  in	  mortality	   rates	   when	   combination	   treatments	   of	   AmB	   and	   FLU	   were	  administered,	  or	  when	  AmB	  was	  used	  as	  a	  stand-­‐alone	  treatment	  [241].	  	  Interestingly,	   Amphotericin	   B	   and	   Fluconazole	   have	   been	   shown	   to	   modulate	  immune	   responses	   in	   macrophages	   by	   bringing	   about	   reductions	   in	   cellular	  charge,	   and	   at	   sub-­‐inhibitory	   levels,	   enhancing	   phagocytosis	   [242].	   However,	  both	  fluconazole	  and	  flucytosine	  described	  above,	   lack	  anticryptococcal	  activity	  within	   the	   phagolysosome	   unlike	   lysosomal	   Amphotericin	   B,	   highlighting	   the	  need	  for	  the	  development	  of	  drugs	  that	  can	  effectively	  penetrate	  cells	  [243].	  As	  drug	   development	   is	   a	   long	   and	   costly	   process,	   the	   repurposing	   of	   previously	  approved	   drug	   candidates	   provides	   an	   alternative	   route	   to	   identifying	   novel	  anticryptococcal	  drug	  targets.	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VACCINE	  DEVELOPMENT	  	  Given	  the	  poor	  prognosis	  HIV-­‐patients	  receive	  following	  positive	  CrAg	  screening,	  in	   addition	   to	   the	   differential	   responses	   to	   treatments	   observed	   between	  patients	   and	   rise	   in	   antifungal	   drug	   resistance,	   there	   is	   an	   urgent	   need	   to	   find	  preventative	  measures	   that	   reduce	   the	   risk	   of	   acquiring	   cryptococcosis	   in	   this	  group	  of	   immunocompromised	  patients.	  HIV	  patients	  characteristically	  present	  with	  diminished	  CD4+	  T-­‐cell	  counts;	  recommending	  T	  cell	  and	  B	  cell	  signaling	  as	  a	   potential	   target	   for	   vaccine	   development	   [126,	   244].	   Furthermore,	  cryptococcosis	   in	   non-­‐HIV	   patients	   has	   been	   shown	   to	   present	   as	   acute	   or	  reactivated	  disease,	  Therefore,	  a	  potential	  anti-­‐cryptococcal	  vaccine	  would	  need	  to	  prevent	  disease	  regardless	  of	  infection	  phase	  [244].	  	  	  Kleinnijenhuis	   et	   al.	   have	   previously	   provided	   evidence	   for	   the	   concept	   of	  “trained	   immunity”,	   where	   epigenetic	   reprogramming	   of	   innate	   immune	   cells	  induced	   adaptive	   features	   (namely	   in	   monocytes,	   macrophages	   and	   dendritic	  cells)	   that	   allow	   them	   to	   respond	   more	   effectively	   to	   secondary	   C.	   albicans	  infections	   [245].	   The	   group	   demonstrated	   that	   bacille	   Calmette-­‐Guerin	   (BCG)	  vaccination	  of	  severe	  combined	  immunodeficiency	  (SCID)	  mice	  conferred	  100%	  protection	  from	  disseminated	  candidiasis,	   in	  comparison	  to	  the	  30%	  protection	  observed	  in	  control	  mice	  [245].	  It	  is	  likely	  that	  these	  innate	  immune	  cells	  could	  provide	   a	   strategic	   approach	   to	   preemptive	   protection	   from	   cryptococcosis,	  because	  of	  previous	  exposure	  to	  the	  β-­‐glucan	  component	  of	  the	  fungal	  cell	  wall	  that	  is	  also	  present	  in	  Cryptococcus	  spp.	  [246].	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Monoclonal	   antibodies	   against	   cryptococcal	   GXM	   have	   also	   been	   proposed	   as	  potentially	   effective	   treatments	   against	   cryptococcosis	   by	   reducing	   CNS	   fungal	  burdens	   in	   mice	   [128].	   Anti-­‐cryptococcal	   antibodies	   are	   able	   to	   enhance	  phagocytosis	   of	   Cryptococcus	   spp.,	   regulate	   the	   subsequent	   innate	   immune	  response	  and	  alter	  the	  pathogen’s	  gene	  expression	  [247].	  This	  approach	  may	  be	  ineffective	   at	   conferring	   protection	   to	  HIV	   patients	   given	   their	   defective	   B	   cell	  populations,	   which	   are	   heavily	   relied	   upon	   by	   antibody-­‐mediated	   immunity	  (AMI)	  [248];	  but	  may	  be	  overcome	  by	  immunization.	  	  Wormley	  et	  al.	  previously	  showed	  that	   infecting	  CD8+	  and	  CD4+	  T	  cell	  depleted	  mice	  with	  a	  C.	  neoformans	  strain	   genetically	   engineered	   to	   produce	   IFN-­‐γ,	   protected	   100%	   of	   the	  population	   from	  acquiring	  a	   secondary	  C.	  neoformans	   infection	   [249,	  250].	  The	  short	  term	  protection	  provided	  by	  these	  approaches	  is	  encouraging	  (4	  weeks	  for	  AMI	   approach,	   and	   up	   to	   100	   days	   for	   immunization	   route),	   although	   more	  enduring	   protection	   would	   be	   required	   of	   an	   ideal	   anti-­‐cryptococcal	   vaccine	  [128].	   In	   2015,	   Wager	   and	   Wormley	   published	   an	   article	   discussing	   the	  feasibility	  of	  developing	  an	  anti-­‐cryptococcal	  vaccine	  [128].	  Given	  the	   impaired	  innate	  immune	  function	  in	  HIV	  positive	  patients,	  the	  authors	  speculated	  whether	  the	   provision	   of	   prophylactic	   anticryptococcal	   approach	   would	   predispose	  patients	   to	   cryptococcus-­‐related	   Immune	   Reconstitution	   Inflammatory	  Syndrome	   (IRIS)	   [128],	   a	   fatal	   condition,	   thought	   to	   be	   caused	   by	   recovery	   of	  cryptococcus-­‐specific	   immune	  responses	  [251].	  Furthermore,	  whilst	  there	   is	  no	  conclusive	   evidence	   to	   suggest	   that	   AMI	   alone	   can	   confer	   protection	   from	  cryptococcal	  disease,	  monoclonal	   antibody	   treatments	  may	   reduce	   the	   severity	  of	  disease	  in	  cases	  of	  diminished	  but	  not	  depleted	  cell-­‐mediated	  immunity	  [252].	  There	  is	  evidence	  that	  CD8+	  T-­‐cells	  display	  anticryptococcal	  functions	  in	  cases	  of	  
	   68	  
impaired	   CD4+	   T	   cell	   activity	   [253],	   releasing	   IFN-­‐γ	   capable	   of	   enhancing	  macrophage	   responses	   to	   Cryptococcus	   spp.	   [253][252].	   Efforts	   to	   develop	   an	  anticryptococcal	  vaccine	  are	  conducted	  in	  animal	  models	  of	  disease;	  despite	  the	  provision	   of	   evidence	   that	   immune	   responses	   in	   these	   models	   mirrors	   that	  observed	   in	   human	   hosts,	   it	   is	   imperative	   that	   species-­‐specific	   responses	   and	  susceptibilities	  be	  taken	  into	  account.	  The	  growing	  incidence	  of	  cryptococcosis	  in	  non-­‐HIV	  patients	  as	  well	  as	   the	  varied	  host	  responses	   to	  cryptococcal	   infection	  highlights	  the	  desperate	  need	  to	  develop	  an	  effective	  anti-­‐cryptococcal	  vaccine.	  	  	  
Discussion	  
	  Whilst	  the	  reduction	  in	  global	  HIV-­‐associated	  CM	  is	  testament	  to	  improved	  ART	  and	   antifungal	   treatment	   strategies,	   the	   rise	   in	   frequency	  of	   non-­‐HIV	   and	  non-­‐transplant	  associated	  cryptococcosis	  in	  the	  developed	  world	  represents	  a	  cause	  for	   concern.	   HIV-­‐associated	   CM	   remains	   the	   most	   extensively	   investigated	  among	   the	   three	   groups.	   Whilst	   the	   majority	   of	   cryptococcal	   infections	   in	  previously	   healthy	   individuals	   are	   asymptomatic,	   clinical	   manifestations	   and	  prognoses	  vary	  greatly.	  Current	  clinical	  guidelines	   for	   this	  group	  are	  generated	  from	  immunocompromised	  cohorts	  and	  thus	  may	  not	  be	  appropriate	  for	  disease	  management	   in	   immunocompetent	   hosts.	   Whilst	   numerous	   case	   reports	   of	  ‘unusual’	   cryptococcosis	   cases	   have	   been	   published,	   there	   is	   a	   scarcity	   of	  prospective	  data	  on	  the	  management	  of	  CM	  in	  previously	  healthy	  individuals.	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A	  recent	  article	  by	  Pirofski	  and	  Casadevall	  discussed	  the	  effects	  of	  host-­‐mediated	  damage	   on	   the	   progression	   of	   cryptococcosis	   [254].	   Given	   the	   variety	   of	   host-­‐microbe	   interactions	   that	   occur	   within	   the	   different	   patient	   groups	   discussed	  above,	  and	  the	  associated	  alteration	  of	  the	  inflammatory	  immune	  responses,	  this	  damage-­‐response	   framework	   (DRF)	   model	   may	   be	   particularly	   helpful	   for	  understanding	   infections	   in	   otherwise	   healthy	   individuals.	   Clearly,	   however,	  there	   is	   currently	   a	   lack	   of	   characterization	   studies	   in	   non-­‐HIV	   cryptococcal	  patients	  with	  which	  to	  inform	  this	  model.	  	  	  	  It	   has	   previously	   been	   shown	   that	   cytokine	   expression	   by	  macrophages	   is	   not	  permanently	  biased	  to	  either	  M1	  or	  M2	  responses,	  and	  may	  be	  modulated	  [135];	  hence,	  the	  fluidity	  in	  macrophage	  activation	  states	  instigates	  varied	  responses	  in	  individuals	   with	   robust	   immune	   systems	   [155].	   Furthermore,	   the	   genetic	  contribution	   to	   phenotypic	   challenges	   in	   anti-­‐cryptococcal	   responses	   among	  cryptococcosis	  sufferers	  provides	  an	  additional	  tool	  for	  early	  diagnosis	  in	  at-­‐risk	  cohorts.	   However,	   difficulties	   arise	   in	   the	   case	   of	   non-­‐HIV	   immunocompetent	  hosts	  who	  may	  not	  be	  considered	  at-­‐risk	  and	   therefore	  subject	   to	  presumptive	  genetic	   testing	   in	   comparison	   to	   their	   immunocompromised	   counterparts.	   In	  addition,	  it	  was	  brought	  to	  light	  in	  a	  recent	  article	  by	  Netea,	  that	  the	  association	  of	   the	   above-­‐mentioned	   polymorphisms	   with	   susceptibility	   to	   severe	  cryptococcosis	   was	   not	   descriptive	   of	   all	   patients	   across	   different	   cohorts	   as	  these	   polymorphisms	   only	   predisposed	   individuals	   of	   certain	   ethnic	   groups	   to	  CM	  [255].	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Whilst	   therapeutic	   approaches	   for	   HIV-­‐associated	   cryptococcal	   disease	   in	  combination	  with	  ARTs	  are	  successfully	  being	  established,	  efforts	   to	  determine	  protective	  features	  of	  the	  innate	  immunity	  in	  non-­‐HIV-­‐associated	  disease	  are	  still	  underway,	  as	  are	  attempts	  to	  develop	  an	  effective	  vaccine	  against	  cryptococcosis.	  Knowledge	   of	   cryptococcal	   pathogenesis	   remains	   minimal	   in	   patients	   with	  known	   immunological	   defects	   beside	   HIV,	   and	   treatment	   strategies	   remain	  unspecific.	  This	  may	  be	  at	   least	  partially	  due	   to	   the	   inappropriate	  clustering	  of	  these	   two	   groups	   together	   into	   a	   single	   “non-­‐HIV-­‐associated	   cryptococcosis”	  category,	   when	   in	   fact	   they	   represent	   at	   least	   two	   distinct	   cohorts.	   A	   better	  understanding	  of	  the	  sources	  of	  variation	  between	  and	  within	  patient	  groups	  is	  urgently	  needed	  in	  order	  to	  help	  inform	  strategies	  to	  appropriately	  modulate	  the	  immune	  responses	  at	  the	  level	  of	  the	  individual	  to	  improve	  disease	  outcomes.	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Study	  aims	  and	  objectives	  
	  Above,	   we	   have	   reviewed	   current	   knowledge	   of	   C.	   neoformans’	   pathogenicity	  towards	  different	  groups	  of	  patients.	  As	  we	  highlighted	  the	  gaps	  in	  knowledge	  of	  cryptococcal	  interactions	  with	  macrophages	  derived	  from	  healthy	  human	  hosts,	  we	  aim	   to	  decipher	   the	  extent	  of	  variation	  of	  host	  macrophage	  responses	   to	   in	  
vitro	  challenge	  with	  the	  intracellular	  pathogen.	  By	  deriving	  macrophages	  from	  a	  group	   of	   individuals	   with	   no	   reported	   immunocompromises,	   we	   hypothesize	  that	   phagocytic	   cells	   from	   each	   individual	   will	   exhibit	   consistent	   anti-­‐cryptococcal	   responses	  over	   time.	  We	  also	  anticipate	   that	  whilst	   the	   intra-­‐host	  rates	   of	   vomocytosis	   may	   be	   analogous,	   differences	   in	   vomocytosis	   between	  individuals,	  paired	  with	  cytokine	  profiles	  from	  each	  in	  vitro	  challenge	  will	  bring	  to	   light	   the	   molecular	   components	   involved	   in	   orchestrating	   cryptococcal	  expulsion	  from	  macrophages.	  	  As	  previous	  studies	  have	  implicated	  the	  pattern	  recognition	  receptor	  (PRR),	  toll-­‐like	  receptor	  4	  (TLR4)	  in	  the	  expulsion	  of	  bacteria	  from	  host	  epithelial	  cells,	  we	  aim	   to	  probe	   the	   involvement	   of	   this	  PRR	   in	   the	   vomocytosis	   of	  C.	  neoformans	  from	  host	  macrophages.	  	  Furthermore,	  we	  hypothesize	   that	   cases	  of	   varied	  control	  of	   intracellular	  yeast	  proliferation	   and	   vomocytosis	  may	  be	  due	   to	   genetic	   factors.	   Single	   nucleotide	  polymorphisms	   (SNPs)	   that	   cause	   functional	   and	   structural	   alterations	   in	   host	  macrophage	   anti-­‐cryptococcal	   machinery	   may	   result	   in	   either	   impaired	   or	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improved	   fungal	   clearance.	   As	   the	   molecular	   mechanisms	   that	   determine	  vomocytosis	  of	  C.	  neoformans	  from	  macrophages	  remain	  unknown,	  we	  believe	  an	  understanding	  of	  host	  genetic	  contribution	  to	  PRRs	  and	  downstream	  regulatory	  and	   effector	   proteins	   involved	   in	   this	   process	   will	   present	   a	   novel	   target	   for	  therapeutic	  development.	  In	  addition,	  given	  the	  inability	  of	  current	  treatments	  to	  clear	   intracellular	   cryptococci	   from	  macrophages,	  we	   also	   aim	   to	   identify	   host	  macrophage	  pathways	  that	  may	  be	  augmented	  therapeutically	  to	  increase	  killing	  of	  phagocytosed	  yeasT-­‐cells.	  	  Altogether,	   we	   aim	   to	   establish	   the	   parameters	   of	   variation	   in	   intracellular	  control	   and	   expulsion	   of	   yeasT-­‐cells	   from	   host	   macrophages;	   check	   the	  contribution	   of	   genetics	   to	   any	   observed	   variation;	   question	   the	   association	   of	  TLR4	   with	   vomocytosis;	   and	   identify	   a	   anti-­‐cryptococcal	   compound	   able	   to	  eliminate	  intracellular	  yeast.	  It	  is	  anticipated	  that	  this	  work	  will	  provide	  a	  better	  understanding	   of	   the	   interactions	   between	   healthy	   host	   macrophages	   and	   C.	  
neoformans	   and	   ultimately	   improve	   the	   diagnosis	   and	   treatment	   of	   the	  ‘otherwise	  healthy’	  group	  of	  cryptococcosis	  patients.	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Chapter	   2	   –	   Variation	   in	   host	  macrophage	   responses	   to	  Cryptococcus	  
neoformans	  
	  Parts	   of	   this	   chapter	   have	   been	   published	   in	   a	  manuscript	   titled:	   “Quantifying	  donor-­‐to-­‐donor	   variation	   in	   macrophage	   responses	   to	   the	   human	   fungal	  pathogen	  Cryptococcus	  neoformans”	  by	  Garelnabi	  et	  al.	  	  
Abstract	  
	  Cryptococcosis	   remains	   the	   leading	   cause	   of	   fungal	   meningitis	   worldwide,	  caused	   primarily	   by	   the	   pathogen	   Cryptococcus	   neoformans.	   Symptomatic	  cryptococcal	  infections	  typically	  affect	  immunocompromised	  patients.	  However,	  environmental	   exposure	   to	   cryptococci	   is	   ubiquitous	   and	   most	   healthy	  individuals	  are	  thought	  to	  harbor	  infections	  from	  early	  childhood	  onwards	  that	  are	  either	  resolved	  or	  become	  latent.	  Since	  macrophages	  are	  a	  key	  host	  cell	   for	  cryptococcal	  infection,	  we	  sought	  to	  quantify	  the	  extent	  of	  individual	  variation	  in	  this	   early	   phagocyte	   response	  within	   a	   small	   cohort	   of	   healthy	   volunteers.	  We	  compared	   the	   effects	   of	   complement-­‐mediated	   opsonization,	   with	   those	   of	  antibody-­‐mediated	  opsonization	  on	  the	  intracellular	  parasitism	  and	  expulsion	  of	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C.	   neoformans	   from	   human	   monocyte-­‐derived	   macrophages	   (MDMs).	   Our	  findings	  show	  that	  whilst	  the	  host’s	  MDM	  killing	  of	  intracellular	  Cryptococci	  was	  not	   dependent	   on	   the	   method	   of	   opsinization;	   the	   rate	   of	   expulsion	   was	  enhanced	  by	  antibody-­‐opsonization	  in	  some	  individuals.	  We	  also	  show	  that	  rates	  of	  both	   intracellular	   fungal	  proliferation	  and	  non-­‐lytic	   expulsion	   (vomocytosis)	  are	  remarkably	  variable	  between	  individuals,	  irrespective	  of	  gender,	  and	  that	  in	  
vitro	  host	  inflammatory	  cytokines	  profiles	  are	  not	  determinants	  of	  this	  variation.	  	  Despite	  our	  small	  sample	  size,	  we	  conducted	  post-­‐hoc	  power	  calculations	  based	  on	   our	   data	   and	   determined	   that	   the	   sample	   size	   required	   to	   achieve	   reliable	  statistical	  value	  for	  IPR	  and	  vomocytosis	  to	  be	  238	  and	  274,	  respectively.	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Introduction	  
Host-­‐Specific	  Variation	  In	  The	  Macrophage	  Response	  To	  Cryptococcal	  
Infection	  In	  Healthy	  Individuals	  	  Cryptococcosis	  is	  the	  leading	  cause	  of	  fungal	  meningitis	  worldwide,	  with	  the	  vast	  majority	  of	  clinical	  cases	  being	  caused	  by	  Cryptococcus	  neoformans.	  The	  last	  two	  decades	  have	  seen	  a	  decline	  in	  HIV-­‐associated	  CM	  in	  developed	  countries	  due	  to	  improved	   access	   to	   a	   combination	   of	   antiretroviral	   therapies	   and	   effective	  antifungal	  treatments	  [194].	   It	  has	  been	  estimated	  that	  20%	  of	  global	  CM	  cases	  afflict	   non-­‐HIV	   patients	   [193],	   with	   more	   recent	   reports	   indicating	   a	   growing	  concern	   over	   CM	   due	   to	   C.	   neoformans	   in	   otherwise	   healthy	   individuals	   [193-­‐195].	  	  	  Despite	   the	   global	   distribution	   of	   this	   species,	   the	   highest	   frequency	   of	   CM	   in	  immunocompetent	   individuals	   appears	   to	   come	   from	   South	   East	   Asia,	   with	  mortality	   rates	   in	   China,	   Taiwan	   and	   Japan	   estimated	   to	   be	   at	   17%,	   70%	   and	  35%,	   respectively	   [196-­‐198].	   Whilst	   time	   to	   presentation	   following	   initial	  symptoms	   of	   infection	   does	   not	   differ	   between	   HIV	   positive	   and	   negative	  patients	  [195],	  one	  of	  the	  issues	  restricting	  effective	  disease	  management	  is	  that	  non-­‐HIV	  CM	  patients	  represent	  a	  highly	  heterogenous	  group.	   In	  a	  retrospective	  study	   that	   assessed	   predictors	   of	   disease	   mortality	   in	   different	   groups	   of	  cryptococcosis	   patients,	   it	   was	   shown	   that	   it	   took	   an	   average	   of	   68	   days	   to	  diagnose	  otherwise	  healthy	   individuals	  with	  cryptococcosis,	  while	  HIV	  patients	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were	   diagnosed	   within	   22	   days	   [256].	   This	   may	   be	   due	   to	   differences	   in	  presentation	  of	  symptoms	  e.g.	  CM	  patients	  with	  HIV	  are	  more	   likely	   to	  present	  with	   fever	  whilst	   the	   non	  HIV	   group	  more	   frequently	   presents	  with	   abnormal	  mental	  status,	  lung	  involvement	  and	  lesions	  in	  the	  central	  nervous	  system	  (CNS)	  [195]	  or	  due	   to	  clinician	  awareness	  of	  cryptococcosis	  as	  a	  complication	  of	  HIV.	  Treatment	   regimens	   for	   HIV-­‐negative	   cryptococcosis	   patients	   are	   primarily	  based	  on	  data	  from	  studies	  on	  HIV	  patients,	  due	  to	  the	  scarcity	  of	  data	  within	  a	  more	   relevant	   context	   [227].	   Hence,	   an	   understanding	   of	   the	   immunological	  status	   that	   enables	   ‘otherwise	   healthy’	   individuals	   to	   overcome	   cryptococcal	  disease	  would	   allow	   healthcare	   providers	  more	   robust	   treatment	   strategies	   in	  this	  group,	  and	  ultimately	  improve	  survival	  rates.	  	  Macrophages	   represent	   a	   key	   target	   cell	   for	  C.	  neoformans.	  Mice	  with	  depleted	  macrophages	   infected	  with	   this	  pathogen	  showed	  enhanced	  survival	  over	   their	  wild	   type	   counterparts	   and	   significantly	   lower	   CNS	   involvement	   [257].	   Most	  isolates	  of	   cryptococci	   are	   remarkably	   resistant	   to	  macrophage	  killing,	   and	  are	  able	  to	  adapt	  and	  survive	  within	  macrophages	  causing	  latent	  infections	  that	  may	  later	   disseminate	   upon	   immune	   suppression	   to	   cause	   cryptococcal	  meningoencephalitis	   (CM)	   [258,	   259].	   Evidence	   for	   latent	   infections	   is	   derived	  from	  the	  detection	  of	  anti-­‐cryptococcal	  antibody	  in	  a	  large	  percentage	  of	  children	  by	   the	   age	   of	   10	   in	   different	   parts	   of	   the	   world	   [260,	   261];	   Also,	   reactivated	  cryptococcal	  disease	  has	  been	  shown	  to	  occur	  up	  to	  60	  years	  following	  the	  initial	  advent	  of	  infection	  by	  the	  same	  cryptococcal	  species	  [262].	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Given	   that	   both	   latent	   and	   symptomatic	   infections	   likely	   arise	   from	   an	   early	  intracellular,	  macrophage-­‐associated,	  fungal	  colonization,	  a	  key	  question	  is	  how	  variable	   this	   early	  macrophage	   response	   is	   to	   the	   fungus.	  Engulfed	   cryptococci	  are	   able	   to	   manipulate	   host	   phagosome	   maturation,	   enabling	   the	   yeast’s	  intracellular	   survival	   [122,	   143].	   As	   described	   in	   Chapter	   1,	   an	   interesting	  feature	   of	   Cryptococcus’s	   intracellular	   parasitism	   is	   its	   ability	   to	   undergo	  vomocytosis	  (non-­‐lytic	  expulsion)	  from	  the	  host	  macrophage	  either	  immediately	  or	   a	   few	   hours	   after	   engulfment	   [169,	   170].	   This	   rapid	   process	   has	   been	  suggested	   to	   facilitate	   cryptococcal	   dissemination	   throughout	   the	   host	   whilst	  evading	   immune	  detection,	  ultimately	  resulting	   in	  passage	   into	   the	  CNS	  via	   the	  Trojan	  horse	  model	  [66,	  71].	  Hence,	  we	  hypothesize	  that	  the	  mode	  of	  uptake	  of	  Cryptococci	   by	   human	   phagocytes	   could	   influence	   vomocytosis	   in	   vitro,	   we	  anticipate	   that	   this	   will	   provide	   an	   incite	   into	   how	   vomocytosis	   influences	  cryptococcal	  dissemination,	  and	  progression	  of	  cryptococcal	  disease	  depending	  of	  the	  site	  of	  infection	  in	  vivo.	  	  As	   the	   cryptococcal	   capsule	   conveys	   anti-­‐phagocytic	   advantages	   to	   the	   yeast,	  allowing	   for	   evasion	  of	   immune	  detection	   and	  dissemination	   towards	   the	  CNS,	  understanding	  how	  the	  host	  is	  able	  to	  overcome	  issues	  with	  pathogen	  detection	  is	   paramount.	   The	   complement	   system	   is	   a	   major	   component	   of	   the	   innate	  immune	   system,	   comprising	  of	   a	  number	  of	  plasma	  proteins	   that	   interact	  with	  each	  other	  to	  opsonize	  invading	  pathogens,	  and	  trigger	  inflammatory	  responses	  [263].	   Opsonization	   essentially	  marks	   pathogens	   for	   engulfment	   and	   killing	   by	  leukocytes	   bearing	   receptors	   that	   detect	   opsonins	   on	   the	   pathogen’s	   surface.	  Pathogens	   are	   able	   to	   activate	   complement	   via	   the	   classical	   (antibody-­‐
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dependent),	   alternative	   (antibody-­‐independent)	   or	   the	   lectin	   pathways	  (antibody-­‐independent)	   [263,	   264].	   These	   three	   pathways	   involve	   a	   series	   of	  proteolytic	  reactions	  that	  converge	  in	  the	  formation	  of	  the	  opsonin	  C3b	  [12].	  The	  enzyme	   C3	   convertase	   splits	   the	   complement	   component	   C3	   into	   two	  components,	  C3a	  and	  C3b;	  C3b	  then	  covalently	  binds	  to	  the	  pathogen	  surface	  and	  is	  recognized	  by	  C3b	  receptors	  on	  the	  surface	  of	  phagocytes	  to	  initiate	  pathogen	  engulfment.	   C3b	   can	   also	   bind	   to	   C3	   convertases	   to	   produce	   C5	   convertase,	  which	  cleaves	  C5	  to	  C5a	  and	  C5b	  [12].	  Whilst	  these	  three	  pathways	  are	  initiated	  by	  different	  molecules,	   they	  ultimately	  converge	  to	  bring	  about	  phagocytosis	  of	  the	   C3b-­‐opsonized	   pathogen;	   and	   increased	   recruitment	   of	   phagocytic	   effector	  cells,	   and	   facilitation	   of	   inflammatory	   responses	   by	   C3a	   and	   C5a	   to	   promote	  pathogen	  elimination	  [12,	  263].	  	  	  Early	  on,	  the	  alternative	  activation	  pathway	  was	  reported	  as	  a	  major	  protective	  component	   against	   cryptococcal	   infections	   [265];	   However,	   it	   has	   since	   been	  shown	   that	   in	   the	  absence	  of	   complement	  proteins,	   anti-­‐cryptococcal	  anti-­‐GXM	  antibodies	  are	  able	  to	  act	  as	  effective	  opsonins	  that	  activate	  phagocytosis	  in	  the	  J774	   murine	   macrophage-­‐like	   cell	   line,	   and	   improve	   anti-­‐cryptococcal	   activity	  [266-­‐268].	   In	   experiments	   by	   Mukherjee	   et	   al.,	   various	   murine	   antibody	  subclasses	  (IgM,	   IgG1,	   IgG2a,	   IgG2b,	   IgG3,	  and	  IgA)	  were	  shown	  to	  enhance	  the	  anticryptococcal	   activity	   of	   J774	   cells	   which	   was	   measured	   by	   a	   reduction	   in	  cryptococcal	   colony-­‐forming	   units	   (CFUs),	  where	   IgG2a	  monoclonal	   antibodies	  were	   the	   most	   effective	   at	   enhancing	   macrophage	   elimination	   of	   engulfed	  Cryptococci	   [267].	   In	   subsequent	   experiments,	   the	   group	   showed	   that	   in	   vitro	  infection	   of	   J774	   cells	   with	   C.	   neoformans	   in	   the	   absence	   or	   presence	   of	   the	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monoclonal	  antibody	  2H1,	  reduced	  CFU	  counts	  by	  26.1%	  and	  >95%,	  respectively	  [268].	  	  	  However,	  with	  regards	   to	  vomocytosis,	  Ma	  et	  al.	   also	  showed	   that	  expulsion	  of	  engulfed	  cryptococci	  was	  independent	  of	  the	  route	  of	  uptake	  [170];	  interestingly,	  antibody-­‐mediated	   phagocytosis	   has	   been	   associated	   with	   the	   expulsion	   of	  cryptococci	  as	  clumps	  of	  cells	  as	  opposed	  to	  the	  singular	  expulsion	  of	  yeast	  cells	  following	   complement-­‐mediated	   uptake	   [180].	   Since	   the	   effects	   of	   different	  complement	  activation	  pathways	  on	  fungal	  killing	  are	  still	  to	  be	  fully	  established,	  and	  given	   the	  observed	  variation	   in	  host	   responses	   to	  cryptococcosis,	  we	  were	  interested	   to	   find	   out	   whether	   the	   route	   of	   opsonization	   affected	   anti-­‐cryptococcal	  activity	  of	  immunocompetent	  human	  MDMs	  in	  vitro.	  	  	  In	  addition,	  the	  phospholipase	  B	  (Plb),	  an	  enzyme	  secreted	  by	  C.	  neoformans	  	  and	  crucial	   in	   cryptococcal	   virulence,	   is	   essential	   for	   dissemination	   to	   the	   CNS.	  	  Chayakulkeeree	  et	   al.	   showed	   that	   this	  enzyme	  was	  also	   shown	   to	  be	  essential	  for	  vomocytosis	  [181].	  The	  group	  showed	  that	  deletion	  of	  Plb	  and	  Sec14-­‐1p,	  the	  transfer	  protein	  essential	  for	  the	  secretion	  of	  Plb,	  reduced	  vomocytosis	  by	  ∼60%	  from	   the	   murine	   macrophage-­‐like	   J774	   cell	   line;	   they	   also	   showed	   that	  vomocytosis	  fully	  restored	  in	  the	  reconstituted	  C.	  neoformans	  H99	  strain	  [181].	  	  CSF	  cytokine	  and	  chemokine	  profiles	  have	  been	  shown	  to	  be	  predictive	  of	  risk	  of	  early	   mortality	   and	   Immune	   Reconstitution	   Inflammatory	   Syndrome	   (IRIS)	   in	  HIV-­‐associated	   Cryptococcal	   Meningitis	   [214].	   Aside	   from	   high	   CSF	   fungal	  burden,	   rate	   of	   clearance	   of	   Cryptococcus	   and	   altered	   mental	   status,	   the	   host	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cytokine	   profile	   has	   been	   identified	   as	   deterministic	   of	   fungal	   disease	  progression	  in	  HIV	  patients	  [213,	  214].	  Clinical	  studies	  to	  evaluate	  baseline	  CSF	  and	  sera	  cytokine	  profiles	   in	  HIV	  patients	  with	  CM,	  also	  showed	  that	  Th1-­‐	  type	  immune	   responses	   (IL-­‐8,	   IL-­‐12p40,	   IL-­‐17A,	   TNF-­‐alpha,	   INF-­‐gamma	   and	   sera	  TNF-­‐alpha)	  played	  a	  role	   in	  reducing	  CSF	  fungal	  burden	  and	  improved	  survival	  in	  comparison	  to	  those	  with	  advanced	  immunodeficiency	  [215].	  More	  recent	  in-­‐depth	   analysis	   of	   the	  mechanisms	   regulating	  M1	   and	  M2	   activation	   states	   also	  revealed	  that	  macrophages	  are	  able	  to	  shift	  between	  the	  two	  polarization	  states,	  highlighting	  the	  potential	  impact	  of	  this	  fluidity	  on	  host	  susceptibility	  to	  disease	  [269,	   270].	   The	   ability	   of	   macrophages	   to	   be	   reprogrammed	   may	   explain	   the	  variation	  in	  host	  responses	  to	  cryptococcal	  infection.	  	  Remarkably,	  it	  has	  been	  shown	  that	  IFN-­‐γ	  levels	  were	  negatively	  correlated	  with	  fungal	  burden	  at	  the	  site	  of	  infection	  [271],	  despite	  the	  successful	  use	  of	  IFN-­‐γ	  as	  an	   adjunctive	   treatment	   against	   cryptococcosis	   [272].	   Siddiqui	   et	   al.	   analysed	  CSF	   fungal	  cultures	   in	  62	  HIV-­‐associated	  cryptococcosis	  patients	  over	   time	  and	  found	  that	  levels	  of	  the	  pro-­‐inflammatory	  cytokines	  IFN-­‐γ,	  TNF-­‐α,	  IL-­‐6	  and	  IL-­‐8	  were	  higher	   in	  survivors	   than	  those	  who	  succumbed	  to	   infection;	  however,	   the	  levels	   IFN-­‐γ,	  TNF-­‐α	  and	   IL-­‐6	  were	  negatively	   correlated	  with	   cryptococcal	  CFU	  counts	   [271].	   In	   the	   context	   of	   macrophages,	   high	   levels	   of	   these	   pro-­‐inflammatory	  cytokines	  may	  contribute	  to	  lowering	  CFU	  counts	  by	  encouraging	  vomocytosis	   of	   C.	   neoformans	   from	   within	   macrophages;	   exposing	   expelled	  cryptococci	  to	  killing	  by	  other	  immune	  mechanisms.	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Despite	   the	   advances	   made	   in	   characterizing	   the	   pathogenic	   capabilities	   of	  
Cryptococcus	   and	   the	   considerable	   body	   of	   data	   on	   fungal	   disease	   within	   the	  context	   of	   HIV	   positive	   patients,	   little	   is	   known	   about	   the	   innate	   immune	  characteristics	   in	   non-­‐HIV	   patients	   that	   predispose	   them	   to	   developing	  cryptococcal	  meningitis	  (CM).	  Therefore,	  an	  understanding	  of	  the	  host-­‐pathogen	  interactions	  outside	  the	  context	  of	  HIV	  would	  provide	  better-­‐tailored	  treatment	  approaches	  to	  combat	  cryptococcal	  meningoencephalitis	  in	  this	  group.	  	  	  The	   data	   presented	   here	   examines	   the	   extent	   to	   which	   macrophage	  heterogeneity	   contributes	   to	   innate	   immune	   control	   of	   infection	   in	   host	  macrophages	   taken	   from	   healthy	   individuals.	   We	   aimed	   to	   identify	   the	  determinants	  of	  host	  susceptibility	  cryptococcosis	  by	  studying	  variation	  in	  host	  macrophage	   responses	   to	   Cryptococcus,	   and	   characterizing	   how	   these	  interactions	   may	   either	   facilitate	   or	   impede	   C.	   neoformans	   invasion	   and	  progression	  to	  CM.	  Bases	  for	  variation	  under	  consideration	  include	  the	  ability	  of	  host	   macrophages	   to	   phagocytose	   and	   kill	   Cryptococcus	   neoformans,	   and	   the	  level	  to	  which	  they	  promote	  or	  restrict	  clearance	  of	  the	  fungal	   load,	  preventing	  dissemination	  to	  the	  central	  nervous	  system.	  	  	  Below,	   we	   present	   quantitative	   data	   from	   the	   in	   vitro	   challenge	   of	   monocyte-­‐derived	  macrophages	   (MDMs)	   from	  15	  healthy	   individuals	  with	  C.	   neoformans	  var.	  grubii.	  We	  compare	  the	  outcomes	  of	  in	  vitro	  infection	  of	  human	  MDMs	  with	  the	   C.	   neoformans	   Kn99α-­‐GFP	   strain,	   opsonized	   with	   either	   the	   murine	  monoclonal	   antibody	   (MAb)	   18B7	   [273]	   to	   activate	   antibody-­‐mediated	  immunity,	   or	   pooled	   human	   serum	   (PHS)	   to	   invoke	   alternative	   complement	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activation.	  We	   also	   compare	   the	   cytokine	   profiles	   of	   each	   independent	   donor;	  and	   investigate	   how	   levels	   of	   secreted	   cytokines	   compare	   to	   intracellular	  cytokine	   production	   between	   individuals	   within	   our	   group	   of	   donors.	  Furthermore,	   we	   assess	   whether	   gender	   and	   seasonal	   variation	   play	   a	   role	   in	  promoting/impairing	  anticryptococcal	  defense	  in	  macrophages.	  	  	  Despite	  the	  relatively	  small	  cohort,	  there	  is	  remarkable	  variation	  in	  macrophage	  ability	  to	  control	  both	  intracellular	  parasitism	  and	  vomocytosis	  of	  C.	  neoformans.	  Surprisingly,	   this	   variation	   in	   intracellular	   proliferation	   and	   expulsion	   of	   the	  yeast	   appears	   to	   be	   driven	  primarily	   by	   the	   local	   environment	   experienced	  by	  the	  monocyte	  prior	   to	   in	  vitro	   differentiation.	  We	   show	   that	   neither	   intra-­‐	   and	  extra-­‐cellular	  cytokine	  profiles,	  nor	  gender,	  play	  a	  significant	  role	   in	  describing	  the	  outcome	  of	  infection.	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Materials	  and	  methods	  
	  Ethical	   approval	   for	   this	   study	   was	   obtained	   from	   the	   Science,	   Technology,	  Engineering	   and	   Mathematics	   Ethical	   Review	   Committee	   of	   the	   University	   of	  Birmingham	  (ERN_15-­‐0804).	  	  
Sample	  collection	  and	  randomization	  	  30-­‐60ml	  venous	  blood	   samples	  were	   collected	   in	   lithium	  heparin	  VACUTAINER®	  tubes	  obtained	  from	  healthy	  volunteers	  with	  full	  informed	  consent.	  Immediately	  after	   donation,	   the	   identities	   of	   fifteen	   participants	   were	   randomized	   and	  assigned	   donor	   IDs	   (RG001	   -­‐	   RG016)	   that	   were	   maintained	   throughout	   the	  experimentation	  process.	  Donor	  RG008	  was	  excluded	  from	  the	  study.	  	  	  VACUTAINER®	  tubes	  with	  silica	  bead	  clot	  activator	  (CAT)	  were	  used	  to	  collect	  serum	  during	  each	  blood	  donation,	  and	  incubated	  at	  37°C,	  5%	  CO2	  for	  one	  hour	  prior	   to	   centrifugation	   at	   800	   x	   g	   for	   10	   minutes.	   Live	   serum	   aliquots	   were	  thereafter	   stored	  at	   -­‐80°C	   for	   cytokine	  profiling,	   and	   the	   remaining	   serum	  was	  heat-­‐inactivated	   in	   a	  water	   bath	   at	   57°C	   for	   30	  minutes	   and	   stored	   at	   4°C,	   for	  later	  use.	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Monocyte	  isolation,	  differentiation	  and	  culture	  	  Peripheral	   blood	  mononuclear	   cell	   (PBMCs)	  were	   isolated	   from	   fifteen	  healthy	  volunteers	   by	   double	   gradient	   centrifugation	   using	   Percoll®	   (Sigma-­‐Aldrich,	  H4522).	  The	  dual	  gradient	  was	  created	  by	  layering	  6	  ml	  of	  1.098	  g/ml	  Percoll®	  (70.9%	  Percoll®,	  19.1%	  H2O,	  10%	  1.5M	  NaCl)	  underneath	  1.079	  g/ml	  Percoll®	  (56.3%	   Percoll®,	   33.7%	   H2O,	   10%	   1.5M	   NaCl);	   onto	   which	   6	   ml	   of	   undiluted	  donor	   blood	  was	   layered	   on	   top	   of,	   and	   centrifuged	   for	   8	  minutes	   at	   150	   x	  g,	  followed	  by	  10	  minutes	  at	  1200	  x	  g	  with	  no	  brake,	  or	  acceleration.	  The	  top	  layer	  of	  monocytes	   separated	  by	   the	  dual	   gradient	  were	   removed	  and	   added	   to	  Red	  Blood	  Cell	  (RBC)	  lysis	  Buffer	  (1L	  –	  8.3g	  NH4Cl,	  1g	  KHCO3,	  0.04g	  Na2	  EDTA	  2H2O,	  2.5g	  BSA)	  at	  a	  ratio	  of	  1:3	  and	  incubated	  for	  3	  minutes	  at	  room	  temperature	  with	  gentle	  mixing	  then	  spun	  at	  400	  x	  g	  for	  6	  minutes.	  The	  buffer	  was	  removed,	  and	  monocytes	   washed	   twice	   with	   50	   ml	   of	   PBS	   (Sigma-­‐Aldrich),	   and	   PBS	  supplemented	   with	   Ca+	   and	   Mg++	   at	   4	   °C	   (Sigma-­‐Aldrich)	   to	   enhance	   cell	  adhesion.	  	  Isolated	   monocytes	   were	   thereafter	   resuspended	   in	   1	   ml	   adhesion	   media	  (RPMI	  1640	  with	  L-­‐glutamine;	  Thermo	  Fisher	  Scientific,	  supplemented	  with	  heat	  inactivated	  (56°C	  for	  30	  mins)	  5%	  pooled	  human	  AB	  serum;	  Sigma-­‐Aldrich,	  and	  100	  U/ml	  streptomycin,	  100	  U/ml	  penicillin;	  Sigma-­‐Aldrich).	  Cells	  were	  counted	  on	   haemocytometer	   and	   then	   seeded	   into	   48-­‐well	   cell	   culture	   plates	   at	   a	  concentration	   of	   1x106	   cells/well	   and	   incubated	   at	   37°C	   at	   5%	   CO2.	   The	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supernatant	  was	  removed	  2	  hours	  later,	  and	  replaced	  with	  differentiation	  media	  (adhesion	  media	  supplemented	  with	  5%	  pooled	  human	  AB	  serum;	  Sigma-­‐Aldrich	  and	  20	  ng/ml	  human	  M-­‐CSF).	  Subsequent	  media	  replacements	  occurred	  on	  day	  3	  and	  day	  6	  post-­‐isolation	  with	  adhesion	  media,	  and	  serum-­‐free	  adhesion	  media,	  respectively.	   Human	  monocyte	   derived	  macrophages	   (HMDMs)	  were	   activated	  on	   day	   7	   with	   RPMI	   1640	   supplemented	   with	   5%	   human	   AB	   serum	   (Sigma-­‐Aldrich),	  100	  U/ml	   streptomycin,	  100	  U/ml	  penicillin,	  0.5	  μg/ml	  human	   IFN-­‐γ;	  ImmunoTools;	  and	  1	  μg/ml	  E.	  coli	  LPS;	  Sigma-­‐Aldrich)	  24	  hours	  before	  carrying	  out	  the	  phagocytosis	  assay.	  Cell	  culture	  media	  from	  donor	  MDMs	  was	  collected	  at	  each	  media	  replacement,	  divided	  into	  3	  aliquots	  and	  stored	  at	  -­‐80°C	  for	  cytokine	  profiling.	  	  
Cryptococcus	  Infection	  of	  HMDMs	  	  Green	  Fluorescent	  Protein	  (GFP)	   -­‐labeled	  C.	  neoformans	  var.	  grubii	  serotype	  A,	  strain	  KN99α	  [199]	  was	  used	  in	  all	  macrophage	  challenge	  experiments.	  	  	  An	  overnight	  culture	  of	  the	  yeast	  was	  started	  by	  inoculating	  3	  mL	  of	  YPD	  (10	  g/L	  yeast	  extract,	  20	  g/L	  bacteriological	  peptone,	  and	  20	  g/L	  glucose	  (Sigma-­‐Aldrich)	  media,	   and	   incubated	   on	   a	   rotor	   at	   20	   rpm	   at	   25	   °C,	   prior	   to	   conducting	   the	  phagocytosis	  assay.	  In	  preparation	  for	  phagocytosis,	  yeasT-­‐cells	  were	  washed	  in	  PBS,	  counted	  on	  a	  haemocytometer,	  and	  opsonized	  with	  either	  mouse	  IgG	  anti-­‐Crypto18B7	  (18B7)	  antibody,	  or	  pooled	  human	  serum	  (PHS)	  in	  the	  initial	  phase	  of	   the	   study	   to	   establish	   the	   effects	  of	   opsonization	  on	  macrophage	   responses;	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and	   thereafter	   opsonized	   solely	   with	   5%	   heat-­‐inactivated	   human	   AB	   serum	  (Sigma-­‐Aldrich).	   Assuming	   10%	   of	   the	   isolated	   monocytes	   had	   adhered	   and	  differentiated,	   human	   monocyte	   derived	   macrophages	   (hMDMs)	   where	   then	  infected	  with	  1x106	  yeasT-­‐cells	  per	  well	  (MOI	  10:1),	  and	  incubated	  at	  37°C,	  5%	  CO2	  for	  2	  hours.	  At	  0	  (T0)	  and	  18	  (T18)	  hours	  post-­‐infection,	  extracellular	  yeasT-­‐cells	  were	  washed	  away	  using	  PBS	  and	  macrophages	  containing	  yeasT-­‐cells	  were	  lysed	   in	   dH2O	   at	   37	   °C,	   5%	   CO2	   for	   30	   minutes.	   For	   live	   imaging	   to	   quantify	  vomocytosis,	   hMDMs	   were	   washed	   at	   T	   (0),	   fresh	   serum-­‐free	   RPMI	   added	   to	  infection	  wells	  and	  taken	  for	  imaging.	  Infection	  media	  from	  T	  (0)	  and	  T	  (18)	  was	  also	  divided	  into	  3	  aliquots	  and	  stored	  at	  -­‐80°C	  for	  cytokine	  profiling.	  
	  
CFU	  counts	  	  Serial	  dilutions	  of	  lysates	  from	  the	  phagocytosis	  assay	  were	  prepared	  and	  plated	  onto	   2%	   YPD,	   1%	   agar	   (Sigma-­‐Aldrich)	   plates	   then	   incubated	   for	   48	   hours	   at	  25°C.	  Intracellular	  proliferation	  rates	  were	  measured	  by	  dividing	  the	  number	  of	  counting	  colony-­‐forming	  units	  per	  milliliter	  at	  T	  (18)	  by	  those	  at	  T	  (0).	  	  
Live	  cell	  imaging	  	  All	  time	  lapse	  images	  were	  captured	  on	  a	  Zeiss	  Axio	  Observer	  Live	  cell-­‐imaging	  microscope	   enclosed	   within	   a	   humidified	   Okolab	   microscope	   chamber	   set	   at	  37°C,	  5%	  CO2,	  a	  Hamamatsu	  digital	  camera,	  LD	  Plan-­‐Neofluar	  20x/0.4	  Korr	  Ph	  2	  M27	   objective,	   38	   HE	   Green	   Fluorescent	   reflector,	   using	   Zen	   software	   (Zeiss).	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217	   frames	   (1	   frame,	   every	   5	   minutes	   for	   18	   hours)	   were	   taken	   from	   four	  different	   positions	   within	   each	   well	   to	   produce	   movies	   for	   manual	   analysis.	  Vomocytosis	   was	   measured	   as	   the	   percentage	   of	   intracellular	   cryptococci	  expelled	  from	  macrophages	  over	  the	  18-­‐hour	  period	  in	  all	  well	  positions.	  
	  
Cytokine	  profiling	  
Extracellular	  cytokine	  profiling	  Cell	   culture	   supernatants	   collected	   from	   donor	  MDMs	   prior	   to	   infection,	   at	   T0	  and	   at	   T18	   post-­‐infection,	   along	   with	   live	   serum	   aliquots	   that	   had	   been	  previously	   stored	   at	   -­‐80	   °C	   were	   thawed	   on	   ice	   in	   preparation	   for	   cytokine	  profiling.	  The	   IFN-­‐γ	   levels	  were	  quantified	  using	  a	  Human	   IFN-­‐	  gamma	  DuoSet	  ELISA	  kit	  (R&D	  Systems,	  DY285);	  whilst	  a	  qualitative	  Human	  Th1	  /	  Th2	  /	  Th17	  Cytokines	   Multi-­‐Analyte	   ELISArray™	   Kit	   (QIAGEN,	   MEH-­‐003A)	   was	   used	   to	  detect	   increases	   or	   decreases	   in	   cytokine	   production	   relative	   to	   the	   positive	  controls	  provided	  in	  the	  kit.	  	  	  Further,	  quantitative	  cytokine	  profiling	  was	  carried	  out	  using	  the	  Luminex	  Bio-­‐plex	   (27-­‐plex)	   (Bio-­‐Rad,	  M500KCAF0Y).	   Initially,	   samples	   from	   6	   donors	  were	  probed	   for	   alternative	   or	   differential	   production	   of	   27	   human	   cytokines	   and	  chemokines	   using	   the	   Luminex	   Bio-­‐plex	   (27-­‐plex;	   Bio-­‐Rad);	   which	   were	   then	  narrowed	   down	   to	   a	   panel	   of	   7	   cytokines	   that	   had	   previously	   been	   associated	  with	   cryptococcosis	   in	   HIV	   patients	   (IL-­‐1β,	   IL-­‐6,	   G-­‐CSF,	   GM-­‐CSF,	   IFN-­‐γ,	   MCP-­‐1	  (MCAF),	   and	   TNF-­‐α)	   due	   to	   unavailability	   of	   data	   in	   non	   HIV	   patients.	   We	  incorporated	  these	  cytokines	  into	  a	  custom-­‐made	  Bio-­‐plex	  Pro	  Human	  Cytokine	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7-­‐plex	   express	   assay	   for	   subsequent	   cytokine	   detection	   in	   12	   donors,	   in	  accordance	   with	   the	   manufacturer’s	   protocol.	   The	   fold	   change	   (pg/mL)	   in	  cytokines	   released	   by	   donor	   MDMs	   was	   calculated	   by	   dividing	   the	   cytokine	  concentrations	  at	  T18	  by	  those	  at	  T0	  for	  each	  donor.	  Correlation	  with	  matched	  vomocytosis	  and	  IPR	  data	  was	  carried	  out	  using	  the	  Graphpad	  Prism	  6	  software.	  	  	  
Intracellular	  cytokine	  profiling	  Flow	  Cytometry	  was	   used	   to	  measure	   intracellular	   cytokine	   produced	   by	   non-­‐activated,	  M1	  and	  M2	  donor	  MDMs.	  During	   the	  18-­‐hour	   in	  vitro	  challenge	  with	  Kn99α-­‐GFP,	   At	   T	   (13)	   post-­‐infection,	   a	   1:1000	   dilution	   of	   Brefeldin	   A	   (Sigma-­‐Aldrich,	  B7651)	  was	  added	  to	  the	  48-­‐well	  plate	  to	  block	  extracellular	  trafficking	  of	   cytokines,	   and	   reincubated	   at	   37	   °C,	   5%	   CO2	   for	   5	   hours.	   At	   T	   (18),	  extracellular	   cryptococci	   were	   washed	   off,	   and	   250	   μl	   of	   Accutase	   (Sigma-­‐Aldrich,	  A6964)	  was	  added	  to	  dislodge	  the	  MDMs.	  Cells	  were	  then	  transferred	  to	  v-­‐bottom	  96-­‐well	   plates	   and	   spun	   at	   1200	   rpm	   for	   3	  mins.	   The	   cell	   pellet	  was	  fixed	   with	   3.7%	   formaldehyde	   for	   10	   mins,	   washed	   with	   PBS,	   and	   then	  permeabilised	   with	   0.1%	   Saponin	   for	   10	   mins,	   and	   washed	   again	   with	   PBS.	  Query	  MDMs	  were	  then	  stained	  for	  20	  mins	  in	  the	  dark	  with	  either	  IFN-­‐-­‐gamma	  APC	  (BD	  biosciences,	  554702)	  at	  a	  1/167	  dilution	  in	  0.1%	  Saponin;	  or	  TNF-­‐alpha	  eFluor450	  (eBioscience,	  48-­‐7349-­‐42)	  at	  a	  1/50	  dilution	  in	  0.1%	  Saponin.	  Isotype	  controls	  were	  also	  stained	  for	  20	  mins	  in	  the	  dark	  with	  Mouse	  anti-­‐IgG2b	  V450	  (MBL	  International,	  FP20644010)	  at	  a	  1/200	  dilution,	  and	  Mouse	  anti-­‐IgG1	  APC	  (BD	  biosciences,	  550854)	  at	  a	  1/167	  dilution.	  Data	  was	  collected	  using	  Beckman	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Coulter	  CyAn	  ADP	  —	  Flow	  Cytometry	  Core	  Facility,	   and	  analyzed	  using	  FlowJo	  Version	  10.0.7.	  
	  
Power	  calculations	  	  In	   order	   to	   assess	   the	   sample	   size	   that	   would	   generate	   statistically	   relevant	  results,	   we	   conducted	   a	   power	   calculation	   in	   order	   to	   identify	   the	   required	  population	  size	  “n”,	  necessary	  for	  adequate	  power.	  In	  order	  to	  do	  this,	  we	  used	  the	  formula	  below;	  where	  “z”	  is	  the	  critical	  value	  of	  the	  normal	  distribution	  for	  a	  confidence	   level	   of	   95%	  with	   a	   critical	   value	   of	   1.96;	   and	   “e”	   is	   the	  margin	   of	  error	  of	  0.05;	  and	  p	  is	  the	  sample	  proportion.	  The	  value	  of	  “p”	  was	  derived	  from	  the	  population	  the	  either	  had	  an	  IPR	  below	  1,	  or	  vomocytosis	  rate	  above	  the	  75%	  confidence	  interval	  (CI).	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Results	  
Effects	  of	  opsonization	  on	  host	  responses	  to	  C.	  neoformans	  infection	  To	   assess	   the	   effects	   of	   complement-­‐mediated	   immunity	   in	   comparison	   to	  antibody-­‐mediated	  immunity	  on	  the	  intracellular	  parasitism	  of	  the	  yeast	  (Fig.	  7)	  and	  on	  vomocytosis	  of	  cryptococci	   from	  macrophages	  (Fig.	  8),	  we	  opsonized	  C.	  neoformans	   var.	   grubbi	   with	   either	   pooled	   human	   serum	   (PHS),	   or	   the	   anti-­‐cryptococcal	  antibody	  18B7,	  respectively.	  Opsonization	  lasted	  for	  1	  hour	  prior	  to	  infection	  of	  hMDMs	  from	  6	  of	  the	  cohort’s	  participants.	  We	  thereafter	  measured	  the	  release	  of	  the	  Th1	  cytokine	  IFN-­‐γ	  into	  the	  cell	  culture	  supernatant	  by	  ELISA	  prior	   to	   activation	   of	  MDMs	  with	   LPS	   and	   IFN-­‐γ,	   and	   at	   0-­‐	   and	  18-­‐	   hours	   post	  infection	  with	  cryptococci	  (Fig.	  9).	  We	  also	  established	  baseline	  levels	  of	  serum	  IFN-­‐γ	  for	  each	  individual	  at	  the	  point	  of	  blood	  donation	  (Fig.	  9).	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Figure	   7.	   Intracellular	   Proliferation	   Rates	   (IPRs)	   of	   6	   healthy	   donors’ 	   monocyte-­‐derived	  
macrophages	   (MDMs)	   challenged	   with	   C.	   neoformans	   Kn99α -­‐GFP	   opsonized	   with	   either	   the	  
antibody	   18B7,	   or	   Pooled	   Human	   Serum	   (PHS).	   Each	   point	   represents	   an	   independent	   blood	  
donation	  where	  N=3	  for	  RG001,	  RG002,	  RG003	  and	  RG004;	  N=1	  for	  RG005	  and	  N=2	  for	  RG006.	  Error	  
bars	   are	   representative	   of	  means	   and	   standard	   deviations.	   Table	   of	  means	   is	   included	   below	   the	  
graph.	  
	  Our	  findings	  show	  that	  opsonizing	  Cryptococci	  with	  either	  the	  anti-­‐cryptococcal	  antibody	  (18B7)	  or	  pooled	  human	  serum	  (PHS),	  does	  not	  affect	  the	  intracellular	  parasitism	   of	   C.	   neoformans	   Kn99α-­‐GFP	   in	   monocyte-­‐derived	   macrophages	  (hMDMs)	  from	  6	  healthy	  donors	  (RG001-­‐RG006).	  Two-­‐way	  analysis	  of	  variance	  revealed	  no	  significant	  differences	  between	  the	  two	  methods	  of	  opsonization	  (P	  =	   0.7611).	   We	   observed	   high	   intra-­‐donor	   variability	   amongst	   donors	   RG001-­‐RG004,	  and	  consistent	  IPRs	  for	  RG006	  (Fig.	  7).	  Whilst	  donor	  identity	  accounted	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for	   27.17%	   of	   the	   total	   variance,	   there	  were	   no	   significant	   differences	   in	   IPRs	  among	  the	  6	  donors	  (P	  =	  0.2317).	  	  	  
	  
Figure	   8.	   Vomocytosis	   Rates	   (%)	   of	   C.	   neoformans	   Kn99α -­‐GFP	   from	   monocyte-­‐derived	  
macrophages	  of	  6	  healthy	  donors	  following	  opsonization	  with	  either	  the	  antibody	  18B7,	  or	  Pooled	  
Human	  Serum	  (PHS).	  Each	  point	  represents	  an	   independent	  blood	  donation	  where	  N=3	  for	  RG001	  
(18B7-­‐	  and	  PHS-­‐opsonized),	  N=2	  for	  RG002	  (PHS-­‐opsonized),	  N=3	  for	  RG002	  (18B7-­‐opsonized),	  N=3	  
for	   RG003	   (18B7-­‐opsonized),	   N=2	   for	   RG003	   (PHS-­‐opsonized),	   N=3	   for	   RG004	   (18B7-­‐opsonized),	  
N=1	  for	  RG004	  (PHS-­‐opsonized),	  N=2	  for	  RG005	  (18B7-­‐opsonized),	  N=3	  for	  RG005	  (PHS-­‐opsonized),	  
N=1	   for	   RG006	   (18B7-­‐opsonized),	   and	   N=2	   for	   RG006	   (PHS-­‐opsonized).	   Error	   bars	   are	  
representative	   of	   means	   and	   standard	   deviations.	   Methods	   of	   opsonization	   were	   significantly	  
different	  for	  RG003,	  and	  RG006.	  Table	  of	  means	  is	  included	  below	  the	  graph.	  
We	  also	  measured	  yeast	  expulsion	  rates	  from	  each	  individual’s	  MDMs	  following	  
in	  vitro	  challenge	  with	  C.	  neoformans	  Kn99α-­‐GFP	  that	  had	  been	  opsonized	  with	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either	   the	   18B7	   antibody	   or	   pooled	   human	   serum	   (PHS;	   Fig.	   8).	   Two-­‐way	  analysis	   of	   variance	   revealed	   that	   the	   method	   of	   opsonization	   accounted	   for	  approximately	  3.58%	  of	   the	  total	  variance,	  and	  found	  no	  significant	  differences	  in	   vomocytosis	   between	   18B7-­‐	   and	   PHS-­‐	   opsonized	   Cryptococci	   (P	   =	   0.1138).	  However,	   donor	   identity	   accounted	   for	   approximately	   30.11%	   of	   the	   total	  variance,	  and	  showed	  that	  vomocytosis	  varied	  significantly	  between	  donors	  (P	  	  =	  0.0078).	   Bonferroni’s	   multiple	   comparisons	   test	   showed	   that	   the	   method	   of	  opsonization	   significantly	   affected	   yeast	   expulsion	   from	   MDMs	   from	   donors	  RG003	  and	  RG006	  (p	  <	  0.05).	  For	  both	  individuals,	  18B7-­‐opsonized	  Cryptococci	  were	  more	   likely	   to	  be	  expelled.	  These	   findings	  suggest	   that,	  depending	  on	   the	  individual;	   the	  method	   of	   opsonization	  would	   affect	   the	   extent	   of	   cryptococcal	  expulsion	  from	  macrophages.	  	  
	  
Figure	   9.	   Human	   Gamma-­‐interferon	   IFN-­‐γ 	   in	   donor	   sera	   at	   time	   of	   blood	   donation,	   and	   that	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either	  the	  antibody	  18B7,	  or	  Pooled	  Human	  Serum	  (PHS).	  Error	  bars	  represent	  standard	  deviation;	  
Each	  point	  represents	  an	  independent	  blood	  donation	  where	  N=2	  for	  all	  donors.	  
	  We	  also	  measured	  the	  amounts	  of	  IFN-­‐γ	  in	  donor	  sera,	  as	  well	  as	  that	  released	  by	  MDMs	  prior	  to	  activation	  with	  IFN-­‐γ	  and	  LPS;	  and	  at	  0-­‐hours	  and	  18-­‐hours	  after	  infection	  with	  either	  PHS-­‐	  of	  18B7-­‐	  opsonized	  C.	  neoformans	   (Fig.	  9).	  Two-­‐way	  ANOVA	   revealed	   that	   a	   significant	   interaction	   between	   donor	   identity	   and	  method	   of	   opsonization	   (P	   =	   0.0152)	   that	   accounted	   for	   11.62%	   of	   the	   total	  variance.	   Whilst	   the	   opsonization	   method	   accounted	   for	   55.16%	   of	   the	   total	  variance	   (after	   adjusting	   for	   matching),	   this	   variance	   was	   not	   significant	   (P	   =	  0.1268).	  In	  addition,	  even	  though	  donor	  identity	  accounted	  for	  only	  2.91%	  of	  the	  total	   variance	   (after	   adjusting	   for	   matching);	   donor	   identity	   significantly	  contributed	  to	  the	  observed	  variance	  (P	  =	  0.0309).	  We	  found	  that	  serum	  levels	  of	  IFN-­‐γ	  varied	  significantly	  between	  donors,	  but	  no	  significant	  differences	  in	  IFN-­‐γ	  release	  were	  found	  in	  all	  other	  culture	  supernatant	  samples.	  RG004	  and	  RG006	  sera	   contained	   significantly	   higher	   levels	   of	   IFN-­‐γ	   compared	   to	   the	   rest	   of	   the	  group	   (Bonferroni’s	  multiple	   comparisons	   test;	  RG004,	  p	  <	  0.05;	   and	  RG006,	  p	  <0.0001).	  Whilst	  were	  detected	  high	  sera	  levels	  of	  IFN-­‐γ	  for	  RG004	  and	  RG006	  that	   may	   be	   residual,	   these	   were	   within	   normal	   limits	   for	   healthy	   adults,	   as	  baseline	  IFN-­‐γ	  levels	  can	  vary	  greatly	  between	  individuals.	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Figure	  10.	  Average	  amounts	  of	  IFN-­‐γ 	  in	  sera	  from	  6	  participants,	  and	  that	  released	  by	  MDMs	  prior	  
to	   activation,	   and	   following	   infection	  with	   either	  Antibody/18B7-­‐	   or	  Pooled	  Human	   Serum	   (PHS)-­‐	  
opsonized	  C.	  neoformans.	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  Furthermore,	  grouped	  analysis	  of	  the	  6	  donors	  proved	  there	  was	  no	  significant	  difference	   in	   IFN-­‐γ	   levels	   between	   serum	   and	   pre-­‐activation	   (p>	   0.9999);	   pre-­‐activation	  and	  18B7-­‐opsonized	  (p>	  0.9999)	  nor	  PHS-­‐opsonized	  (p=	  0.1445).	  At	  T	  (0)	  and	  T	  (18)	  there	  were	  no	  significant	  differences	  between	  MDM	  responses	  to	  either	   18B7-­‐opsonized	   or	   PHS-­‐opsonized	   cryptococci	   (at	   T	   (0),	   p=0.0610;	   at	   T	  (18),	   p=0.8598).	   For	   the	   18B7-­‐opsonized	   cryptococcal	   challenge,	   there	  was	   no	  significant	  difference	  in	  amounts	  of	  IFN-­‐γ	  between	  T	  (0)	  and	  T	  (18)	  (p>	  0.9999).	  	  	  Overall,	   all	   donors	   showed	   heightened	   IFN-­‐γ	   production	   in	   response	   to	  complement-­‐opsonized	   cryptococci	   at	   T	   (0),	   but	   not	   to	   antibody-­‐opsonized	  yeast;	   that	   subsequently	   reduced	  by	   the	  end	  of	   the	   cryptococcal	   challenge	  at	  T	  (18).	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Host	  responses	  to	  C.	  neoformans	  infections	  vary	  within	  and	  between	  
donors	  	  To	  compare	   intra-­‐donor	  and	   inter-­‐donor	  variation	   in	  macrophage	  responses	   to	  infection	  with	  C.	  neoformans,	  we	  took	  repeated	  blood	  samples	   from	  a	  cohort	  of	  15	  healthy	   volunteers	   over	   a	   period	   of	   2-­‐3	   years,	   taking	   into	   account	   seasonal	  effects	   on	   host	   immunity.	   We	   derived	   macrophages	   in	   vitro	   with	   macrophage	  colony-­‐stimulating	   factor	   (M-­‐CSF),	   and	   then	   analyzed	   both	   intracellular	   fungal	  proliferation	  rates	  (IPR;	  Fig.	  11A)	  and	  the	  rate	  of	  non-­‐lytic	  yeast	  expulsion	  from	  within	   macrophages	   (Fig.	   11B).	   Intracellular	   proliferation	   rate	   varied	  dramatically	  between	  and	  within	  donors	  (Fig.	  11A	  and	  Table	  1;	  2)	  and	  there	  was	  no	  significant	  difference	  in	  mean	  IPR	  between	  individual	  donors,	  suggesting	  that	  environmental	  variation	  (e.g.	  in	  the	  inflammatory	  status	  of	  the	  donor	  at	  the	  time	  of	  donation)	   is	  a	  more	  significant	  driver	  of	  variation	   in	   IPR	   than	  donor	  genetic	  background.	   In	   contrast,	   vomocytosis	   rate	   (calculated	   as	   the	   proportion	   of	  cryptococcal	  cells	  expelled	  from	  donor	  MDMs	  over	  an	  18-­‐hour	  period)	  was	  much	  less	  variable	  between	  repeat	  samples	  with	  no	  significant	  inter-­‐donor	  difference	  in	  expulsion	  (p	  =	  0.0820,	  one-­‐way	  ANOVA;	  Fig.	  11B).	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Figure	   11.	   Variation	   in	   host	   responses	   to	   C.	   neoformans	   infections;	   A)	   measured	   intracellular	  
proliferation	  rate	  (IPR)	  for	  each	  donor	  showing	  median	  of	  at	  least	  2	  biological	  repeats	  each	  (mean=	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observed	  between	  and	  within	  donors	  showing	  median	  of	  at	  least	  2	  biological	  repeats	  each	  (mean=	  
41.55%,	   SD=	   15.53	   and	   Coefficient	   of	   variation=	   37.37%);	   C)	   Correlation	   between	   intracellular	  
parasitism	  and	  non-­‐lytic	  expulsion	  events	  (R	  square=	  0.2501,	  P-­‐value=	  0.0005).	  
	  
We	  thereafter	  analyzed	  our	  donor-­‐specific	  matched	  data	  to	  check	  for	  correlation	  between	   IPR	   and	   vomocytosis	   rates	   (Fig.	   11C).	   Whilst	   low	   intracellular	  proliferation	   rates	   corresponded	   with	   low	   vomocytosis	   rates,	   IPRs	   above	   0.8	  could	  not	  be	  associated	  with	  either	  low	  or	  high	  vomocytosis	  rates;	  leading	  to	  an	  overall	  weak	  correlation	  between	  the	  two	  variables	  (R	  square=	  0.2501,	  P-­‐value=	  0.0005).	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Table	   2.	   Quantitation	   of	   variation	   in	   intracellular	   proliferation	   rates	   and	   vomocytosis	   rates	   (%)	  
across	  15	  donors.	  














variationRG001 0.97 0.84 0.50 51.59% 58.75 58.25 8.35 14.20%RG002 1.19 1.59 0.72 60.50% 58.00 57.17 4.15 7.15%RG003 0.90 0.65 0.99 109.89% 36.83 36.83 7.07 19.20%RG004 0.58 0.70 0.29 49.88% 39.78 42.50 5.45 13.71%RG005 0.32 0.37 0.21 65.20% 38.43 31.83 16.93 44.05%RG006 0.61 0.48 0.36 58.89% 27.60 28.67 7.49 27.15%RG007 0.49 0.31 0.52 106.27% 41.06 41.00 9.87 24.05%RG009 0.20 0.14 0.21 107.18% 36.61 38.00 13.64 37.25%RG010 0.72 0.76 0.11 15.56% 51.39 53.00 13.82 26.90%RG011 0.60 0.62 0.40 66.73% 56.78 53.00 19.61 34.54%RG012 0.19 0.19 0.16 81.88% 28.56 28.56 17.76 62.18%RG013 1.02 0.76 1.16 113.76% 40.44 32.33 23.57 58.28%
RG014 0.97 1.20 0.79 81.35% 29.05 28.17 12.34 42.49%RG015 0.70 0.91 0.43 61.94% 32.25 29.00 23.30 72.23%RG016 0.33 0.22 0.23 68.50% 36.22 35.67 5.52 15.24%
Intracellular*Proliferation*Rate Vomocytosis*(%)
Donor*ID
Table	  1.	  Intra-­‐donor	  variation	  in	  monocyte-­‐derived	  macrophage	  (MDM)	  responses	  to	  C.	  neoformans	  
infections	  in	  vitro.	  Means	  and	  medians	  shown	  are	  of	  at	  least	  2	  biological	  repeats	  per	  donor	  
extrapolated	  from	  at	  least	  2	  technical	  repeats.	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Cytokine	   profiles	   are	   not	   predictive	   of	   varied	   responses	   to	   C.	  
neoformans	  infections	  	  Host	   cytokine	   profile	   has	   previously	   been	   shown	   to	   impact	   strongly	   on	   the	  response	   to	   cryptococcocal	   infection	   [210,	   214].	   We	   therefore	   wondered	  whether	   differences	   in	   the	   secreted	   cytokine	   and	   chemokine	   milieu	   during	   in	  
vitro	  culture	  might	  influence	  their	  subsequent	  response	  to	  cryptococci.	  	  	  To	  assess	  this,	  we	  examined	  cell	  culture	  supernatants	  for	  T	  (0)	  and	  T	  (18)	  from	  6	  donors	  for	  increases	  or	  decreases	  in	  the	  release	  of	  Th1,	  Th2	  and	  Th17	  cytokines	  (Table	   3).	   No	   consistent	   cytokine	   profile	   was	   observed;	   IL2	   and	   TGF-­‐β	   was	  undetected	  in	  RG005,	  while	  only	  RG012	  showed	  decreased	  production	  of	  IL2	  in	  comparison	   to	   the	   rest	   of	   the	   group.	   An	   increase	   in	   IL6	   and	  G-­‐CSF	   production	  was	  observed	  in	  3	  individuals,	  and	  decreased	  in	  the	  other	  3	  donors.	  An	  increase	  in	  IL10	  and	  IFN-­‐γ	  release	  was	  only	  observed	  in	  RG006	  and	  RG001,	  respectively;	  while	   TNF-­‐α	   production	   was	   lowered	   in	   only	   two	   of	   the	   donors	   (RG013	   and	  RG014).	   Except	   for	   RG005,	   TGF-­‐β	   production	   decreased	   over	   the	   18-­‐hour	  infection	  period	  (Table	  3).	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Table	   3.	   Th1,	   Th2	   and	   Th17	   qualitative	   cytokine	   release	   by	   MDMs	   from	   6	   donors	   showing	  
inconsistent	  cytokine	  profiles.	  Cells	  highlighted	  purple	   indicate	  a	  varied	  profile	  of	  a	  each	  donor	   in	  
comparison	   to	   other	  donors.	  Upward	   arrows	   indicate	   an	   increase	   in	   cytokine	   release	  over	   an	  18-­‐
hour	  period,	  while	  downward	  arrows	  indicate	  a	  reduction.	  
We	  thereafter	  quantified	  levels	  of	  seven	  cytokines	  and	  chemokines	  (interferon-­‐γ	  (IFN-­‐γ),	   TNF-­‐α,	   interleukin-­‐1b	   (IL-­‐1b),	   interleukin-­‐6	   (IL-­‐6),	   MCP-­‐1,	   G-­‐CSF	   and	  GM-­‐CSF)	  in	  the	  media	  immediately	  following	  cryptococcal	  infection	  and	  again	  18	  hours	   later.	  We	   correlated	   them	  with	  measured	   IPRs	   (Figure	   12;	   Table	   4)	   and	  vomocytosis	  rates	  for	  each	  donor	  (Figure	  13;	  Table	  4).	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Figure	  12.	  Correlations	  of	  fold	  changes	  in	  pro-­‐inflammatory	  cytokines	  with	  IPR.	  Cytokines	  released	  
over	   18	   hours	   were	   correlated	   with	   intracellular	   proliferation	   rates	   of	   KN99α-­‐GFP	   from	   donor	  
MDMs	  for	  13	  donors.	  No	  significant	  associations	  were	  found	  between	  IPR	  and	  with	  a)	  IFN-­‐γ ;	  b)	  TNF-­‐
α ;	   c)	   IL-­‐1b;	  d)	   IL-­‐6;	   f)	  G-­‐CSF;	  nor	  g)	  GM-­‐CSF.	  Note	   that	  only	  data	  points	   that	  crossed	   the	  detection	  
threshold	  are	  shown	  hence	  not	  all	  graphs	  contain	  all	  data	  points.	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Figure	  13.	  Correlation	  of	  pro-­‐inflammatory	  cytokine	  profile	   from	  donor	  MDMs	  over	  18-­‐hours	  with	  
non-­‐lytic	   expulsion	   (vomocytosis)	   of	   KN99α -­‐GFP.	   No	   significant	   correlations	   were	   observed	  
vomocytosis	  data	  from	  13	  donors	  with	  a)	  IFN-­‐γ ;	  b)	  TNF-­‐α ;	  c)	  IL-­‐1b;	  d)	  IL-­‐6;	  e)	  MCP-­‐1;	  f)	  G-­‐CSF;	  nor	  
g)	  GM-­‐CSF.	  Note	  that	  only	  data	  points	  that	  crossed	  the	  detection	  threshold	  are	  shown	  hence	  not	  all	  
graphs	  contain	  all	  data	  points.	  






























































































































	   105	  
	  
	  
Table	  4.	  Correlation	  data	  for	  fold	  changes	  in	  detected	  cytokines	  with	  Intracellular	  Proliferation	  Rate	  
(IPR)	  and	  vomocytosis	  of	  KN99α-­‐GFP	  from	  MDMs	  from	  13	  healthy	  donors.	  
We	  found	  that	  cytokine	  levels	  varied	  dramatically	  between	  samples	  there	  was	  no	  significant	  correlation	  with	  either	  vomocytosis	  or	  IPR.	  	  	  To	  test	  whether	  vomocytosis	  was	  dependent	  on	  intracellular	  cytokine	  signaling	  as	   opposed	   to	   the	   above	   measurements	   of	   extracellular	   cytokines	   in	   the	   cell	  culture	  supernatants,	  we	  measured	  the	  amount	  of	  intracellular	  IFN-­‐γ	  and	  TNF-­‐α	  in	  two	  of	  the	  study	  participants	  (RG002	  and	  RG006)	  between	  13	  and	  18-­‐	  hours	  post-­‐infection	  with	  C.	  neoformans	   Kn99α-­‐GFP	   (Fig.	   15)	   as	   their	  MDMs	   showed	  relatively	  varied	  average	  vomocytosis	  rates	  of	  58.00%	  and	  27.60%,	  respectively	  (Fig.11).	  	  The	   amounts	   of	   each	   proinflammatory	   cytokine	   released	   by	   each	   donor’s	  infected	  M1	   and	  M2	  macrophages	  were	   compared	   to	   their	   own	   control	  MDMs	  that	  had	  not	  been	  activated,	  nor	  infected.	  For	  RG002,	  whilst	  similar	  amounts	  of	  intracellular	   IFN-­‐γ	   were	   detected	   in	   test	   and	   control	   sample,	   C.	   neoformans–
Spearman(r P*value Spearman(r P*value
IL*1b 0.2520 0.2242 0.0873 0.6781
IL*5 -0.2008 0.5015 -0.5989 0.0340
IL*6 0.0704 0.7380 0.0950 0.6514
IL*17 0.0332 0.9201 -0.3923 0.1795
IFN*γ 0.2185 0.2939 0.1466 0.4845
TNF*α 0.0067 0.9757 0.0905 0.6814
G*CSF 0.3478 0.1039 0.0702 0.7505
GM*CSF 0.2370 0.2540 -0.0635 0.7631
MCP*1 0.4917 0.0467 0.1054 0.6161
IPR Vomocytosis
Cytokine/chemokine
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infected	   macrophages	   released	   higher	   amounts	   of	   TNF-­‐α	   than	   uninfected	  macrophages	  with	  M2-­‐activated	  macrophages	  releasing	   the	  highest	  amounts	  of	  the	  cytokine	  (Fig.	  15).	   In	  opposition,	  we	   found	  no	  differences	  between	   infected	  M1,	  M2	  and	  uninfected	  macrophages	   in	   intracellular	   IFN-­‐γ	  and	  TNF-­‐α	  released	  by	  MDMs	  from	  RG006	  (Fig.	  15).	  Thus,	  donor	  variation	  in	  autocrine	  inflammatory	  signaling	   during	   culture	   contributes	   to,	   but	   cannot	   fully	   explain,	   the	   observed	  differences	  in	  vomocytosis.	  	  
	  
Figure	   14.	   Intracellular	   cytokine	   measurements	   for	   M1	   and	   M2	   activated	   macrophages	   from	   2	  
healthy	  donors	  between	  13	  and	  18-­‐	  hours	  post-­‐infection	  with	  C.	  neoformans	  Kn99α-­‐GFP:	  A)	  RG002	  
TNF-­‐α;	  B)	  RG002	  IFN-­‐γ;	  C)	  RG006	  TNF-­‐α;	  and	  D)	  RG006	  IFN-­‐γ.	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Variation	   in	   immunocompetent	   host	   macrophage	   responses	   to	   C.	  
neoformans	  is	  not	  driven	  by	  gender	  	  Given	  the	  established	  enhanced	  risk	  of	  cryptococcosis	  in	  men	  with	  HIV	  [274],	  but	  lack	   of	   gender	   bias	   in	   previously	   immunocompetent	   cryptococcosis	   patients	  [201]	   we	   tested	   whether	   gender	   impacts	   on	   these	   macrophage	   responses	   in	  
vitro.	   	   Consistent	   with	   the	   latter,	   neither	   IPR	   nor	   vomocytosis	   rate	   showed	  variation	  with	  donor	  gender	  in	  this	  cohort	  (Fig.	  12).	  
	  
	  
Figure	   15.	   Analysis	   of	   gender	   contribution	   to	   observed	   variation.	   Two-­‐tailed	   t-­‐tests	   revealed	   no	  
significant	   differences	   in	   a)	   intracellular	   virulence	   of	   KN99α-­‐GFP	   (P-­‐value	   =	   0.9856);	   and	   b)	   non-­‐
lytic	   yeast	   expulsion	   from	   donor	   MDMs	   (P-­‐value	   =	   0.3181).	   Plot	   shows	   means,	   error	   bars	   are	  
representative	  of	  standard	  deviations	  and	  n.s.	  states	  for	  non	  significant.	   	  
	  
Power	  calculations	  Based	   on	   the	   formula	   described	   in	   the	   Materials	   and	   methods	   section,	   we	  calculated	   that	   the	  sample	  size	   required	   to	  achieve	  a	  magnitude	  of	   significance	  for	  IPR	  and	  Vomocytosis	  was	  238	  and	  274,	  respectively.	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Discussion	  
	  Studies	   comparing	   clinical	   outcomes	   of	   different	   groups	   of	   cryptococcosis	  patients	  show	  that	  HIV	  negative	  patients	  suffer	  higher	  mortality	  rates	  than	  those	  with	   HIV.	   The	   high	   death	   rates	   in	   otherwise	   healthy	   individuals	   have	   been	  attributed	   to	   delayed	   diagnosis,	   inadequate	   treatment	   strategies,	   and	  exacerbated	   responses	   to	   cryptococcal	   infections	   that	   arise	   from	   otherwise	  ‘intact’	   immune	   systems.	   Previous	   attempts	   to	   characterize	   the	   differences	   in	  disease	   presentation	   and	   outcomes	   between	   HIV	   positive	   and	   negative	   CM	  patients	   suggest	   that	   exacerbated	   immune	   responses	   in	   otherwise	   healthy	  individuals	  contribute	  to	  the	  high	  mortality	  rates	  in	  non-­‐HIV	  CM	  patients	  [275].	  	  We	  have	  compared	  primary	  immune	  responses	  to	  Cryptococcosis	  by	  monitoring	  the	   intracellular	   pathogenicity	   of	   cryptococci	   in	   host	   monocyte-­‐derived	  macrophages	  –	  a	  critical	  cell	  type	  in	  anti-­‐cryptococcal	  defense	  -­‐	  from	  15	  healthy	  individuals.	  We	   have	   documented	   reproducible	   person-­‐to-­‐person	   variability	   in	  the	  rates	  of	  intracellular	  proliferation	  and	  vomocytosis,	  or	  non-­‐lytic	  extrusion,	  of	  the	   pathogen;	   and	   aimed	   to	   relate	   these	   effects	   to	   varying	   M1/M2	   cytokine	  responses.	  	  	  	  In	   cryptococcosis	  patients,	   the	   ability	   of	  macrophages	   to	  phagocytose	   infecting	  cryptococci	  plays	  a	  crucial	  role	  in	  determining	  the	  outcome	  of	  the	  infection.	  The	  varied	  clinical	  outcomes	  in	  immunocompetent	  individuals	  raises	  the	  question	  of	  whether	  the	  immune	  responses	  mounted	  against	  cryptococci	  were	  dependent	  on	  
	   109	  
which	   opsonization	   strategy	   was	   utilized	   by	   macrophages	   in	   the	   presence	   of	  differentially	   opsonized	   C.	   neoformans.	   Ma	   et	   al.	   previously	   showed	   that	  expulsion	  of	  engulfed	  cryptococci	  was	  independent	  of	  the	  route	  of	  uptake	  [170].	  However,	  whilst	  our	  data	  set	  suggest	  that	  vomocytosis	  may	  differ	  based	  on	  the	  opsonization	   route	   in	   some	   individuals.	   We	   show	   that	   there	   is	   a	   marked	  difference	   in	   individual	   responses	   to	   cryptococcal	   infection,	   and	   overall	  improved	  clearance	  of	  serum-­‐opsonized	  Cryptococcus;	  however,	  this	  preliminary	  dataset	   is	   too	   small	   to	   provide	   statistical	   deductions	   relative	   to	   the	   wider	  population.	  Given	  that	  intracellular	  parasitism	  of	  C.	  neoformans	  was	  similar	  in	  of	  serum-­‐opsonized	   and	   antibody-­‐opsonized	   yeast	   cells	   (Fig.	   7),	   and	   despite	   the	  similar	  expulsion	  rates	  of	  antibody-­‐	  and	  serum-­‐	  opsonized	  yeast	  cells	  in	  4	  of	  the	  6	  donors	  (Fig.	  8);	  we	  would	  recommend	  repetition	  of	  these	  experiments,	  as	  we	  did	   not	   quantify	   the	   pooled	   human	   serum	   used	   in	   our	   investigations	   for	   anti-­‐cryptococcal	  antibodies.	  As	  a	  majority	  of	  individuals	  from	  different	  geographical	  regions	   test	   positively	   for	   anti-­‐cryptococcal	   antibodies	   by	   the	   age	   of	   10	  (discussed	  in	  chapter	  1);	  it	  is	  likely	  that	  the	  serum	  used	  to	  opsonized	  cryptococci	  in	   our	   study	   constituted	   said	   antibodies.	   In	   order	   to	   eliminate	   donor-­‐specific	  opsonization	  biases,	  we	  tested	  the	  reliability	  of	  standardized	  human	  AB	  serum.	  We	   found	   no	   differences	   in	   phagocytosis	   rates	   between	   cryptococci	   opsonized	  with	  autologous	  donor	  serum,	  and	  those	  opsonized	  with	  standardized	  human	  AB	  Serum.	  Hence,	  we	  chose	   to	  proceed	  with	   the	   latter	   in	   subsequent	  phagocytosis	  experiments.	  	  	  We	   recently	   showed	   that	   the	   rate	   of	   vomocytosis	   may	   be	   increased	   via	   the	  inhibition	   of	   a	   MAP	   kinase,	   ERK5	   [184].	   However,	   the	   molecular	   mechanisms	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that	   orchestrate	   the	   expulsion	   of	   this	   yeast	   from	   macrophages	   are	   yet	   to	   be	  deciphered	  [257].	  Even	  within	  the	  small	  cohort	  characterized	  here,	  it	  is	  clear	  that	  vomocytosis	   rates	   show	   significant,	   intra-­‐donor	   variation.	   Whilst	   there	   is	   no	  observable	   correlation	   with	   vomocytosis	   and	   IPRs	   at	   the	   individual	   level,	  matched,	   singlet	   data	   points	   are	   positively	   correlated	   (P-­‐value=	   0.0167,	   R2=	  0.2544).	  However,	  the	  results	  from	  our	  study	  depart	  from	  previous	  observations	  by	   Chayakulkeeree	   et	   al.	   that	   the	   deletion	   of	   the	   cryptococcal	   virulence	   factor	  Phosoplipase	   B	   (Plb),	   reduced	   the	   rate	   of	   cryptococcal	   expulsion	   from	  macrophages	   [181].	  These	   findings	   suggest	   an	   inverse	   correlation	  between	   the	  two	   measures,	   and	   extensive,	   more	   details	   investigations	   of	   the	   relationship	  between	  intracellular	  parasitism	  and	  vomocytosis	  would	  need	  to	  be	  carried	  out.	  	  In	   contrast,	   the	   ability	   of	   macrophages	   to	   control	   cryptococcal	   intracellular	  proliferation	   is	   highly	   variable	   even	   between	   samples	   from	   the	   same	   donor,	  suggesting	   that	   thus-­‐far	   unidentified	   environmental	   factors	   such	   as	   allergies,	  seasonal	  flu	  and	  smoking	  may	  impact	  strongly	  on	  this	  phenotype.	  	  	  	  Levels	   of	   key	   inflammatory	   cytokines	   have	   been	   shown	   to	   impact	   strongly	   on	  cryptococcal	   disease	   progression	   in	   HIV	   patients	   [214].	   However,	   the	   results	  obtained	   from	   the	   qualitative	   cytokine	   profiling	   showed	   inconsistent	   cytokine	  profiles	  that	  were	  validated	  using	  the	  quantitative	  Luminex	  system.	  The	  data	  we	  present	   here	   shows	   that	   varying	   cytokine	   profile	   does	   not	   explain	   the	   in	   vitro	  variation	   in	   vomocytosis	   or	   IPR.	   The	   results	   from	   extracellular	   cytokine	  detection	  appear	  to	  be	  consistent	  with	  data	  suggesting	  the	  involvement	  of	  IFN-­‐γ	  in	  anticryptococcal	  responses,	  but	  are	  not	  consistent	  with	  data	  showing	  that	  IFN-­‐
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γ	   and	   vomocytosis	   are	   negatively	   correlated	   [271].	   These	   disparities	  may	   be	  attributed	   to	   the	   small	   sample	   of	   donors	   in	   this	   study	   that	   we	   propose	   is	  expanded	  to	  provide	  more	  reliable	  statistical	  conclusions.	  Hence,	  we	  conducted	  post-­‐hoc	  power	  calculations	  based	  on	  our	  data	  and	  determined	  that	  the	  sample	  size	   required	   to	   achieve	   said	   statistical	   validity	   for	   IPR	   and	   vomocytosis	   to	   be	  238	  and	  274,	  respectively.	  	  Of	   the	   donors	   with	   average	   IPRs	   lower	   than	   1	   (RG003,	   RG004,	   RG005	   and	  RG006),	   higher	   amounts	   of	   IFN-­‐γ	   were	   released	   in	   comparison	   to	   RG001	   and	  RG002.	  Although	  the	  high	  concentration	  of	  IFN-­‐γ	  detected	  in	  the	  sera	  of	  RG004	  and	  RG006	  were	  significantly	  high	  in	  comparison	  to	  the	  rest	  of	  the	  group	  (Fig.	  6),	  these	  results	  are	  representative	  of	  two	  independent	  MDM	  isolations	  (taken	  two	  or	   more	   weeks	   apart),	   and	   may	   be	   reflective	   of	   underlying	   asymptomatic	  inflammatory	   responses.	   The	   serum	   IFN-­‐γ	   levels	   detected	   for	   these	   two	  individuals	  were	  high	  on	  both	  occasions,	  but	  did	  not	  deviate	  outside	  the	  range	  of	  serum	  IFN-­‐γ	  in	  healthy	  adults.	  	  Analysis	   of	   intracellular	   cytokine	   release	   of	   TNF-­‐α	   and	   IFN-­‐γ	   by	   M1	   and	   M2	  macrophages	   from	   2	   donors	   showed	   no	   significant	   differences	   between	  macrophage	   activation	   states	   when	   compared	   to	   non-­‐activated	   macrophages.	  One	   particular	   reason	   for	   this	   might	   be	   the	   delayed	   addition	   of	   Brefeldin	   A	  (added	  at	  T	  (13)).	  Since	  macrophage	  responses	  to	  pathogens	  are	  rapid	  and	  occur	  within	   the	   first	   few	   hours	   of	   infection,	   it	   is	   likely	   that	   cytokine	   release	   had	  tapered	  off	  over	  the	  course	  of	  13	  hours.	  As	  Brefeldin	  A	  induces	  macrophage	  lysis	  at	  prolonged	  exposure,	   further	  optimization	  of	  this	  assay	  would	  be	  required	  by	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blocking	  extracellular	  trafficking	  within	  1-­‐hour	  post	  exposure	  to	  Brefeldin	  A,	  and	  not	  more	  than	  5	  hours	  following	  exposure	  to	  the	  fungal	  pathogen.	  	  Thus	  the	  in	  vivo	  impact	  of	  cytokine	  profile	  on	  cryptococcosis	  most	  likely	  does	  not	  act	   at	   the	   level	   of	   single	   macrophage/fungus	   interactions,	   and	   together,	   these	  data	   suggest	   that,	   even	   in	   immunocompetent	   individuals,	   intrinsic	   differences	  due	  to	  underlying	  immunogenetic	  defects	  or	  infections	  in	  macrophage	  responses	  may	  play	  an	  important	  role	  in	  regulating	  susceptibility	  to	  this	  fungal	  infection.	  	  Vomocytosis	   respresents	   an	   essential	   mechanism	   in	   the	   study	   of	   cryptococcal	  disease	  as,	  depending	  on	  the	  site	  of	   infection,	  may	  serve	  as	  a	  vehicle	  of	  disease	  progression.	  Expulsion	  of	   cryptococci	   from	  alveolar	  macrophages	  may	  allow	  C.	  
neoformans	   escape	   into	   the	   blood	   stream	   and	   CNS	   invasion.	   Alternatively,	  cryptococci	  may	  ‘hitch-­‐hike’	  within	  macrophages,	  and	  undergo	  vomocytosis	  once	  they	   have	   crossed	   the	   blood-­‐brain	   barrier	   (BBB)	   via	   the	   Trojan	   horse	   model.	  Alternatively,	   vomocytosis	  may	   also	   serve	   as	   a	   potential	   therapeutic	   target,	   as	  induced	   expulsion	   of	   cryptococci	   from	   M2	   macrophages	   following	   failed	  destruction	  of	   the	   fungus	  within	   the	  phagolysosome,	  may	   render	   vomocytosed	  fungal	   cells	   vulnerable	   to	   killing	   by	   antifungal	   drugs.	   Hence,	   a	   more	   in-­‐depth	  understanding	   of	   this	   process	   in	   various	   models	   of	   disease	   pathology	   is	  necessary.	   Ultimately,	   further	   understanding	   of	   the	   basis	   of	   varied	   expulsion	  rates	   between	   ‘otherwise	   healthy’	   individuals	   may	   help	   explain	   disease	  heterogeneity	  in	  non-­‐HIV	  cryptococcosis	  patients	  and	  shed	  light	  on	  how	  disease	  progression	  to	  cryptococcal	  meningitis	  occurs	  in	  this	  patient	  group.	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Chapter	   3	   –	   The	   role	   of	   TLR4	   in	   the	  expulsion	   of	   Cryptococcus	   neoformans	  from	  host	  macrophages	  
Abstract	  
	  Among	  the	  10	  Toll-­‐like	  receptors	  (TLRs)	  discovered	  in	  humans	  to	  date,	  TLR2	  and	  TLR4	   have	   been	   associated	   with	   the	   detection	   of	   fungal	   pathogens.	   During	  cryptococcal	   infections,	   TLR2	   and	   TLR4	   detect	   the	   cryptococcal	   capsular	  polysaccharide	   galactoxylomannan	   (GXM)	   in	   association	  with	   CD14	   and	   CD18.	  The	  recent	  involvement	  of	  TLR4	  in	  the	  expulsion	  of	  intracellular	  uropathogenic	  
Escherichia	  coli	  (UPEC)	  within	  bacteria-­‐containing	  vesicles	  (BCVs)	  from	  bladder	  epithelial	   cells	   (BECs)	  has	  prompted	  questions	   surrounding	  TLR4’s	   association	  with	  the	  vomocytosis	  of	  cryptococci	  from	  macrophages.	  Below,	  we	  provide	  data	  associating	   TLR4	   with	   the	   vomocytosis	   of	   C.	   neoformans	   from	   mouse	   bone	  marrow	   derived	   macrophages	   (bMDMs)	   deficient	   in	   TLR4,	   in	   comparison	   to	  their	  wild	  type	  Balb/c	  counterparts.	  We	  also	  investigated	  the	  effects	  of	  TLR4	  on	  the	   rate	   of	   intracellular	   parasitism	   (IPR)	   of	   cryptococci	   within	   macrophages.	  Whilst	  our	  results	  showed	  no	  significant	  IPR	  differences	  between	  knockout	  and	  wild	  type	  mice,	  we	  also	  found	  that	  gender	  of	  wild	  type	  mice	  did	  not	  affect	  IPRs	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nor	   vomocytosis	   of	   C.	   neoformans,	   corroborating	   previous	   results	   observed	   in	  human	  monocyte	  derived	  macrophages	  (hMDMs).	  
	  
Introduction	  
	  Toll-­‐like	   receptors	   (TLRs)	   are	   a	   major	   class	   of	   pattern	   recognition	   receptors	  (PRRs)	   that	   recognize	   pathogen-­‐associated	   molecular	   patterns	   (PAMPs)	   to	  activate	   signaling	   cascades	   and	   mount	   innate	   immune	   responses	   against	  pathogens	   [276,	   277].	   The	   role	   of	   these	   type	   1	   transmembrane	   receptors	   in	  innate	  immunity	  was	  first	  reported	  when	  Lemaitre	  et	  al.	  showed	  that	  Drosophila	  
melanogaster	  mutants	  with	   aberrations	   along	   the	   Toll	   signaling	   pathway	  were	  more	   likely	   to	   succumb	   to	   fungal	   and	   bacterial	   infections	   such	   as	   Aspergillus	  
fumigatus	   and	   Gram-­‐positive	   bacteria,	   respectively	   [278].	   The	   discovery	   of	  structural	   and	   functional	   similarities	   between	   the	   Toll	   signaling	   pathway	   in	  
Drosophila	   and	   the	   intracellular	   pathways	   initiated	   by	   IL-­‐1RI	   signaling	   in	  humans	  [279],	  highlighted	  the	  importance	  of	  Toll-­‐like	  proteins	  in	  innate	  immune	  responses	  to	  pathogens	  and	  inspired	  more	  extensive	  study	  [277].	  Currently,	  10	  toll-­‐like	   receptors	   are	   known	   in	   humans	   (TLR	   1-­‐10),	   each	   responsible	   for	   the	  recognition	  of	  specific	  ligands	  [277,	  280].	  	  	  These	  receptors	  carry	  out	  their	  function	  either	  as	  homodimers,	  or	  through	  cis-­‐	  or	  trans-­‐	  heterodimerization	  with	  other	  TLRs	  or	  cell	  surface	  receptors.	  Whilst	  TLR4	  homodimerizes	   [282];	   TLR2	   is	   able	   to	   form	   dimers	  with	   either	   TLR1	   or	   TLR6	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[276,	  281,	  282].	  Their	  ability	   to	  homodimerize	  or	  hetrodimerize	   influences	   the	  outcome	  and	  intensity	  of	  immune	  reactions	  [282].	  Studies	  of	  knockout	  mice	  have	  revealed	   that	   the	   main	   TLRs	   associated	   with	   fungal	   pathogen	   recognition	   are	  TLR4	   (previously	   shown	   to	   detect	   LPS	   of	   Gram-­‐negative	   bacteria),	   and	   TLR2	  (binds	  lipoteichoic	  acid,	  bacterial	  lipoproteins	  and	  zymosan)	  [276,	  281].	  	  	  However,	   other	   TLRs	   may	   be	   involved	   in	   the	   detection	   and	   engulfment	   of	   C.	  
neoformans.	  Redlich	  et	  al.	   showed	   that	   stimulation	  of	  TLR1/2,	  TLR3,	  TLR4	  and	  TLR9	  with	  their	  agonists	   in	  murine	  microglial	  cells	  –	  the	  resident	  macrophages	  in	  the	  CNS-­‐	  increased	  the	  phagocytosis	  of	  C.	  neoformans	  [283].	  Induction	  of	  these	  receptors	   activated	  microglial	   cells	   and	   increased	   the	   release	   of	   TNF-­‐α,	   CXCL1	  (KC),	   IL-­‐6,	   IL-­‐10	   and	   MIP-­‐2,	   and	   increased	   the	   elimination	   of	   intracellular	  cryptococci.	   In	   line	   with	   other	   investigations,	   MyD88-­‐deficienT-­‐cells	   showed	  impaired	   ability	   to	   phagocytose	   C.	   neoformans	   than	   wild-­‐type	   cells.	   These	  findings	  provide	  an	  insight	  to	  CNS-­‐associated	  cryptococcosis,	  and	  how	  infection	  may	  be	  eliminated	  in	  the	  brain	  in	  cases	  of	  disseminated	  disease	  [283].	  	  Further	   investigations	   into	   the	   immune	   recognition	   of	   Cryptococcus	   spp.	   have	  shown	  that	  both	  TLR2	  and	  TLR4	  associate	  with	  CD14	  [138]	  and	  CD18	  [284]	  to	  bind	   the	   cryptococcal	   capsular	   polysaccharide	   glucuronoxylomannan	   (GXM),	  driving	  localized	  immune	  recognition	  and	  enhanced	  phagocytosis	  [62,	  139-­‐141,	  284].	  Activation	  of	  TLR2	  and	  TLR4	  leads	  to	  the	  activation	  of	  the	  NF-­‐κB	  signaling	  pathway	   (described	   in	   chapter	   1),	   which	   modulates	   the	   expression	   of	  proinflammatory	   cytokines	   by	   phagocytes	   to	   induce	   killing	   of	   the	   pathogen.	  Shoham	  et	  al.	   transfected	  Chinese	  hamster	  ovary	  fibroblasts	  with	  human	  TLR2,	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TLR4,	   and/or	   CD14;	   and	   showed	   that	   the	  NF-­‐κB	   pathway	  was	   activated	  when	  these	   fibroblasts,	   as	  well	   as	   PBMC	   and	   RAW	  264.7	   cells	   transfected	  with	   both	  CD14	   and	   TLR4	   bound	   fluorescently	   labeled	   cryptococcal	   Galactoxylomannan	  (GXM)	  [138],	  resulting	  in	  nuclear	  translocation	  of	  NF-­‐κB.	  However,	  the	  mitogen-­‐activated	   protein	   kinase	   pathways	   that	   leads	   to	   the	   production	   of	   the	  proinflammatory	   cytokine	   TNF-­‐α	  was	   not	   induced	   in	   these	   experiments	   [138],	  suggesting	  more	  complex	  signaling	  modifications	  along	  the	  pathway.	  	  	  Following	   the	   association	   of	   these	   toll-­‐like	   receptors	   with	   GXM	   recognition,	  Yauch	   et	   al.	   	   Showed	   that	   the	   TLR-­‐associated	   adaptor	   protein	   MyD88	   plays	   a	  crucial	   role	   in	   response	   to	   cryptococcal	   infection	   [141].	  MYD88	   knockout	   (-­‐/-­‐)	  mice	  were	  significantly	  less	  likely	  to	  survive	  intranasal	  (IN)	  and	  intravenous	  (IV)	  infection	  with	  C.	  neoformans	  in	  comparison	  to	  wild-­‐type	  C57BL/6	  mice	  [141].	  	  Activation	  of	  TLR4	  elicits	  the	  production	  of	  either	  pro-­‐inflammatory	  cytokines	  or	  Type	  I	  interferons	  and,	  more	  recently,	  has	  been	  associated	  with	  modulating	  the	  intracellular	  trafficking	  system	  [285].	  Miao	  et	  al.	  showed	  that	  TLR4	  was	  able	  to	  enhance	   the	   expulsion	   of	   intracellular	   uropathogenic	   E.	   coli	   (UPEC)	   within	  bacteria-­‐containing	   vesicles	   (BCVs)	   from	   bladder	   epithelial	   cells	   (BECs);	   and	  demonstrated	   that	   this	   process	   occurs	   via	   a	   unique	   modification	   of	   the	  downstream	  element	  TRAF3	  –	  a	  member	  of	   the	  TNF	  receptor	  associated	   factor	  (TRAF)	  protein	   family	  –	   that	   led	   to	   the	  activation	  of	  exocyst	  complex	  assembly	  [285].	  The	  group	  also	  showed	  that	  the	  TIR-­‐domain-­‐containing	  adapter-­‐inducing	  interferon-­‐β	  (TRIF),	   and	   the	   TRIF-­‐related	   adaptor	   molecule	   (TRAM)	   adapter	  proteins	  were	  also	   involved	   in	  TLR4-­‐mediated	  expulsion	  of	  UPEC	  from	  bladder	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epithelial	   cells	   or	   mouse	   bladders,	   as	   they	   were	   able	   to	   localise	   to	   UPEC-­‐containing	  vacuoles	  [285].	  	  Cryptococcus	   spp.	   have	   been	   described	   to	   undergo	   extrusion	   from	   within	  phagosomes	   in	   a	   process	   known	   as	   vomocytosis	   [169,	   170];	   however,	   it	   is	  unknown	  if	  the	  above	  mechanism	  is	  also	  involved	  in	  the	  expulsion	  of	  cryptococci	  from	  macrophages.	   Therefore,	   we	   aimed	   to	   investigate	   whether	   TLR4	   plays	   a	  role	  in	  C.	  neoformans	  vomocytosis,	  with	  a	  hope	  that	  further	  understanding	  of	  this	  mechanism	   will	   inspire	   the	   design	   of	   new	   therapeutic	   approaches	   to	  cryptococcal	  infections.	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Materials	  and	  Methods	  
Maintenance	   and	   euthanasia	   of	   TLR4	   knockout	   animals	   and	  wildtype	   controls	  was	  done	   in	  accordance	  with	  the	  Animals	  (Scientific	  Procedures)	  Act	  of	   the	  UK	  and	  under	   the	   licence	  and	  oversight	  of	   the	  Biomedical	  Services	  Unit	   (BMSU)	  at	  the	  University	  of	  Birmingham.	  	  All	  the	  work	  reported	  here	  was	  conducted	  on	  ex	  vivo	  tissues	  obtained	  from	  uninfected	  animals	  killed	  by	  an	  approved	  Schedule	  1	  method.	  	  
Isolation	  of	  bone	  Marrow	  Derived	  Macrophages	  	  Bone	   Marrow	   Derived	   Macrophages	   (bMDMs)	   were	   extracted	   from	   16	   age-­‐matched	  homozygous	  TLR4	  knockout	  (-­‐/-­‐)	  mice,	  as	  well	  as	  from	  Balb/c	  wild	  type	  mice	  (4	  wild	  type	  males,	  4	  wild	  type	  females,	  4	  TLR4	  knockout	  -­‐/-­‐	  males	  and	  4	  TLR4	  knockout	  -­‐/-­‐	  females).	  Following	  extraction,	  cells	  were	  counted	  and	  seeded	  at	   a	   concentration	   of	   1x106	   cells/well	   in	   RPMI	   1640	   (with	   100	   U/ml	  streptomycin,	  100	  U/ml	  penicillin,	  10%	  FBS	  and	  10%	  L929	  cell	   culture	  media)	  and	   incubated	   at	   37	   °C,	   5%	   CO2	   .	   At	   day	   3	   and	   6	   post-­‐extraction,	   cells	   were	  maintained	  in	  RPMI	  1640	  (with	  100	  U/ml	  streptomycin,	  100	  U/ml	  penicillin,	  and	  10%	   FBS).	   bMDMs	   were	   challenged	   as	   described	   in	   the	   phagocytosis	   assay	  (Chapter	  2).	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Cryptococcus	  Infection	  of	  bMDMs	  	  C.	   neoformans	   var.	   grubii	   serotype	   A,	   strain	   KN99α	   expressing	   GFP	   [286]	  was	  used	  in	  all	  macrophage	  challenge	  experiments.	  	  	  An	  overnight	  culture	  of	  the	  yeast	  was	  started	  by	  inoculating	  3	  mL	  of	  YPD	  (10	  g/L	  yeast	  extract,	  20	  g/L	  bacteriological	  peptone,	  and	  20	  g/L	  glucose	  (Sigma-­‐Aldrich)	  media,	   and	   incubated	   on	   a	   rotor	   at	   20	   rpm	   at	   25	   °C,	   prior	   to	   conducting	   the	  phagocytosis	  assay.	  In	  preparation	  for	  phagocytosis,	  yeasT-­‐cells	  were	  washed	  in	  PBS,	   counted	   on	   a	   haemocytometer,	   and	   opsonized	   with	   mouse	   IgG	   anti-­‐Crypto18B7	   (18B7)	   antibody.	   bMDMs	   where	   then	   infected	   with	   1x106	   yeasT-­‐cells	  per	  well	  (MOI	  10:1),	  and	  incubated	  at	  37°C,	  5%	  CO2	  for	  2	  hours.	  At	  0	  (T0)	  and	  18	  (T18)	  hours	  post-­‐infection,	  extracellular	  yeasT-­‐cells	  were	  washed	  away	  using	  PBS	  and	  macrophages	  containing	  yeasT-­‐cells	  were	  lysed	  in	  dH2O	  at	  37	  °C,	  5%	  CO2	  for	  30	  minutes.	  For	  live	  imaging	  to	  quantify	  vomocytosis,	  bMDMs	  were	  washed	   at	   T0,	   fresh	   serum-­‐free	   RPMI	   added	   to	   infection	   wells	   and	   taken	   for	  imaging.	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CFU	  counts	  	  Serial	   dilutions	   of	   the	   lysate	   from	   the	   phagocytosis	   assay	   were	   prepared	   and	  plated	  onto	  2%	  YPD,	  1%	  agar	  (Sigma-­‐Aldrich)	  plates	  then	  incubated	  for	  48	  hours	  at	  25°C.	  Intracellular	  proliferation	  rates	  were	  measured	  by	  dividing	  the	  number	  of	  counting	  colony-­‐forming	  units	  per	  milliliter	  at	  T18	  by	  those	  at	  T0.	  	  
Live	  cell	  imaging	  	  Time-­‐lapse	  imaging	  was	  performed	  on	  bMDMs	  from	  8	  mice	  (2	  wild	  type	  males,	  2	  wild	  type	  females,	  2	  TLR4	  knockout	  -­‐/-­‐	  males	  and	  2	  TLR4	  knockout	  -­‐/-­‐	  females).	  All	  time	  lapse	  images	  were	  captured	  on	  a	  Zeiss	  Axio	  Observer	  Live	  cell-­‐imaging	  microscope	   enclosed	   within	   a	   humidified	   Okolab	   microscope	   chamber	   set	   at	  37°C,	  5%	  CO2,	  a	  Hamamatsu	  digital	  camera,	  LD	  Plan-­‐Neofluar	  20x/0.4	  Korr	  Ph	  2	  M27	   objective,	   38	   HE	   Green	   Fluorescent	   reflector,	   using	   Zen	   software	   (Zeiss).	  217	   frames	   (1	   frame,	   every	   5	   minutes	   for	   18	   hours)	   were	   taken	   from	   four	  different	  positions	  within	  each	  well	  to	  produce	  movies	  for	  manual	  analysis.	  	  
Power	  calculations	  	  In	   order	   to	   assess	   the	   sample	   size	   that	   would	   generate	   statistically	   relevant	  results,	   we	   conducted	   a	   power	   calculation	   in	   order	   to	   identify	   the	   required	  population	  size	  “n”,	  necessary	  for	  adequate	  power.	  In	  order	  to	  do	  this,	  we	  used	  the	  formula	  below;	  where	  “z”	  is	  the	  critical	  value	  of	  the	  normal	  distribution	  for	  a	  confidence	   level	   of	   95%	  with	   a	   critical	   value	   of	   1.96;	   and	   “e”	   is	   the	  margin	   of	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error	  of	  0.05;	  and	  p	  is	  the	  sample	  proportion.	  The	  value	  of	  “p”	  was	  derived	  from	  the	  population	  the	  either	  had	  an	  IPR	  below	  1,	  or	  vomocytosis	  rate	  above	  the	  75%	  confidence	  interval	  (CI).	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Results	  
	  Bone	  Marrow	  Derived	  Macrophages	  (bMDMs)	  from	  5	  wild	  type	  Balb/c	  mice	  (1:1	  male:	   female	   ratio),	   and	   5	   TLR4	   knockout	   -­‐/-­‐	   Balb/c	   mice	   (1:1	   male:	   female	  ratio)	   were	   challenged	   in	   vitro	   with	   the	   cryptococcal	   strain	   KN99α-­‐GFP.	   CFU	  counts	   were	   used	   to	   extrapolate	   the	   rate	   of	   intracellular	   parasitism	   (IPRs)	   of	  KN99α-­‐GFP	  within	  bMDMs	  (Fig.	  16,	  Fig.	  18);	  and	  vomocytosis	  was	  measured	  as	  the	  percentage	  of	  intracellular	  cryptococci	  expelled	  from	  macrophages	  over	  the	  18-­‐hour	  period	  in	  all	  well	  positions	  (Fig.	  17,	  Fig.	  19).	  To	  evaluate	  the	  impact	  of	  gender	   on	   the	   above	   data,	   we	   divided	   our	   test	   group	   of	   mice	   into	   male	   and	  female	   to	   assess	   where	   hormonal	   differences	   influenced	   cryptococcal	  intracellular	   parasitism	   (IPR)	   and	   vomocytosis.	   Vomocytosis	   data	   is	   only	  available	  for	  8	  mice	  (2	  male	  controls,	  2	  female	  controls,	  2	  male	  TLR4	  -­‐/-­‐,	  and	  2	  female	  TLR4	  -­‐/-­‐).	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Figure	   16.	   Comparison	   of	   cryptococcal	   intracellar	   parasitist	   in	   control	   and	   knockout	   TLR4	   mice	  
within	  Bone	  Marrow	  Derived	  Macrophages	  (bMDMs).	  No	  significant	  differences	  in	  IPRs	  observed	  (2-­‐
way	  ANOVA;	  p	  =	  0.7345).	  Error	  bars	  represent	  mean	  and	  standard	  deviations	  where	  for	  control	  mice	  
N=8	  and	  TLR4	  -­‐/-­‐	  mice	  N=8.	  
	  Two-­‐way	   analysis	   of	   variance	   to	   determine	   whether	   genetic	   background	   or	  gender	  had	  an	   influence	  on	  the	   intracellular	  parasitism	  of	  C.	  neoformans	  within	  murine	   bMDMs	   was	   performed.	   Our	   results	   show	   no	   significant	   difference	  between	  IPRs	  recorded	  for	  TLR4	  -­‐/-­‐	  mice	  in	  comparison	  to	  control	  mice	  (Fig.	  16;	  p	   =	   0.7345)	   where	   genetic	   background	   contributed	   to	   0.64%	   of	   the	   variation.	  However,	  we	  found	  that	  gender	  significantly	  contributed	  to	  the	  variation	  in	  IPR	  values	   (Fig.	   17;	   2-­‐way	   ANOVA;	   p	   =	   0.0255)	   and	   accounted	   for	   34.55%	   of	   the	  variation	  in	  our	  data.	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Figure	  17.	  Comparison	  of	  cryptococcal	  intracellar	  parasitism	  in	  Bone	  Marrow	  Derived	  Macrophages	  
(bMDMs)	  from	  male	  and	  female	  Balb/c	  mice.	  Both	  populations	  consist	  of	  a	  1:1	  ratio	  of	  wild-­‐type	  and	  
TLR4	  knockout	  -­‐/-­‐	  Balb/c	  mice.	  Two-­‐way	  ANOVA	  revealed	  significant	  differences	  between	  male	  and	  
female	  control	  mice	  (p	  =	  0.0255).	  Error	  bars	  represent	  standard	  deviations	  where	  N=8	  for	  both	  sets	  
of	  data.	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Figure	  18.	   Vomocytosis	   of	  C.	  neoformans	   from	  Bone	  Marrow	  Derived	  Macrophages	   (bMDMs)	   from	  
wild	   type	   and	  TLR4	  knockout	   -­‐/-­‐	  Balb/c	  mice.	  Results	   show	  a	   significant	  difference	  between	  both	  
groups	   (2-­‐way	   ANOVA;	   p	   =	   0.0198).	   Error	   bars	   represent	  means	   and	   standard	   deviations.	  Where	  
N=4	  for	  both	  control	  and	  TLR4	  -­‐/-­‐	  mice.	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Figure	  19.	  Vomocytosis	  of	  C.	  neoformans	   from	  Bone	  Marrow	  Derived	  Macrophages	   (bMDMs)	   from	  
wild	  type	  Balb/c	  mice	  and	  TLR4	  knockout	   -­‐/-­‐	  Balb/c	  mice.	  Two-­‐way	  ANOVA	  showed	  no	  significant	  
differences	   between	   male	   and	   female	   control	   mice	   (P>0.9999).	   Error	   bars	   represent	   standard	  
deviations.	  
Elimination	   of	   TLR4	   reduced	   the	   rate	   of	   cryptococcal	   extrusion	   from	   within	  murine	   bMDMs	   by	   approximately	   50%,	   suggesting	   a	   role	   for	   this	   toll-­‐like	  receptor	  in	  the	  vomocytosis	  of	  C.	  neoformans.	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Discussion	  
	  We	   have	   probed	   the	   involvement	   of	   TLR4	   in	   controlling	   the	   intracellular	  parasitism	  and	  vomocytosis	   of	  C.	  neoformans	   KN99α-­‐GFP	   in	  bMDMs	   from	  wild	  type	  Balb/c	  mice	  and	  TLR4	  knockout	  (-­‐/-­‐)	  Balb/c	  mice.	  Whilst	  our	  data	  suggest	  that	  elimination	  of	  TLR4	  bears	  no	  effects	  on	  IPRs	  between	  control	  and	  test	  mice	  bMDMs,	  we	  have	  found	  a	  significant	  difference	  in	  the	  effects	  of	  gender	  on	  IPR.	  Conversely,	   gender	   did	   not	   influence	   vomocytosis,	   but	   we	   show	   that	   the	  elimination	  of	  TLR4	  reduces	  the	  rate	  of	  cryptococcal	  extrusion	  from	  bMDMs	  by	  ~2-­‐fold.	  	  Our	  finding	  that	  a	  gender	  bias	  exists	  in	  the	  control	  of	  intracellular	  parasitism	  is	  not	   novel.	   However,	   it	   is	   contrary	   to	   what	   is	   currently	   known	   of	   gender	  susceptibility	  to	  cryptoccocosis.	  Men	  have	  been	  shown	  to	  be	  more	  prone	  to	  fatal	  cryptococcal	  disease	  than	  women.	  Given	  the	  small	  sample	  size	  of	  male	  (N=8)	  and	  female	   (N=8)	   mice,	   we	   strongly	   recommend	   increasing	   the	   number	   of	   test	  subjects	  in	  order	  to	  provide	  more	  reliable	  results.	  	  A	  recent	  review	  by	  Campuzano	  and	  Wormley	  discussed	  the	  contribution	  of	  PRRs	  to	   cryptococcal	   disease	   elimination	   in	   innate	   immune	   cells	   [287].	   The	   authors	  referred	  to	  studies	  using	  TLR4-­‐knockout	  mice,	  which	  showed	  that	  TLR4	  was	  not	  an	   essential	   component	   in	   anti-­‐cryptococcal	   immunity	   [138,	   141,	   288].	  Conversely,	  Shoham	  et	  al.	  showed	  that	  both	  CD14	  and	  TLR4	  bound	  fluorescently	  labeled	  GXM	  [138],	  resulting	  in	  nuclear	  translocation	  of	  NF-­‐κB	  but	  no	  activation	  
	   128	  
of	  the	  mitogen-­‐activated	  protein	  kinase	  pathways	  that	  lead	  to	  the	  production	  of	  the	   proinflammatory	   cytokine	   TNF-­‐α	   [138].	   In	   2005,	   Yauch	   et	   al.	   showed	   that	  whilst	   TLR2,	   TLR4,	   CD14	   and	   CD18	   were	   able	   to	   detect	   cryptococcal	   GXM	   in	  
vitro,	   these	   PRRs	   were	   not	   required	   for	   serum	   clearance	   in	   vivo	   [289].	   The	  disparities	   in	   data	   surrounding	   the	   involvement	   of	   TLR4	   in	   the	   detection	   and	  expulsion	  of	  C.	  neoformans	   from	  macrophages	  will	   therefore	  need	   to	  be	  settled	  through	   further	   experimentation	   using	   both	   in	   vitro	   and	   in	   vivo	   models	   of	  disease.	  	  Whilst	   out	   data	   is	   in	   line	  with	   previous	   studies	   by	  Miao	   et	   al.,	   the	   sample	   size	  used	  to	  evaluate	  differences	  in	  vomocytosis	  of	  C.	  neoformans	  from	  macrophages	  is	  too	  small	  to	  conclude	  the	  involvement	  of	  TLR4	  in	  cryptococcal	  expulsion.	  Our	  power	   calculations	   predicted	   that	   the	   sample	   size	   required	   to	   achieve	   a	  magnitude	   of	   significance	   for	   both	   IPR	   and	   Vomocytosis	   for	   control	   mice	   was	  360	  and	  288,	  respectively;	  while	  that	  required	  for	  IPR	  and	  Vomocytosis	  for	  TLR4	  knockout	   mice	   was	   288	   and	   341,	   respectively.	   In	   addition,	   Balb/c	   mice	   have	  previously	  shown	  to	  be	  resistant	  to	  C.	  neoformans	  [186].	  Hence,	  we	  recommend	  repetition	  of	  these	  results	  in	  alternative	  mouse	  strains	  to	  confirm	  our	  findings.	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  A	   report	   by	   Redlich	   et	  al.	   where	  murine	  microglial	   cells	  were	   stimulated	  with	  TLR	   agonists	   for	   TLR1/2,	   TLR3,	   TLR4	   and	   TLR9	   for	   24	   h	   showed	   that	  phagocytosis	  and	  pro-­‐inflammatory	  cytokines	  secretion	  (TNF-­‐alpha,	  CXCL1	  (KC),	  IL-­‐6,	  IL-­‐10	  and	  MIP-­‐2)	  were	  increased	  [283].	  Interestingly,	  they	  also	  found	  that	  Intracellular	   killing	   of	   cryptococci	   was	   also	   increased	   in	   TLR-­‐stimulated	   cells	  compared	   to	   unstimulated	   microglial	   cells	   [283].	   Whilst	   TLR4	   may	   not	   be	  required	   for	   serum	   clearance	   of	   C.	   neoformans	   in	   vivo,	   intracellular	   TLR4	  may	  play	  a	  different	  role	  following	  phagocytosis	  of	  the	  yeast	  that	  culminates	  in	  either	  cryptococcal	   killing	   or	   expulsion	   from	   macrophages.	   The	   increased	  proinflammatory	  response	  mounted	  following	  TLR4	  stimulation	  with	  an	  agonist	  recommends	   it	   as	   a	   potential	   supplementary	   treatment,	   particularly	   in	  cryptococcosis	  patients	  receiving	  immunosuppressive	  therapies.	  	  Furthermore,	   two	   polymorphisms	   within	   the	   TLR4	   gene	   (rs4986790	   and	  rs4986791)	  have	  been	   implicated	  as	  predispositions	   for	  acquiring	  bloodstream	  
Candida	   infections	   in	   humans	   (Discussed	   in	   Chapter	   4)	   [290].	  We	   hypothesize	  that	   individuals	   facing	   the	   phenotypic	   consequences	   of	   these	   polymorphisms	  would	   present	   with	   impaired	   phagocytosis	   and	   intracellular	   killing	   of	   C.	  
neoformans,	  as	  well	  as	  reduced	  anti-­‐cryptococcal	  inflammatory	  responses.	  	  	  Given	   the	   complexity	   of	   immune	   response	   pathways	   associated	   with	  cryptococcal	   infection,	   and	   the	   compensatory	   responses	   to	   sensory	   defects	  observed	  in	  knockout	  experiments,	  further,	  more	  detailed	  study	  of	  the	  molecular	  patterns	   that	   orchestrate	   the	   extrusion	   of	   C.	   neoformans	   from	   macrophages	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would	   be	   required	   as	   TLR4	   can	   transduce	   signals	   via	   either	   the	   MyD88-­‐dependent	  or	  TRIF-­‐dependent	  pathways	  [291].	  	  Altogether,	   our	   data	   advocate	   TLR4	   as	   a	   component	   in	   the	   vomocytosis	   of	  cryptococci;	  however,	  further	  investigation	  of	  this	  receptor’s	  involvement	  in	  this	  process	  is	  highly	  warranted.	  Our	  data	  has	  been	  generated	  from	  a	  small	  group	  of	  test	  mice	   (16	   for	   IPR;	   8	   for	   vomocytosis)	   that	  would	   need	   to	   be	   expanded	   for	  more	  reliable	  statistical	  inferences	  to	  be	  made.	  We	  also	  recommend	  that	  further	  
in	  vitro	  experimentation	  be	  carried	  out	  on	  alternative	  macrophage	  cell	   lines;	  as	  well	  as	  in	  vivo	  study	  of	  infection	  progression	  in	  TLR4	  knockout	  model	  organisms	  compared	   to	   wild	   type	   individuals.	   We	   anticipate	   these	   findings	   will	   lend	   to	  personalizing	   treatment	   strategies	   for	   the	   diverse	   range	   of	   cryptococcosis	  patients	  worldwide.	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Chapter	   4	   –	   Contribution	   of	   single	  nucleotide	   polymorphisms	   to	  variation	   in	   host	   macrophage	  responses	  
Abstract	  
	  Cryptococcosis	   is	   a	   fungal	   disease	   that	   affects	   immunocompromised	   and	  immunocompetent	   individuals	   following	   infection	   with	   Cryptococcus	  
neoformans.	   Macrophages	   play	   a	   critical	   role	   in	   anticryptococcal	   defense	   by	  either	   eliminating	   or	   disseminating	   the	   pathogen.	   We	   have	   previously	  established	   that	  macrophage	   responses	   to	   in	  vitro	   infection	  with	  C.	  neoformans	  vary	  between	  and	  within	  individuals;	  however,	  the	  determinants	  of	  the	  observed	  variance	  remain	  unknown.	  GWAS	  studies	  have	  demonstrated	  a	  genetic	  basis	  for	  variation	   in	   many	   parameters	   of	   innate	   immune	   cells	   in	   healthy	   adults;	   and	  susceptibility	   studies	   have	   identified	   single	   nucleotide	   polymorphisms	   (SNPs)	  that	   predispose	   otherwise	   healthy	   individuals	   to	   invasive	   fungal	   diseases	  including	   cryptococcosis.	  Consequently,	  we	  hypothesized	   that	  genetic	  variation	  in	   known	   innate	   immune	   genes	   may	   underlie	   some	   of	   the	   person-­‐to-­‐person	  variation	  were	  previously	  reported.	  Below,	  we	  assess	  the	  contribution	  of	  SNPs	  in	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some	   of	   these	   genes	   (Toll-­‐like	   receptor	   2	   (TLR2);	   TLR4;	   the	   C-­‐type	   Lectin,	  Dectin-­‐1;	  the	  mitogen-­‐activated	  protein	  (MAP)	  kinase,	  ERK5;	  and	  the	  autophagy	  protein,	   Galectin-­‐8	   (GAL8))	   to	   regulating	   variation	   in	   macrophage	   control	   of	  intracellular	   parasitism	   and	   vomocytosis	   of	   C.	   neoformans.	   Although	  we	   found	  one	   SNP	   (TLR4-­‐rs4986791)	   among	   9	   healthy	   adults,	   we	   conclude	   that	   larger	  GWAS	   studies	   would	   be	   required	   to	   verify	   the	   association	   of	   these	  polymorphisms	  with	  susceptibility	  to	  cryptococcosis	  in	  immunocompetent	  hosts.	  
Introduction	  
	  To	  date,	  cryptococcosis	  has	  largely	  been	  described	  as	  an	  HIV-­‐associated	  infection	  that	  leads	  to	  cryptococcal	  meningitis	  and	  subsequent	  death	  in	  patients.	  However,	  the	   rising	   frequency	   of	   this	   fungal	   disease	   due	   to	   C.	   neoformans	   in	   otherwise	  healthy	   individuals	   is	   cause	   for	   concern.	   Efforts	   to	   understand	   disease	  predispositions	  in	  immunocompetent	  individuals	  are	  underway.	  	  We	  have	  previously	  sought	  to	  quantify	  the	  varied	  responses	  to	  cryptococcosis	  in	  healthy	   adults	   by	   assessing	   in	   vitro	   macrophage	   responses	   to	   cryptococcal	  infections	   including	   control	   of	   intracellular	   parasitism,	   rate	   of	   vomocytosis,	  cytokine	  responses	  and	  gender	  bias.	  However,	  our	  findings	  suggest	  that	  genetic	  factors	   along	   with	   the	   host’s	   immune	   environment,	   rather	   than	   individual	  cellular	   responses	   may	   confer	   susceptibility	   or	   protection	   from	   acquiring	   CM.	  Findings	  from	  Patin	  et	  al.	  support	  this	  concept	  by	  showing	  that	  natural	  variation	  in	   the	   parameters	   of	   innate	   immune	   cells	   is	   predominantly	   driven	   by	   genetic	  factors	  rather	  than	  environmental	  determinants	  [292].	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  The	   majority	   of	   studies	   that	   have	   attempted	   to	   decipher	   the	   genetic	  predisposition	  to	  cryptococcosis	  have	  focused	  mainly	  on	  HIV	  patients	  [255],	  and	  data	  describing	   risk	   factors	   in	  healthy	   individuals	   is	   rare	   and	  non	  definitive.	  A	  review	   by	   Lanternier	   et	   al.,	   suggested	   that	   inborn	   genetic	   defects	   of	   the	   IFN-­‐γ	  and/or	   GM-­‐CSF	   signaling	   pathways	   played	   a	   larger	   role	   in	   predisposition	   to	  fungal	   infections	   than	   is	   currently	   perceived.	   Some	  of	   the	   immune	  deficiencies	  noted	  in	  non-­‐HIV	  cryptococcosis	  patients	  included	  idiopathic	  CD4	  lymphopenia,	  AD	  GATA2	  deficiency,	  and	  in	  a	  few	  cases	  X-­‐linked	  CD40L	  deficiency	  [293].	  More	  recent	  studies	  have	  attempted	   to	   identify	  small	  nucleotide	  polymorphisms	  that	  may	   predispose	   individuals	   to	   cryptococcosis	   [294].	   To-­‐date,	   defects	   in	   the	   Fc	  gamma	  receptor	  (FCGR)	  [217,	  295];	  IL-­‐12	  signaling	  and	  Interleukin	  12	  Receptor	  Subunit	  Beta	  1	   (IL-­‐12RB1)	  cell	   surface	  expression	   [296];	  and	  Mannose-­‐binding	  lectin	  (MBL)	  [297]	  have	  been	  associated	  with	  CM.	  	  	  We	  previously	  showed	  that	  the	  rate	  of	  vomocytosis	  could	  be	  modulated	  via	  the	  inhibition	   of	   the	   mitogen-­‐activated	   protein	   (MAP)	   kinase,	   ERK5	   [184]	   that	   is	  encoded	  by	  the	  MAPK7	  gene;	  and	  that	  TLR4	  plays	  a	  role	  in	  limiting	  the	  expulsion	  of	   engulfed	   cryptococci	   from	   within	   macrophages	   (Chapter	   3).	   Genome	   wide	  studies	   have	   provided	   evidence	   that	   that	   two	   synonymous	   mutations	  (rs2233083	  and	  rs3866958)	  within	  MAPK7	  are	  associated	  with	  increased	  risk	  of	  lung	   cancer	   amongst	   smokers	   [298];	   and	   that	   two	   polymorphisms	   within	   the	  TLR4	   gene	   (rs4986790	   and	   rs4986791)	   present	   as	   risk	   factors	   for	   Candida	  bloodstream	   infections	   [290],	   and	   were	   shown	   to	   increase	   susceptibility	   to	  invasive	  aspergillosis	  in	  donors	  and	  recipients	  of	  hematopoietic	  cell	  transplants	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[299].	  Hence,	  we	  hypothesized	  that	  the	  presence	  of	  these	  SNPs	  may	  influence	  the	  rate	   of	   vomocytosis	   observed	   between	   individuals	   and	   explain	   the	   observed	  variance	  (Fig.	  20).	  	  
	  
Figure	  20.	   Illustration	  of	  pattern	   recognition	   receptors	   (PRRs)	  and	  proteins	  previously	  associated	  
with	  cryptococcosis	  with	  known	  small	  nucleotide	  polymorphisms	  (SNPs).	  	  
	  Macrophage	   cell	   surface	   receptors	   interact	   with	   cryptococcal	   pathogen	  associated	   molecular	   patterns	   (PAMPs)	   to	   bring	   about	   phagocytosis	   and	  antifungal	   responses.	   The	   C-­‐type	   lectin	   receptor	   (CLR)	   Dectin-­‐1,	   encoded	   by	  CLEC7A,	  along	  with	  the	  CD11b	  receptor,	  interact	  with	  cryptococcal	  β-­‐glucans	  to	  induce	   phagocytosis	   and	   increased	   elimination	   of	   the	   fungal	   pathogen[62].	   In	  addition,	   the	   toll-­‐like	   receptors	   TLR2	   and	   TLR4	   detect	   cryptococcal	  galactoxylomannan	   (GXM)	   embedded	   in	   the	   capsule,	   triggering	   intracellular	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signaling	   and	   inflammatory	   responses	   in	   macrophages	   to	   eliminate	   engulfed	  cryptococci	   [138,	   276,	   300].	   Despite	   previous	   findings	   that	   Dectin-­‐1	   was	   not	  required	   for	   protection	   against	   cryptococcosis	   in	  mice	   [301],	   SNPs	   in	  Dectin-­‐1	  (rs16910526)	  and	  in	  TLR2	  (rs121917864,	  and	  rs5743708)	  have	  been	  shown	  to	  predispose	   patients	   with	   Acute	   Myeloid	   Leukemia	   (AML)	   to	   invasive	   fungal	  disease	  [302].	  	  	  Galectins	   are	   a	   class	   of	   soluble	   proteins	   that	   bind	   beta-­‐galactoside	   sugars	   (β-­‐galactoside)	   and	   function	  both	   intra-­‐	   and	   inter-­‐cellularly	   [303,	  304].	  Galectin-­‐8	  (GAL8),	  encoded	  by	  the	  LGALS8	  gene,	   is	  a	  secreted	  protein	  that	  associates	  with	  integrin-­‐bound	   glycans	   to	   activate	   integrin-­‐specific	   signaling	   pathways	   and	  ultimately	   modulate	   cell	   adhesion	   [305].	   This	   galectin	   also	   plays	   a	   role	   in	  autophagy	  where	   it	  has	  been	  shown	   to	  act	   as	  a	   ‘danger’	   receptor	   that	   restricts	  
Salmonella	   proliferation	   [306]	   and	   detects	   damages	   in	   lysosomes	   and	  endosomes	  caused	  by	  engulfed	  pathogens	  [306].	  Given	  that	  C.	  neoformans	  is	  able	  to	   manipulate	   host	   phagosome	   maturation	   and	   bring	   about	   phagosomal	  permeabilization	  [122,	  143],	  allowing	  for	  pathogen	  proliferation	  and	  evasion	  of	  killing	   via	   vomocytosis	   [169,	   170,	   176];	   we	   pondered	   the	   effects	   of	   the	  insertion/deletion	   variants	   (rs35962423	   and	   rs60283046)	   in	   LGALS8	   on	  intraphagosomal	  cryptococcal	  survival	  (Fig.	  17).	  	  	  Therefore,	  we	  questioned	  the	  extent	  to	  which	  the	  above	  nucleotide	  changes	  may	  influence	   or	   limit	  macrophage	   control	   of	   the	   intracellular	   parasitism	   and	   non-­‐lytic	   expulsion	   of	   Cryptococcus	   spp.	   and	   contribute	   to	   the	   varied	   vomocytosis	  rates	  observed	  within	  and	  between	  our	  group	  of	  healthy	  volunteers	  (Chapter	  2).	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To	  assess	  this,	  we	  analyzed	  DNA	  taken	  from	  9	  consenting	  healthy	  donors	  for	  the	  presence	  of	  the	  above	  polymorphisms.	  Our	  search	  revealed	  that	  all	  9	  participants	  carried	  the	  major	  alleles	  within	  the	  regions	  of	  interest,	  in	  exception	  of	  one	  non-­‐synonymous	   missense	   mutation	   in	   TLR4	   (rs4986791)	   in	   one	   individual;	   and	  conclude	  that	   there	  was	  no	  association	  between	  the	  above	  polymorphisms	  and	  observed	  variation.	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Materials	  and	  Methods	  
	  Consent	   for	   DNA	   analysis	   was	   obtained	   from	   9	   of	   the	   donors	   in	   this	   study	  (RG001-­‐RG007,	  RG015	  and	  RG016).	  	  	  
GENOMIC	  DNA	  EXTRACTION	  The	  Wizard	  Genomic	  DNA	  Purification	  kit	  (Promega,	  A1120)	  was	  used	  to	  extract	  genomic	  DNA	   from	  3,	  300	  μl	  whole	  blood	  aliquots	  of	  9	  donors	   (RG001-­‐RG007,	  RG015	   and	   RG016)	   in	   accordance	   with	   the	   manufacturer’s	   protocol.	   A	   1%	  agarose	  gel	  was	  used	  to	  confirm	  successful	  DNA	  extraction.	  	  
Primer	  design	  and	  PCR	  amplification	  	  All	  primer	  sequences	  used	  to	  assess	  TLR2,	  TLR4,	  Galectin-­‐8,	  Dectin-­‐1	  and	  ERK5	  SNPs	  were	  designed	  by	  using	  the	  NCBI/	  Primer-­‐BLAST	  tool	  and	  are	  presented	  in	  Table	   1	   below.	   The	   regions	   encompassing	   the	   SNPs	   described	   above	   were	  obtained	  from	  the	  NCBI	  via	  a	  blast	  of	  the	  Human	  nucleotide	  databases.	  Due	  to	  the	  large	   number	   of	   base	   pairs	   spanning	   the	   polymorphisms	   for	   ERK5,	   TLR2	   and	  GAL8	  we	  wished	  to	  sequence,	   two	  sets	  of	  Forward	  and	  Reverse	  primers	  (Table	  1.)	  were	   designed	   in	   order	   to	   amplify	   donor	   SNP	   regions	   as	   two	   smaller	   DNA	  fragments	  for	  each	  respective	  gene.	  The	  Phusion	  High-­‐Fidelity	  DNA	  Polymerase	  kit	  (New	  England	  BioLabs,	  M0530S),	  and	  DreamTaq	  Green	  PCR	  Master	  Mix	  (2X)	  (Life	   Technologies,	   K1082)	   were	   used	   to	   amplify	   the	   two	   regions	   of	   interest	  following	   the	  manufacturer’s	   recipe	  and	  cycle	   steps,	  and	  a	  1%	  agarose	  gel	  was	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used	   to	   check	   for	   correct	   amplification.	   The	   PCR	   products	   for	   each	   primer	   set	  were	   analyzed	   on	   a	   1%	   agarose	   gel	   stained	   with	   Sybr	   Safe	   (Invivogen),	   and	  purified	  using	  Qiagen’s	  QIAquick	  PCR	  Purification	  Kit.	  	  	  
Fragment	  sequencing	  and	  analysis	  	  For	  sequencing,	  we	  used	  the	  cycle	  sequencing	  technology	  provided	  by	  Eurofins	  Genomics	   on	   an	   ABI	   3730XL	   sequencer.	   Sequence	   data	   was	   visualized	   using	  4Peaks	  software,	  version	  1.8;	  and	  the	  Clustal	  X	  software	  version	  2.1	  was	  used	  to	  generate	   multiple	   sequence	   alignments.	   We	   thereafter	   used	   Seaview,	   version	  4.6.1	  to	  identify	  if	  any	  of	  the	  donors	  expressed	  any	  or	  all	  of	  the	  polymorphisms	  in	  question.	  
	  
Table	   5.	   Details	   of	   small	   nucleotide	   polymorphisms	   in	   pattern	   recognition	   receptors	   under	  
investigation	  for	  association	  with	  cryptococcosis	  in	  healthy	  individuals.	  









F’ 5'%&CAGATGCTTTCTTCCCCTTTGAGA&%3'R’ 5'%&CGGAAATGGGAGAAGTCCAGT&%3'F’ 5'%&TACAGTGAGCGGGATGCCT&%3'R’ 5'%&TATCGCAGCTCTCAGATTTACCC&%3'F’ 5'%&TGCAGCTAGTAGCAGTTCTTG&%3'R’ 5'%CTCCACCCTTCCTCTTACATTGA&&%3'F’ 5'%&GTTCTCAGGCACACCAAAGG&%3'R’ 5'%&AAGGATTGTTCAGGGGGAGTTG&%3'F’ 5'%&CGAACCCTCCACTGACTTCC&%3'R’ 5'%&CCTTTCCTTCCAGCTCACAGT&%3'F’ 5'%&GCACAGACTTGCGGGTTCTA&%3'R’ 5'%&CCTGGAAAGAATTGCCAGCC&%3'F’ 5'%&GCACAGACTTGCGGGTTCTA&%3'R’ 5'%&CCTGGAAAGAATTGCCAGCC&%3'F’ 5'%&TGTTTTTCCTGCTTCCCCCA&%3'R’ 5'%&CTGTAGTGGGAAACCTCGCA&&%3'F’ 5'%&GGAGTTCTTTAGGAGCCAGGT&%3'R’ 5'%&AGAAGCCACTAGGCCAAACC&%3'GAL8 rs60283046 G>T&indel 5'&Near&Gene 0.4918
TLR4 rs4986791 C>T&missense Exon 0.0407
GAL8 rs35962423 C>T&indel 5'&Near&Gene 0.4938
ERK5 rs3866958 G>T Promoter 0.1837
TLR4 rs4986790 A>G&missense Exon 0.0599
DectinD1 rs16910526 T>G&missense 3'&Near&Gene 0.0409
ERK5 rs2233083 C>T&Synonymous Exon 0.0272
TLR2 rs121917864 C>T&missense Intron 0.2849
TLR2 rs5743708 A>G&missense 5'&Near&Gene 0.0068
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Results	  
GENOMIC	  DNA	  EXTRACTION	  
	  
Figure	  21.	  Determination	  of	  successful	  genomic	  DNA	  extraction	  for	  8	  healthy	  donors	  on	  1%	  agarose	  
gel.	  Genomic	  DNA	  for	  RG002	  not	  shown.	  
	  We	   successfully	   obtained	   genomic	   DNA	   from	   8	   consenting	   donors	   (Fig.	   18)	  initially;	  genomic	  DNA	  for	  RG002	  (not	  shown	  in	  Fig.	  18)	  was	  obtained	  later.	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SNP	  Fragment	  Amplification	  	  To	  assess	  whether	  we	  had	  obtained	  the	  correct	  PCR	  fragments	  for	  each	  SNP,	  we	  ran	   the	   purified	   PCR	   products	   on	   1%	   agarose	   gel	   stained	   with	   Sybr	   Safe	  (Invivogen).	  Predicted	  fragments	  for	  all	  SNPs	  under	  investigation	  were	  obtained;	  Fig.	   19-­‐20	   show	   representative	   gel	   images	   for	   ERK5	   rs2233083	   and	   ERK5	  rs3866958,	  respectively.	  
	  
Figure	  22.	  Purified	  PCR	  amplicons	  for	  ERK5	  rs2233083	  from	  9	  healthy	  donors.	  
	  
	  
Figure	  23.	  Purified	  PCR	  amplicons	  for	  ERK5	  rs3866958	  from	  9	  healthy	  donors.	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SNP	  DETECTION	  To	   check	  whether	   each	   of	   the	   9	   donors	   in	   our	   study	   carried	   any	   of	   the	   above	  SNPs,	  we	  generated	  multiple	  sequence	  alignments	  using	  Clustal	  X	  (Fig.	  21-­‐25).	  	  	  
	  
Figure	  24.	  Multiple	  sequence	  alignment	  analysis	   for	  9	  healthy	  donors	  to	  detect	  the	  presence	  of:	  A)	  
ERK5-­‐rs3866958;	  and	  B)	  ERK5-­‐	  rs2233083.	  SNP	  regions	  of	  interest	  are	  highlighted.	  
	  
	  Our	  results	  show	  that	  donors	  possessed	  major	  alleles	  for	  both	  ERK5	  SNP	  regions	  (Fig.	  21);	  both	  TLR2	  SNPs	  (Fig.	  22);	  both	  TLR4	  SNPs	  (Fig.	  23);	  Dectin-­‐1	  (Fig.	  24);	  and	   in	   both	   Galectin-­‐8	   SNPs	   (Fig.	   25).	   The	   TLR4	   SNP	   rs4986791	   was	   only	  detected	   one	   donor	   (RG002;	   Fig.	   23).	   However,	   our	   findings	   are	   inconsistent	  with	  the	  relatively	   low	  minor	  allele	   frequencies	  based	  on	  the	  100,000	  genomes	  project	   described	   above	   (Table	   5),	   suggesting	   that	   our	   data	   departs	   from	  statistical	  projections	  due	  to	  the	  small	  number	  of	  donors	  tested.	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Figure	  25.	  Multiple	  sequence	  alignment	  analysis	   for	  9	  healthy	  donors	  to	  detect	  the	  presence	  of:	  A)	  
TLR2-­‐rs12191786;	  and	  B)	  TLR2-­‐rs5743708.	  SNP	  regions	  of	  interest	  are	  highlighted.	  
	  
	  
Figure	  26.	  Multiple	  sequence	  alignment	  analysis	   for	  9	  healthy	  donors	  to	  detect	  the	  presence	  of:	  A)	  
TLR4-­‐rs4986790;	  and	  B)	  TLR4-­‐rs4986791.	  SNP	  regions	  of	  interest	  are	  highlighted.	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Figure	   27.	   Multiple	   sequence	   alignment	   analysis	   for	   9	   healthy	   donors	   to	   detect	   the	   presence	   of	  
Dectin-­‐1-­‐rs1691052.	  SNP	  regions	  of	  interest	  are	  highlighted.	  
	  	  
	  
Figure	  28.	  Multiple	  sequence	  alignment	  analysis	   for	  9	  healthy	  donors	  to	  detect	  the	  presence	  of:	  A)	  
GAL8-­‐rs35962423;	  and	  B)	  GAL8-­‐	  rs60283046.	  SNP	  regions	  of	  interest	  are	  highlighted.	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Discussion	  
	  To	  investigate	  the	  contribution	  of	  small	  nucleotide	  polymorphisms	  to	  previously	  observed	   variation	   in	   host	   macrophage	   responses	   to	   in	   vitro	   cryptococcal	  infection,	   we	   isolated	   and	   sequenced	   DNA	   fragments	   from	   9	   healthy	   donors.	  Genetic	   variants	   of	   functional	   consequence	   in	  TLR2,	  TLR4,	  Dectin-­‐1,	   ERK5	  and	  GAL8	  were	  absent	  in	  all	  donors	  except	  for	  one	  TLR4	  SNP	  (rs4986791)	  in	  donor	  RG002,	   suggesting	   an	   absence	   of	   association	   of	   these	   polymorphisms	   with	  observed	  variation	  in	  host	  macrophage	  responses	  to	  C.	  neoformans	  infections.	  It	  is	  likely	  that	  alternative	  genetic	  or	  environmental	  determinants	  of	  variation	  may	  be	  at	  play.	  	  	  To	  confirm	  our	  sequencing	  results	  and	  confirm	  the	  validity	  of	  frameshifts	  (such	  as	  Fig.	  25A	  and	  Fig.	  26B),	  we	  conducted	  a	  BLASTX	  search	  of	  all	  sequencing	  data	  that	   confirmed	   the	   identity	   of	   our	   fragments.	  However,	  we	   identified	   errors	   in	  protein	  sequence	  predictions	  rendering	   these	   fragments	  unreliable.	  We	  believe	  these	   errors	   may	   have	   arisen	   as	   a	   result	   of	   gel	   compression	   that	   generated	  insertions	  and	  deletions	  of	  bases.	  As	  the	  number	  of	  donors	  (N=9)	  was	  too	  small	  to	   make	   statistical	   conclusions	   associating	   the	   SNPs	   tested	   in	   this	   study;	   we	  recommend	  expansion	  of	  the	  study	  group	  and	  more	  scrutinized	  methodology	  in	  generating	  the	  required	  fragments.	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Add	  text	  material	  on	  homo/heterozygous	  influence	  here;	  add	  interpretations	  of	  sequencing	   to	   discussion	   (what	   would	   be	   likely	   phenotypic	   outcomes	   if	  sequencing	  correct?)	  	  Bioinformatic	   approaches	   by	   Aguirre-­‐Gamboa	   et	   al.	   to	   assess	   the	   influence	   of	  environmental	   and	   genetic	   factors	   on	   immune	   cell	   populations	   in	   peripheral	  blood	  of	  ~500	  healthy	  volunteers	  revealed	  that	  intrinsic	  factors	  such	  as	  age	  and	  gender	   and	   season	   strongly	   effect	   immune	   traits	   [307].	  Whilst	   genetic	   factors	  contributed	   to	   approximately	   50%	   of	   the	   observed	   variance	   in	   immune	   traits,	  aging	   was	   associated	   with	   increases	   in	   myeloid	   cell	   levels,	   and	   that	   due	   to	  seasonal	   variation;	   monocyte	   levels	   were	   significantly	   higher	   in	   winter	   [307].	  These	   findings	  were	   later	   reiterated	   in	   a	   study	   by	   Patin	   et	  al.	   to	   establish	   the	  composition	   of	  myeloid	   cells	   from	   1,000	   healthy	   people	   of	  Western	   European	  decent.	   It	   was	   found	   that	   age,	   gender,	   smoking	   and	   previous	   exposure	   to	  cytomegalovirus	   (CMV)	   independently	   affected	   the	   constraints	   of	   innate	   and	  adaptive	  immune	  cells	  [292].	  An	  interesting	  finding	  from	  this	   investigation	  was	  that	   innate	   immune	   cell	   counts	   were	   driven	   ‘preferentially’	   by	   genetic	  determinants,	  as	  opposed	  to	  adaptive	  immune	  traits	  that	  we	  shown	  to	  be	  under	  the	  control	  of	  non-­‐genetic,	  environmental	  determinants.	  	  	  The	   TLR4	   missense	   SNP,	   rs4986791,	   causes	   an	   amino	   acid	   change	   +1196C/T	  that	   lowers	   TLR4’s	   affinity	   for	   its	   ligands,	   and	   has	   previously	   been	   associated	  with	   susceptibility	   to	   age-­‐related	   disorders	   such	   as	   late-­‐onset	   Alzheimer’s	  Disease	  (LOAD)	  in	  Han	  Chinese	  people	  [308].	  Interestingly,	  donor	  RG002	  did	  not	  carry	  the	  missense	  rs4986790	  TLR4	  SNP,	  which	  had	  previously	  been	  found	  to	  be	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co-­‐segregated	   and	   form	   haplotypes	   with	   rs4986791.	   We	   speculate	   that	   the	  presence	  of	  both	  these	  polymorphisms	  would	  be	  required	  to	  affect	  macrophage	  detection	   of	   cryptococcal	   GXM	   by	   further	   disrupting	   the	   PRR’s	   binding	   to	   the	  capsular	  element.	  	  	  	  Activation	  of	  TLR2	  and	  TLR4	  leads	  to	  the	  recruitment	  of	  the	  intracellular	  adapter	  MyD88,	   that	   orchestrates	   downstream	   signaling	   cascades	   and	   bring	   about	  inflammatory	   responses	   in	   macrophages.	   Interestingly,	   variants	   in	   TLR2	   and	  TLR4	  have	  been	  associated	  with	  monocyte	  activation	  markers	  that	  Bielinski	  et	  al.	  showed	  to	  differ	  between	   individuals	  of	  different	  ethnicities	  [309].	  While	  TLR4	  has	  been	  shown	  to	  respond	  to	  Cryptococcus	  neoformans	  GXM,	  there	  is	  conflicting	  data	  pertaining	  to	  whether	  it	  is	  TLR2	  or	  TLR4	  that	  is	  involved	  in	  the	  detection	  of	  cryptococcal	   PAMPs,	   as	   both	   TLRs	   activate	   the	   downstream	  MYD88,	   and	   illicit	  pro-­‐inflammatory	  responses	  [138,	  141,	  300].	  This	  adapter	  plays	  a	  crucial	  role	  in	  conferring	  protection	  from	  invasive	  fungal	  disease.	  An	  investigation	  by	  Biondo	  et	  
al.	  revealed	  that	  whilst	  control	  mice	  survived	  infection	  with	  C.	  neoformans;	  only	  38%	  of	  mice	  lacking	  TLR2	  survived,	  and	  all	  of	  the	  MyD88	  KO	  mice	  succumbed	  to	  the	  fungal	  disease	  [300].	  Conversely,	  Nakamura	  et	  al.	  presented	  data	  describing	  the	   weak	   contribution	   of	   TLR2	   and	   TLR4	   to	   protection	   against	   C.	   neoformans	  [288].	   In	   these	   experiments,	   TLR2	   and	   TLR4	   Knockout	  mice	   produced	   similar	  levels	   of	   inflammatory	   cytokines	   to	   control	  mice,	   as	   did	   their	   respective	   bone	  marrow-­‐derived	   dendritic	   cells	   (BM-­‐DCs)	   in	   the	   production	   of	   IL-­‐12p40	   and	  TNF-­‐α	  [288].	  Whilst	  the	  compensatory	  behaviors	  of	  other	  TLRs	  in	  the	  absence	  of	  either	  TLR2	  or	  TLR4	  remain	  unknown,	  along	  with	  previous	  findings	  that	  MyD88	  also	  played	  a	   role	   as	   an	  adapter	   for	   IL-­‐1R,	   IL-­‐18R	  and	  TLR9	   [310,	  311],	   it	  was	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speculated	   that	  protection	  against	   cryptococcal	   infection	  was	  driven	  by	  a	  TLR-­‐independent	  and	  MyD88-­‐dependent	  mechanism.	  Wang	  et	  al.	  went	  on	  to	  describe	  that	   multiple	   signaling	   pathways	   contributed	   to	   MyD88-­‐dependent	   protection	  against	  C.	  neoformans	   in	  vivo	  where	  the	  elimination	  of	  the	  IL-­‐18R	  caused	  a	  shift	  in	   the	   survival	   curves	   of	   mice	   in	   comparison	   to	   wild	   type	   and	   IL-­‐1RKO	   mice	  [311].	   Thus,	   an	   understanding	   of	   MyD88-­‐dependent	   defenses,	   along	   with	   the	  genetic	  determinants	  affecting	  immune	  responses	  may	  highlight	  the	  components	  of	  this	  signaling	  pathway	  that	  modulate	  antifungal	  macrophage	  responses.	  	  Given	  the	  small	  size	  of	  the	  cohort	  in	  our	  study,	  these	  results	  rule	  neither	  in	  nor	  out	   a	   role	   for	   genetic	   variation	   in	   modifying	   the	   macrophage/Cryptococcus	  interaction.	  However,	   at	   least	   for	   the	  data	  we	  present	   elsewhere	   in	   this	   thesis,	  the	  variation	   in	   intracellular	  proliferation	  of	   the	  yeast	   that	  we	  observe	   is	   likely	  driven	   primarily	   by	   variation	   in	   the	   local	   environment	   or	   by	   other,	   untested	  genetic	   loci,	   rather	   than	   by	   genetic	   variation	   within	   the	   donors	   in	   the	   key	  immune	   genes	   tested	   here.	   Given	   the	   complexity	   of	   the	   interactions	   between	  components	   of	   innate	   immune	   cell	   pathways,	   and	   the	   extensive	   regulation	   of	  associated	   molecular	   pathways,	   further	   investigation	   of	   genetic	   variants	   is	  warranted.	  	  
	   148	  
Chapter	   5	   –	   Identifying	   novel	   anti-­‐cryptococcal	  treatments	  
Parts	  of	  this	  chapter	  have	  been	  published	  in	  an	  article	  by	  Samantaray	  et	  al.	  [312]	  
Abstract	  
	  Cryptococcal	  meningitis	  is	  a	  fatal	  fungal	  infection	  of	  both	  immunocompromised	  and	   immunocompetent	   hosts.	   The	   causative	   agent,	   C.	   neoformans,	   is	   an	  intracellular	   pathogen	   that	   has	   evolved	   mechanisms	   to	   evade	   killing	   by	  macrophages,	   including	   manipulating	   phagosome	   maturation.	   This	   trait	   also	  renders	  current	  anticryptococcal	  treatments	  ineffective,	  emphasizing	  a	  need	  for	  identification	   of	   compounds	   able	   to	   traverse	   host	   cell	   compartments	   and	   kill	  intracellular	   cryptococci.	   Below,	  we	   present	   data	   assessing	   the	   potential	   of	   13	  compounds,	  previously	  identified	  from	  an	  intracellular	  screen	  of	  1,200	  off-­‐patent	  drugs	  from	  the	  Prestwick	  Chemical	  Library®	  of	  FDA-­‐approved	  small	  molecules,	  for	   activity	   against	   intracellular	   C.	   neoformans.	   We	   carried	   out	   infection	  experiments	   on	   J774	  macrophages	   using	   a	   GFP-­‐expressing	   C.	   neoformans	   var.	  grubii	   strain	  H99	   to	   study	   the	   effects	   of	   the	   selected	  drug	  hits	   on	  macrophage	  viability	  and	  intracellular	  proliferation	  of	  C.	  neoformans,	  as	  well	  as	  the	  ability	  to	  kill	   extracellular	   fungi.	   Our	   results	   highlight	   Fendiline	  Hydrochloride	   –an	   anti-­‐angina	   drug-­‐	   as	   a	   potential	   anticryptococcal	   drug	   by	   virtue	   of	   its	   ability	   to	  eliminate	  intracellular	  fungi,	  but	  not	  extracellular	  cryptococci.	  However,	  further	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characterization	   of	   this	   compound	   is	   required	   to	   establish	   the	   efficacy	   of	   this	  drug	   in	  clinical	   settings.	  We	  propose	  a	  role	   for	  calcium	  channel	  blockers	   in	   the	  inhibition	  of	  intracellular	  survival	  of	  C.	  neoformans	  within	  the	  host	  and	  anticipate	  that	   further	   understanding	   of	   this	   process	   will	   facilitate	   the	   development	   of	  novel	  antifungal	  compounds	  against	  intracellular	  C.	  neoformans.	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Introduction	  
	  There	   is	   currently	   a	   limited	   range	   of	   effective	   therapies	   available	   for	   the	  treatment	   of	   C.	   neoformans	   infections	   [225].	   Current	   treatment	   regimens	   for	  cryptococcosis	  include	  a	  combination	  of	  Amphotericin	  B	  (AmB),	  flucytosine,	  and	  fluconazole	  [227].	  Although	  the	  provision	  of	  this	  combination	  of	  treatments	  has	  greatly	   improved	   the	   3-­‐month	   prognosis	   of	   HIV	   patients	   with	   cryptococcal	  meningitis	   in	   developed	   nations	   [229],	   the	   mortality	   rates	   in	   developing	  countries	  remain	  high	  [230].	   	   In	  addition,	  both	   fluconazole	  and	  flucytosine	   lack	  anticryptococcal	   activity	   within	   the	   phagolysosome,	   unlike	   liposomal	  Amphotericin	   B,	   highlighting	   the	   need	   for	   the	   development	   of	   drugs	   that	   can	  effectively	  penetrate	  cells	  [243].	  	  Despite	   extensive	   research,	   the	   processes	   by	  which	  C.	  neoformans	  manipulates	  phagosome	   maturation	   remain	   unknown	   [143].	   The	   molecular	   mechanisms	  pertaining	   to	   the	   ability	   of	   this	   fungal	   pathogen	   to	   survive	   and	   thrive	   in	  macrophages,	   in	   the	   presence	   or	   absence	   of	   a	   concurrent	   HIV	   infection	   also	  remain	  to	  be	  understood.	  Furthermore,	  the	  high	  costs	  associated	  with	  delivering	  current	   antifungal	   treatments	   against	   cryptococcosis	   along	  with	   anti-­‐retroviral	  therapeutics	   in	   resource-­‐limited	   settings	   highlights	   a	   need	   to	   develop	   novel	  antifungal	   drugs	   that	   are	   more	   effective,	   affordable	   and	   accessible	   to	   HIV	  patients.	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A	  study	  conducted	  by	  Butts	  et	  al.	  [313]	  used	  a	  high-­‐throughput	  screening	  assay	  to	  test	  the	  effects	  of	  1,120	  off-­‐patent	  drug	  candidates	  from	  the	  Prestwick	  library	  for	   direct	   antifungal	   activity	   against	   cryptococci.	   Among	   the	   screened	   drugs,	   a	  collection	  of	  31	  were	  identified	  as	  having	  fungicidal	  activity	  against	  Cryptococcus,	  and	  8	  potential	  adjunctive	  agents	  were	  identified	  based	  on	  their	  interaction	  with	  fluconazole	  treatment;	  two	  further	  drugs	  were	  shown	  to	  have	  fungicidal	  activity	  against	   intracellular	   C.	   neoformans,	   and	   seven	   drugs	   confirmed	   to	   bind	   C.	  
neoformans	  calmodulin,	  which	  was	  presented	  as	  an	  alternative	  molecular	  target	  for	  antifungal	  drugs	  [313].	  	  	  Based	   on	   the	   above	   protocol,	   Samantaray	   et	   al.	   developed	   a	   high	   throughput	  fluorescence-­‐based	   drug	   screening	  method	   to	   screen	   1,200	   US	   Food	   and	   Drug	  Administration	   (FDA)-­‐approved	   small	   molecules	   for	   potential	   inhibition	   of	  intracellular	  proliferation	  of	  C.	  neoformans	  [312].	  This	  assessment	  shortlisted	  19	  potential	   off-­‐patent,	   anticryptococcal	   compounds	   that	   were	   reduced	   to	   13	  compounds	   following	   further	   characterization	   by	   eliminating	   compounds	  with	  previously	   known	   antimicrobial	   activity,	   significant	   macrophage	   toxicity	   and	  those	  that	  showed	  potential	  extracellular	  fungicidal	  traits	  [312].	  	  Below,	   we	   present	   data	   (not	   included	   in	   Samantaray	   et	   al.,	   2016)	   of	   these	   13	  compounds	   (denoted	   as	   D2-­‐D14)	   generated	   from	   in	   vitro	   intracellular	   killing	  assays	  in	  the	  study	  by	  Samantaray	  et	  al.	  [312].	  The	  findings	  from	  these	  host	  cell	  cytotoxicity	   and	   fungal	   growth	   inhibition	   experiments	   highlight	   Fendiline	  Hydrochloride	   as	   a	   potential	   anticryptococcal	   drug,	   capable	   of	   killing	   engulfed	  cryptococci.	  Subsequent	  phagosomal	  maturation	  studies	  (not	  shown	  here)	  by	  the	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group	  to	  characterize	  the	  mode	  of	  action	  of	  Fendiline	  revealed	  that	  it’s	  activity	  as	  a	   Ca2+	   channel	   blocker	   strongly	   enhanced	   phagosome	   maturation	   in	  macrophages	   leading	   to	   improved	   killing	   of	   cryptococci	   and	   reduced	  intracellular	  replication.	  However,	  due	  to	  the	  high	  doses	  of	  this	  drug	  required	  for	  effective	   antifungal	   clearance	   that	   render	   it	   unfit	   for	   further	   clinical	  development;	   we	   propose	   a	   role	   for	   calcium-­‐channel	   blockers	   as	   potential	  inhibitors	  of	  intracellular	  replication	  of	  C.	  neoformans.	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Materials	  and	  Methods	  
Yeast	  strains	  and	  growth	  conditions	  	  C.	  neoformans	  var.	  grubii	  serotype	  A	  strain	  (H99)	  expressing	  Green	  fluorescence	  protein	  (GFP)	  was	  used	   for	   this	  study	  [314].	  Overnight	  cultures	  were	  grown	   in	  YPD	  medium	  (2%	  glucose,	  1%	  peptone	  and	  1%	  yeast	  extract)	  at	  25 °C.	  	  
Macrophage	  cell	  lines	  and	  culture	  	  The	   murine	   macrophage-­‐like	   cell	   line	   J774A.1	   was	   used	   for	   cryptococcal	  challenge	   experiments	   and	   cytotoxicity	   tests	   between	   passages	   4	   and	   14.	  Dulbecco's	   modified	   Eagle's	   medium	   (DMEM)	   (supplemented	   with	   2 mM	   l-­‐glutamine,	   100 U/mL	  penicillin,	   100 U/mL	   streptomycin	   and	   10%	  Fetal	   bovine	  serum	  (FBS))	  was	  used	  to	  culture	  cells	  at	  37 °C	  and	  5%	  CO2.	  	  
Drug	  preparation	  	  13	  drugs	  (denoted	  D2-­‐D14),	  previously	  short-­‐listed	  for	  anti-­‐cryptococcal	  activity	  from	   the	  Prestwick	  Chemical	  Library®	  of	  FDA-­‐approved	   small	  molecules	  were	  used	   in	   this	   study	   (Table	   1).	   These	   compounds	   were	   dissolved	   in	   dimethyl	  sulphoxide	   (DMSO)	   at	   a	   final	   assay	   concentration	   of	   10 µM.	   Amphotericin	   B	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(AmB)	   was	   used	   as	   a	   positive	   control	   at	   a	   final	   concentration	   of	   1.25 µg/mL;	  while	  DMSO	  served	  as	  a	  negative	  control.	  
	  
Table	   6.	   Details	   of	   compounds	   short-­‐listed	   for	   anti-­‐cryptococcal	   activity	   from	   the	   Prestwick	  
Chemical	  Library®	  of	  FDA-­‐approved	  small	  molecules.	  
	  
Macrophage	  infection	  assay	  	  Macrophages	  were	  seeded	  at	  a	  concentration	  of	  0.25 × 105	  cells/well	   in	  a	  glass-­‐bottom	  96-­‐well	  plate	   (Greiner	  Bio	  One	  Ltd.,	   Stonehouse,	  UK)	  up	   to	  18 h	  before	  infection.	   An	   overnight	   culture	   of	  H99-­‐GFP	  was	   harvested	   by	   centrifugation	   at	  6500 rpm	  for	  2.5 min,	  washed	  three	  times	  with	  phosphate-­‐buffered	  saline	  (PBS)	  and	  opsonized	  with	  5%	  pooled	   live	  human	  serum	  for	  1 h	  at	  room	  temperature.	  Macrophages	  were	   activated	  with	  150 ng/mL	  phorbol	  myristate	   acetate	   (PMA)	  for	   1 h	   in	   DMEM	   without	   FBS	   and	   were	   infected	   with	   opsonized	   yeasT-­‐cells	  [multiplicity	   of	   infection	   (MOI)	   10:1]	   for	   2 h	   at	   37 °C.	   The	   medium	   was	   then	  removed	  and	  cells	  were	  washed	  with	  PBS	  to	  remove	  extracellular	  yeasts.	  	  










D5 Dequalinium(dichloride Yes antiseptic







D9 Fendiline(hydrochloride No calcium(channel(blocker,(LuxR(QSM(inhibitor
D10 Tolazamide Yes oral(blood(glucose(lowering(drug
D11 Amrinone No pyridine(phosphodiesterase(3(inhibitor
D12 Gliquidone No anti7diabetic(drug
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CFU	  counts	  	  To	   measure	   intracellular	   proliferation	   rates	   of	   yeast	   following	   infection	   with	  H99-­‐GFP,	  macrophages	  were	   lysed	  at	  T(0)	  and	  at	  T(18)	  with	  H2O	   for	  15	  mins.	  Serial	   dilutions	   of	   the	   lysate	   from	   the	   phagocytosis	   assay	   were	   prepared	   and	  plated	  onto	  2%	  YPD,	  1%	  agar	  (Sigma-­‐Aldrich)	  plates	  then	  incubated	  for	  48	  hours	  at	  25°C.	  Intracellular	  proliferation	  rates	  were	  measured	  by	  dividing	  the	  number	  of	   counting	   colony-­‐forming	   units	   per	   milliliter	   at	   T(18)	   by	   those	   of	   untreated	  macrophages	   at	   T(0).	   Mann–Whitney	   U-­‐test	   was	   used	   to	   compare	   the	  effectiveness	  of	  each	  drug	  in	  reducing	  IPRs	  with	  that	  of	  Amphotericin	  B.	  	  
Cytotoxicity	  assay	  To	  test	  the	  toxicity	  of	  the	  drugs	  towards	  macrophages,	  cells	  were	  seeded	  into	  96-­‐well	   plates	   at	   a	   density	   of	   either	   0.25 × 105	   cells/well	   or	   0.5 × 105	   cells/well	   in	  triplicate	  for	  each	  treatment	  and	  cultured	  overnight.	  Medium	  was	  replaced	  with	  serum-­‐free	   DMEM	   containing	   either	   5 µM	   or	   10 µM	   of	   drug	   and	   cells	   were	  incubated	  at	  37 °C	  in	  5%	  CO2	  for	  a	  further	  18 h.	  The	  LDH	  Cytotoxicity	  Detection	  Kit	   (Takara	   Bio	   Inc.,	   Kusatsu,	   Japan)	   was	   used	   in	   accordance	   with	   the	  manufacturer's	  protocol	  to	  measure	  the	  release	  of	  Lactate	  dehydrogenase	  (LDH).	  The	  plate	  was	  read	  at	  490 nm	  using	  a	  FLUOstar	  Omega	  Microplate	  Reader	  (BMG	  Labtech).	  1%	  Triton	  X-­‐100	  was	  used	  as	  a	  positive	  control	  to	  represent	  100%	  cell	  death.	   The	   mean	   absorbance	   was	   calculated	   and	   data	   was	   presented	   as	   the	  percentage	  of	  cells	  that	  survived	  each	  treatment	  relative	  to	  the	  positive	  control.	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To	  validate	  the	  cell	  survival	  rates	  extrapolated	  from	  the	  LDH	  cytotoxicity	  assay,	  we	   also	   measured	   cell	   death	   by	   counting	   the	   proportion	   of	   cells	   that	   stained	  positively	  with	  0.2%	  Trypan	  Blue.	  	  	  
Fungal	  growth	  inhibition	  assay	  	  To	   test	   the	   inhibitory	  effects	  of	   the	  drugs	   in	   this	   study	  on	   in	  vitro	   cryptococcal	  growth,	  105	  yeasT-­‐cells	  suspended	   in	  YPD	  broth	  were	  added	  to	  a	  96-­‐well	  plate	  (Greiner	  Bio	  One)	  and	  supplemented	  with	  5 µM	  of	  drug	  or	  the	  respective	  control	  (1.25 µg/mL	  AmB	  or	  0.1%	  DMSO).	  Fungal	  growth	  at	  25 °C	  over	  a	  24-­‐h	  period	  was	  measured	  using	  a	  FLUOstar	  Omega	  Microplate	  Reader	  at	  600 nm	  every	  30 min.	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Results	  
Ability	  to	  eliminate	  intracellular	  C.	  neoformans	  	  	  To	   test	   the	   ability	   of	   each	  drug	   to	  kill	   intracellular	  C.	  neoformans	  H99-­‐GFP,	  we	  counted	   the	   number	   of	   viable	   yeast	   cells	   in	   macrophage	   lysates	   following	  treatment	   with	   the	   drug	   during	   the	   phagocytosis	   assay	   in	   order	   to	   deduce	  intracellular	  proliferation	  rates	  relative	  to	  untreated,	  yeast-­‐infected	  cells	  at	  T(0)	  (Fig.	  26).	  All	  drugs	  were	  used	  at	  a	  working	  concentration	  of	  10	  μM	  unless	  stated	  otherwise.	  	  
	  
Figure	   29.	   Intracellular	   proliferation	   rates	   (IPR)	   of	   phagocytosed	   cryptococci	   following	   treatment	  
with	   drug	   hits	   (D2-­‐D14)	   for	   18	   hours	   relative	   to	   untreated	   (NT)	   cells	   at	   T(0).	   Different	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M.	  Data	  provided	  is	  of	  means	  of	  3	  technical	  replicates;	  Error	  bars	  represent	  Standard	  Deviations.	  IPR	  
analysed	  by	  Mann–Whitney	  U-­‐test,	  *P < 0.05,	  **	  P <	  0.01.	  
	  Mean	   IPRs	   for	   each	   drug	  were	   compared	  with	   the	   positive	   control	   in	   order	   to	  identify	  compounds	  more	  effective	  at	  lowering	  IPR	  than	  AmB.	  Analysis	  using	  the	  Mann–Whitney	  U-­‐test	  showed	  significant	  reductions	  in	  IPR	  following	  treatment	  with	  D3	  (p=	  0.0294);	  D5	  at	  5	  μM	  (p=	  0.0016)	  and	  at	  3	  μM	  (p=	  0.0060);	  D6	  at	  5	  μM	  (p=	  0.0013)	  and	  at	  3	  μM	  (p=	  0.0233);	  D9	  (8	  μM;	  p=	  0.0346)	  and	  D14	  (p=	  0.0068).	  	  Despite	  the	  significantly	  reduced	  IPRs	  by	  action	  of	  D3	  (Diethylcarbamazine	  citrate),	  an	   inhibitor	   of	   arachidonic	   acid	   (AA),	   we	   chose	   to	   exclude	   this	   compound	   as	   a	  potential	   anticryptococcal	   drug	   as	   the	  method	   via	  which	   AA	   is	   incorporated	   into	  cryptococcal	  eicosanoids	  during	  infection	  remains	  unknown	  [109].	  In	  addition,	  the	  anti-­‐malarial	  drug,	  D14	  (Halofantrine	  hydrochloride)	  was	  eliminated	  due	  to	  high	  cytotoxicity	  towards	  macrophages	  in	  vitro.	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Figure	  30.	  Activity	  of	  drug	  hits	  D5,	  D6	  and	  D9	  against	   intracellular	  C.	  neoformans	  over	  18-­‐	  and	  24-­‐
hours	  following	  infection.	  Data	  provided	  shows	  means	  of	  3	  technical	  replicates;	  Error	  bars	  represent	  
Standard	  Deviations.	  Analysed	  by	  Mann–Whitney	  U-­‐test,	  *P < 0.05,	  **	  P <	  0.01.	  
	  We	   further	   investigated	   the	   abilities	   of	   D5,	   D6	   and	   D9	   to	   effectively	   lower	  intracellular	   proliferation	   of	   C.	   neoformans	   -­‐18	   and	   -­‐24	   hours	   following	   in	   vitro	  infection	  of	  J774.1	  macrophages	  (Fig.	  27).	  Though	  we	  observed	  approximately	  2-­‐fold	   increases	   in	   intracellular	   fungal	   loads	   between	   T	   (18)	   and	   T	   (24)	   for	   all	  treatments,	  analysis	  of	  variance	  revealed	  no	  significant	  differences	  in	  mean	  CFU	  counts.	   Mann–Whitney	   U-­‐tests	   show	   that	   18	   hours	   post-­‐infection,	   CFU	   counts	  were	  significantly	  different	  between	  untreated	  and	  D9-­‐treated	  macrophages	  (p=	  0.02541),	   and	   between	  DMSO-­‐treated	   and	  D9-­‐treated	   samples	   (p=	   0.0072).	   At	  T(24),	   CFU	   counts	   following	   treatment	   with	   the	   positive	   control	   (AmB)	   were	  significantly	   higher	   than	   DMSO-­‐treated	   macrophages	   (p=	   0.0087).	   DMSO	   has	  previously	   been	   reported	   to	   bind	   the	   plasma	   membrane	   of	   fungal	   cells	   and	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increase	   membrane	   permeability,	   influencing	   the	   efficacy	   of	   water-­‐insoluble	  antifungal	   agents	   [315],	   in	   comparison	   to	   the	   control	   (AmB),	   which	   is	   water-­‐soluble.	  	  Given	  that	  D5	  (Dequalinium	  dichloride)	  and	  D6	  (Chlorhexidine)	  had	  previously	  been	  shown	   to	   possess	   anti-­‐fungal	   abilities,	   in	   addition	   to	   the	   associated	   cytotoxicity	  towards	  macrophages	   (D5,	   data	  not	   shown;	  D6,	   Fig.	   29-­‐31);	  only	  D9	   (Fendiline	  Hydrochloride)	   remained	   as	   a	   potential	   anticryptococcal	   compound	   during	   the	  secondary	  screening.	  Hence,	  we	  tested	  the	  ability	  of	  this	  drug	  to	  kill	  intracellular	  fungi	  at	  different	  concentrations	  (0.5,	  1,	  2,	  4,	  5	  and	  6	  μM),	   -­‐0,	   -­‐6	  and	  -­‐24	  hours	  following	  the	  phagocytosis	  assay	  (Fig.	  28).	  Again,	  DMSO	  was	  used	  as	  a	  negative	  control	  to	  eliminate	  solvent	  contribution	  to	  fungal	  killing.	  
	  
Figure	  31.	  Establishment	  of	  dose-­‐associated	  antifungal	  activity	  of	  D9	  (0.5,	  1,	  2,	  4,	  5	  and	  6	  μM).	  Means	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We	  observed	  no	  significant	  differences	  in	  CFU	  counts	  between	  all	  treatments	  in	  the	   first	   6	   hours	   of	   the	   intracellular	   infection	   assay.	   However,	   we	   noted	  significant	   rises	   in	   intracellular	   fungal	   loads	   between	   T	   (6)	   and	   T	   (24)	   in	  untreated	   samples	   (P=	   0.0001)	   and	   in	   those	   treated	   with	   0.5	   μM	   DMSO	   (P=	  0.0012),	  1	  μM	  DMSO	  (P=	  0.0001),	  2	  μM	  DMSO	  (P=	  0.0033)	  and	  5	  μM	  DMSO	  (P=	  0.0025)	  (Fig.	  18).	  There	  were	  also	  significant	  increases	  between	  T	  (6)	  and	  T	  (24)	  following	  treatment	  with	  0.5	  μM	  D9	  (P=	  0.0003),	  1	  μM	  D9	  (P=	  0.0002),	  and	  5	  μM	  D9	  (P=	  0.0005)	  (Fig.	  18).	  Whilst	   the	  positive	  control	  (AmB)	  effectively	  reduced	  intracellular	  C.	  neoformans,	   there	  were	  no	  significant	  differences	   in	  CFU	  counts	  between	  T	  (6)	  and	  T	  (24)	  (T-­‐test;	  P=	  0.0174).	  	  We	  also	  compared	  the	  efficacy	  of	  D9	  at	  killing	  macrophage-­‐engulfed	  cryptococci	  with	   that	   of	   AmB.	   Mann–Whitney	   U-­‐tests	   showed	   that	   CFU	   counts	   following	  treatment	   with	   different	   concentrations	   of	   D9	   were	   significantly	   higher	   than	  treatment	  with	  the	  positive	  control	  (0.5	  μM,	  p=	  0.0012;	  1	  μM,	  p=	  0.0012;	  2	  μM,	  p=	   0.0027;	   and	   5	   μM,	   p=	   0.0026).	   However,	   we	   also	   observed	   a	   significant	  difference	   in	   intracellular	   C.	   neoformans	   CFU	   counts	   following	   treatment	   with	  AmB	  and	  the	  negative	  control,	  DMSO	  (0.5	  μM,	  p=	  0.0020;	  1	  μM,	  p=	  0.0007;	  2	  μM,	  p=	  0.0022;	  4	  μM,	  p=	  0.0042;	  5	  μM,	  p=	  0.0024;	  and	  6	  μM,	  p=	  0.0046),	  suggesting	  and	  overwhelming	  solvent	  contribution	  to	  the	  observed	  effects	  of	  D9.	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Cytotoxic	  effects	  on	  host	  macrophages	  To	  assess	  the	  toxicity	  of	  the	  drug	  hits	  (D6,	  D9-­‐14)	  towards	  host	  macrophages,	  we	  measured	  cell	  death	  following	  exposure	  to	  either	  low	  dose	  (5	  μM;	  Fig.	  29)	  or	  high	  dose	  (10	  μM;	  Fig.	  30)	  treatments	  for	  24	  hours.	  These	  measurements	  were	  made	  by	   either	  manually	   counting	   the	   proportion	   of	   hosT-­‐cells	   stained	  with	   Trypan	  blue	  (TB)	  at	  each	  time	  point,	  or	  by	  measuring	  the	  release	  of	  the	  LDH	  enzyme	  -­‐	  a	  marker	  of	  cell	  death-­‐	  using	  the	  LDH	  cytotoxicity	  kit	  (LDH).	  Results	  are	  presented	  as	  percentages	  of	  cell	  survival.	  
	  
Figure	  32.	   Cell	   survival	   following	   treatment	  with	   low	  doses	   (5	  μM)	  of	  potential	   anti-­‐cryptococcal	  
drugs	   measured	   either	   by	   staining	   with	   Trypan	   Blue	   (TB)	   or	   by	   measuring	   LDH	   release	   (LDH).	  
Means	  of	  3	  technical	  replicates	  are	  provided	  with	  Standard	  deviation	  error	  bars.	  Analysed	  by	  One–
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Whilst	   assessing	   the	   cytotoxicity	   of	   each	   drug	   towards	   macrophages,	   we	   also	  assessed	  the	  efficacy	  of	  each	  cytotoxicity	  detection	  method.	  At	  both	  low	  and	  high	  treatment	   doses,	   Two-­‐Way	   Anova	   analysis	   shows	   that	   there	   are	   no	   significant	  differences	  in	  the	  overall	  ability	  for	  each	  method	  to	  detect	  cytotoxicity	  (low	  dose:	  p=	  0.1865;	  high	  dose:	  p=	  0.8301).	  However,	  the	  type	  of	  treatment	  macrophages	  were	   exposed	   to	   contributed	   to	   75.31%	   and	   66.93%	   of	   the	   variation	   in	  cytotoxicity	  readouts	  from	  each	  method	  following	  macrophage	  exposure	  to	  low	  and	  high	  doses	  of	  test	  compounds,	  respectively.	  	  We	  found	  significant	  disparities	  in	  results	  from	  treatments	  with	  5	  μM	  D12,	  D13	  and	  D14	  (t-­‐test;	  p=	  0.0079,	  0.0077	  and	  0.0003,	  respectively);	  and	  from	  treatment	  with	   10	   μM	   DMSO	   and	   D6	   (t-­‐test;	   p=	   0.0059	   and	   0.0031,	   respectively).	  Coefficients	   of	   variation	   between	   each	   cytotoxicity	   detection	   method	   for	   each	  treatment	  at	  low	  and	  high	  doses	  are	  shown	  below	  (Table.	  7-­‐8).	  
	  
Table	   7.	   Descriptive	   statistics	   of	   variation	   in	   cytotoxicity	   detection	   by	   Trypan	  Blue	   (TB)	   and	   LDH	  
methods	  following	  treatment	  with	  low	  doses	  (5	  μM)	  of	  potential	  anti-­‐cryptococcal	  drugs.	  




NT 81.70 81.70 0.43 0.53%
DMSO 85.28 85.28 0.03 0.03%
AmB 79.04 79.04 2.81 3.56%
D6 48.46 48.46 3.03 6.25%
D9 65.84 65.84 5.12 7.78%
D10 79.14 79.14 5.10 6.44%
D11 75.85 75.85 2.97 3.92%
D12 89.83 89.83 12.93 14.39%
D13 84.01 84.01 12.22 14.54%
D14 50.60 50.60 22.01 43.49%
Low-Dose
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Figure	  33.	  Cell	  survival	   following	  treatment	  with	  high	  doses	  (10	  μM)	  of	  potential	  anti-­‐cryptococcal	  
drugs	   measured	   either	   by	   staining	   with	   Trypan	   Blue	   (TB)	   or	   by	   measuring	   LDH	   release	   (LDH).	  
Means	  of	  3	  technical	  replicates	  are	  provided	  with	  Standard	  deviation	  error	  bars.	  Analysed	  by	  One–
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Table	   8.	   Descriptive	   statistics	   of	   variation	   in	   cytotoxicity	   detection	   by	   Trypan	  Blue	   (TB)	   and	   LDH	  
methods	  following	  treatment	  with	  high	  doses	  (10	  μM)	  of	  potential	  anti-­‐cryptococcal	  drugs.	  
We	   thereafter	   compared	   the	   percentages	   of	   macrophages	   surviving	   each	  treatment	   with	   those	   of	   untreated	   cells	   (NT).	   One-­‐way	   ANOVA	   analysis	   found	  significant	  declines	   in	   cell	   survival	   following	   treatment	  with	  both	   low	  (Fig.	  29)	  and	  high	  doses	  (Fig.	  30)	  of	  D6	  (5	  μM,	  p=	  0.0053;	  10	  μM,	  p=	  0.0015)	  and	  D14	  (5	  μM,	  p=	  0.0078;	  10	  μM,	  p=	  0.0021);	  and	  high	  dose	  treatments	  (Fig.	  30)	  of	  D9	  (p=	  0.0013),	  D10	  (p=	  0.0266)	  and	  D13	  (p=	  0.0143).	  	  	  Both	   cytotoxicity	   measurements	   show	   that	   on	   average,	   ~80%	   of	   untreated	  J774.1	  macrophages	  will	  survive	  over	  a	  24-­‐hour	  period.	  As	  results	  from	  the	  LDH	  assay	   showed	   a	   substantial	   effect	   of	   increasing	   DMSO	   concentration	   on	   cell	  death;	  we	  wondered	  whether	  increased	  concentrations	  of	  DMSO,	  the	  solvent	  into	  which	   all	   drugs	   except	   AmB	   were	   dissolved,	   notably	   reduced	   cell	   survival.	  Solvent	  contribution	  to	  the	  observed	  cytotoxicity	  was	  eliminated	  as	  we	  found	  a	  significant	  difference	  in	  cytotoxicity	  between	  DMSO	  and	  5	  μM	  treatments	  of	  D6	  




NT 79.58 79.58 0.95 1.20%
DMSO 66.03 66.03 12.69 19.21%
AmB 76.45 76.45 8.49 11.11%
D6 44.80 44.80 15.02 33.52%
D9 44.29 44.29 3.98 8.99%
D10 58.78 58.78 3.39 5.77%
D11 65.00 65.00 5.22 8.03%
D12 65.86 65.86 3.06 4.65%
D13 55.89 55.89 4.54 8.12%
D14 46.68 46.68 9.86 21.12%
High-Dose
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and	  D14	  (One-­‐way	  ANOVA;	  p=0.0028	  and	  0.0041,	  respectively);	  and	  with	  higher	  doses	   of	   D6,	   D9	   and	   D14	   (One-­‐way	   ANOVA;	   p=	   0.0243,	   0.0217	   and	   0.0363,	  respectively).	  	  	  
Toxicity	  towards	  C.	  neoformans	  	  	  	  Finally,	  we	  compared	  the	  effects	  of	  each	  drug	  hit	  (at	  a	  concentration	  of	  5	  μM)	  on	  limiting	  cryptococcal	  expansion	  over	  a	  24-­‐hour	  period	  (Fig.	  31-­‐32)	  in	  YPD.	  While	  AmB	  effectively	  controlled	  yeast	  growth	  over	  the	  24	  hours,	  no	  yeast	  growth	  was	  observed	  following	  treatment	  with	  D5	  and	  D6.	  
	  
Figure	  34.	  Growth	  curves	  for	  C.	  neoformans	  H99	  in	  YPD	  following	  treatment	  with	  the	  potential	  anti-­‐
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Figure	  35.	  Growth	  curves	  for	  C.	  neoformans	  H99	  in	  YPD	  following	  treatment	  with	  the	  potential	  anti-­‐
cryptococcal	  compounds	  D8-­‐D14	  (5	  μM).	  Error	  bars	  represent	  standard	  error	  of	  the	  mean	  (SEM).	  
	  
Aside	  from	  DMSO	  control,	  only	  D7	  showed	  improved	  inhibition	  of	  fungal	  growth	  in	  comparison	   to	  AmB.	  All	  other	  drugs	   (D2-­‐6,	  Fig.	  31;	  D8-­‐14	  Fig.	  32)	  were	   less	  effective	  than	  AmB	  at	  controlling	  cryptococcal	  expansion	   in	  YPD,	  suggesting	  no	  direct	  fungal	  killing	  by	  these	  drugs.	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Discussion	  
	  Given	  the	  rise	  in	  resistance	  to	  anticryptococcal	  treatments,	  there	  is	  urgent	  need	  for	  the	  identification	  of	  new	  drug	  targets.	  Whilst	  previous	  screens	  have	  identified	  drugs	  with	  direct	  anticryptococcal	  activity	  [313,	  316,	  317],	  we	  sought	  to	  identify	  compounds	  capable	  of	  killing	   intracellular	   fungi.	  Samantaray	  et	  al.	  developed	  a	  method	   to	   screen	   for	   such	   drugs	   that	   uses	   GFP	   fluorescence	   as	   an	   index	   for	  intracellular	  proliferation	  [312],	   that	  was	  used	  to	  explore	  the	  Prestwick	   library	  of	   FDA-­‐approved	   molecules	   identified	   13	   off-­‐patent	   drugs	   as	   potential	  anticryptococcal	  treatments.	  	  	  Above,	  we	   treated	  C.	  neoformans-­‐infected	  macrophages	  with	   each	   drug	   to	   test	  their	   ability	   to	   kill	   intracellular	   yeast,	   and	   assessed	   drug	   cytotoxicity	   towards	  macrophages	  and	  direct	  antifungal	  capabilities.	  	  As	   the	   compounds	   under	   investigation	  were	   dissolved	   in	   dimethyl	   sulphoxide	  (DMSO)	  at	  a	  final	  assay	  concentration	  of	  10 µM,	  we	  chose	  to	  use	  this	  solvent	  as	  a	  negative	  control	   in	  our	  experiments.	  Amphotericin	  B	  (AmB)	  was	  used	  at	  a	  final	  concentration	  of	  1.25 µg/mL,	  as	  a	  positive	  control	  as	  it	  has	  previously	  been	  used	  as	  an	  anticryptococcal	  drug.	  However,	   results	   from	  our	  experiments	   show	   that	  AmB	   failed	   to	   eliminate	   both	   extracellular	   and	   intracellular	   Cryptococci,	  rendering	   the	   data	   acquired	   unreliable.	   We	   believe	   the	   concentration	   of	   AmB	  used	  was	  insufficient,	  as	  this	  drug	  has	  been	  used	  at	  higher	  concentrations	  for	  in	  
vitro	   experiments	   at	   concentrations	   ranging	   from	   1-­‐100	   µg/mL.	   Alternatively,	  errors	  in	  serial	  dilutions	  during	  drug	  preparation	  may	  have	  resulted	  in	  failure	  to	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kill	   C.	   neoformans	   in	   vitro.	   This	   was	   not	   the	   case	   for	   data	   presented	   in	  Samantaray	  et	  al.,	  where	  AmB	  behaved	  as	  predicted	  suggesting	  a	  user-­‐generated	  error.	  	  Despite	  the	  negation	  of	  our	  positive	  control,	  our	  findings	  suggest	  D9	  (Fendeline	  Hydrochloride)	   as	   a	   potential	   anticryptococcal	   compound	   based	   on	   the	   above	  attributes.	  This	  compound	  was	  able	  to	  effectively	  kill	  intracellular	  cryptococci	  at	  concentrations	  above	  5	  μM,	  over	  a	  24-­‐hour	  period.	  Following	  treatment	  with	  low	  (5	   μM)	   and	   high	   (10	   μM)	   doses	   of	   D9,	   macrophages	   survival	   was	   ~60%	   and	  ~40%,	   respectively.	   However,	   growth	   curves	   reveal	   that	   D9	   does	   not	   kill	  extracellular	  yeast.	  	  	  Fendeline	  Hydrochloride	  is	  used	  in	  the	  treatment	  of	  angina	  due	  to	  its	  activity	  as	  an	   l-­‐type	   calcium-­‐channel	   blocker	   [318].	  Whilst	   the	   drug	   did	   not	   demonstrate	  direct	   antifungal	   traits,	   we	   speculated	   that	   this	   drug	   promoted	   macrophage	  killing	  of	  intracellular	  cryptococci	  by	  inducing	  phagosomal	  acidification.	  Further	  characterization	   experiments	   presented	   by	   Samantaray	   et	   al.	   showed	   that	   at	  concentrations	   of	   fendiline	   above	   5	   μM,	   an	   increase	   in	   [Ca2+]	  was	   observed;	   a	  process	   inhibited	   by	   blocking	   calcium	   release	   from	   the	   endoplasmic	   reticulum	  with	   thapsigargin	   [312].	   These	   findings	   support	   the	   previous	   hypothesis	   that	  Fendiline	   interacts	   with	   intracellular	   endoplasmic	   reticulum	   calcium	   stores	   to	  transiently	  elevate	  [Ca2+]	  in	  certain	  cell	  types	  [319,	  320].	  	  Whilst	  Fendiline	  Hydrochloride	  was	  identified	  a	  novel	  anticryptococcal	  drug,	  the	  authors	   highlighted	   the	   limitations	   of	   intracellular	   screens	   and	   potential	   false-­‐
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negative	  rates	  associated	  with	  identifying	  anticryptococcal	  drugs.	  Therefore,	  it	  is	  likely	   that	   the	   initial	   screening	   of	   the	   Prestwick	   library	   may	   have	   excluded	  additional	  potential	  anti-­‐cryptococcal	   compounds.	  Knowledge	  of	  C.	  neoformans’	  ability	  to	  manipulate	  phagosome	  maturation	  [143]	  instigated	  the	  hypothesis	  that	  fendiline	   reversed	   the	   effects	   of	   cryptococcal	   influences,	   effectively	   reinstating	  phagosome	   maturation,	   and	   consequently	   fungal	   killing	   [312].	   The	   group	  recommended	  further	  investigation	  of	  calcium	  flux	  in	  phagosomes,	  and	  testing	  of	  this	   hypothesis	   in	   animal	   models.	   They	   also	   discussed	   the	   pharmacological	  advantages	  of	  using	  Fendiline	  as	  an	  anticryptococcal	  drug,	  as	  it	  is	  trafficked	  into	  the	   phagosome	   [321,	   322],	   and	   is	   able	   to	   cross	   the	   blood	   brain	   barrier	   (BBB)	  [323].	  	  	  However,	  further	  characterization	  of	  this	  drug	  for	  clinical	  use	  would	  be	  required	  as	  the	  concentration	  of	  Fendiline	  required	  to	  eliminate	  C.	  neoformans	  in	  vitro	  was	  more	  that	  10-­‐fold	  higher	  than	  typical	  serum	  Fendiline	  levels	  in	  patients	  receiving	  this	  drug	  for	  cardiovascular	  complaints	  [324].	  	  	  In	   conclusion,	   our	   results	   highlight	   Fendiline	   Hydrochloride	   as	   a	   potential	  anticryptococcal	   drug	   by	   virtue	   of	   its	   ability	   to	   eliminate	   intracellular	   fungi.	  Furthermore,	   in	   line	   with	   additional	   data	   presented	   by	   Samantaray	   et	   al.,	   we	  propose	   a	   role	   for	   calcium	   channel	   blockers	   in	   the	   inhibition	   of	   intracellular	  survival	   of	   C.	   neoformans	   within	   host	   macrophages	   based	   on	   previous	  association	  with	  M.	  tuberculosis	  [312].	  We	  anticipate	  that	  further	  understanding	  of	   this	   process	   will	   facilitate	   the	   development	   of	   novel	   antifungal	   compounds	  against	  intracellular	  C.	  neoformans.	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SYNOPSIS	  
Cryptoccosis	   remains	   the	   leading	   cause	  of	   fungal	  meningitis	  worldwide.	  Whilst	  one	   of	   the	   causative	   agents,	   C.	   neoformans	   has	   been	   described	   as	   an	  opportunistic	  pathogen	  of	   the	   immunocompromised,	   there	   is	  growing	  evidence	  of	   its’	   abilities	   as	   a	   primary	   pathogen	   towards	   otherwise	   healthy	   individuals.	  This	   necessitates	   further	   understanding	   of	   the	   epidemiology	   and	   pathology	   to	  cryptococcosis	   in	   the	   immunocompetent	   patient	   group,	   as	   the	   majority	   of	  research	  has	  been	  conducted	  within	  the	  context	  of	  HIV.	  	  	  In	   this	   thesis,	   we	   discuss	   how	   underlying	   host	   innate	   immune	   responses	   vary	  between	   human	   hosts	   in	   response	   to	   cryptococcal	   disease	   caused	   by	   C.	  
neoformans.	  We	  also	  assess	  current	  understanding	  of	  how	  immune	  responses	  in	  different	   hosts	   may	   be	   predictive	   of	   protection	   from,	   or	   susceptibility	   to	  cryptococcal	  meningitis	  (CM).	  	  As	   macrophages	   play	   a	   crucial	   role	   in	   the	   innate	   immune	   response	   to	   C.	  
neoformans,	  we	  have	  presented	  quantitative	  data	   from	  the	   in	  vitro	  challenge	  of	  monocyte-­‐derived	   macrophages	   (MDMs)	   from	   15	   healthy	   individuals,	   and	  described	  the	  variability	  in	  macrophage	  responses	  to	  cryptococcal	  infections.	  We	  have	  shown	  that	  phagocytic	  cells	  from	  each	  individual	  do	  not	  exhibit	  consistent	  anti-­‐cryptococcal	   responses	   over	   time,	   with	   varied	   control	   of	   intracellular	  proliferation	   rates	   and	   yeast	   expulsion	   (vomocytosis)	   from	   macrophages.	  Cytokine	  profiles	   play	   an	   important	   part	   in	   the	   anticryptococcal	   response,	   and	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have	   been	   shown	   to	   be	   predictive	   of	   disease	   progression	   in	   HIV-­‐positive	  patients.	   However,	   we	   are	   yet	   to	   establish	   markers	   of	   susceptibility	   in	   HIV-­‐negative,	  immunocompetent	  patients.	  We	  compared	  the	  cytokine	  profiles	  of	  each	  independent	  donor;	  and	  investigated	  how	  levels	  of	  secreted	  cytokines	  compare	  to	   intracellular	   cytokine	   production	   between	   individuals	   within	   our	   group	   of	  donors.	   Understanding	   the	   effects	   of	   cytokine	   signalling	   is	   also	   pertinent	   to	  determining	  the	  role	  that	  different	  macrophage	  activation	  states	  play	  at	  different	  stages	  of	  infection.	  Whilst	  mainly	  two	  macrophage	  activation	  states	  (M1	  and	  M2)	  are	  considered	  in	  the	  context	  of	  cryptococcal	  disease,	  a	  plethora	  of	  investigations	  have	   described	   a	   ‘gradient’	   of	   macrophage	   activation	   states	   that	   may	   interact	  variably	   with	   the	   intracellular	   pathogen	   to	   either,	   hinder	   or	   promote	  dissemination.	  	  	  We	  probed	  the	  association	  of	  Toll-­‐like	  receptor	  4	  (TLR4)	  with	  the	  vomocytosis	  of	  
C.	  neoformans	  from	  murine	  bone	  marrow-­‐derived	  macrophages	  (bMDMs),	  based	  on	  findings	  from	  previous	  research.	  Despite	  the	  small	  sample	  size	  of	  mice	  used	  in	  these	   experiments,	   we	   have	   shown	   that	   elimination	   of	   TLR4	   reduces	   the	  expulsion	   of	   yeast	   from	   macrophages.	   Our	   suggestion	   is	   that	   further	  experimentation	   be	   carried	   out	   to	   confirm	   these	   findings	   and	   characterize	   the	  signaling	  cascades	  that	  orchestrate	  this	  phenomenon.	  	  	  We	   also	   assessed	   the	   contribution	   of	   SNPs	   in	   TLR2;	   TLR4;	   the	   C-­‐type	   Lectin,	  Dectin-­‐1;	  the	  mitogen-­‐activated	  protein	  (MAP)	  kinase,	  ERK5;	  and	  the	  autophagy	  protein,	  Galectin-­‐8	  (GAL8).	  However,	  due	  to	  the	  small	  cohort	  of	   individuals,	  we	  recommend	  that	  larger	  GWAS	  studies	  be	  carried	  out	  to	  verify	  the	  association	  of	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these	  polymorphisms	  with	  susceptibility	  to	  cryptococcosis	  in	  immunocompetent	  hosts.	  	  Lastly,	   we	   contributed	   to	   experiments	   that	   highlighted	   the	   off-­‐patent	   drug,	  Fendiline	   Hydrochloride,	   as	   a	   potential	   anticryptococcal	   treatment.	   While	   this	  drug	   was	   able	   to	   eliminate	   intracellular	   Cryptococci,	   it	   was	   not	   able	   to	   kill	  extracellular	   fungi	  and	  showed	  relatively	  high	  toxicity	   towards	  macrophages	   in	  
vitro.	   However,	  we	  proposed	   a	   role	   for	   calcium	   channel	   blockers	   in	   restricting	  intracellular	   proliferation	   of	   C.	   neoformans	   and	   anticipate	   that	   further	  understanding	   of	   this	   process	   will	   lead	   to	   the	   development	   of	   novel	  anticryptococcal	  drugs.	  	  We	   anticipate	   that	   the	   findings	   from	   this	   research	   will	   provide	   indications	   of	  variation	   in	  macrophage	   responses	   to	   cryptococcosis	   that	  may	  provide	  greater	  insight	  to	  disease	  progression,	  and	  pave	  way	  to	  understanding	  the	  mechanisms	  that	  drive	  intra-­‐	  and	  inter-­‐	  host	  variation.	  We	  hope	  that	  our	  findings	  will	  inspire	  larger	  cohorts	  of	   immunocompetent	  participants,	  and	  more	  specifically,	  a	  more	  detailed	   understanding	   of	   the	   parameters	   of	   macrophage	   responses	   to	  cryptococcal	  disease	  both	  in	  vitro	  and	  in	  vivo.	  This	  will	  allow	  for	  development	  of	  more	  effective	  screening	  and	  personalized	  treatment	  strategies	  for	  patients	  with	  previously	  robust	  immune	  systems.	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